var title_f41_17_42256="Contents: Acute coronary syndromes";
var content_f41_17_42256=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?5/3/5182\">",
"       Cardiovascular Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Acute coronary syndromes",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Acute coronary syndromes",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cardiac catheterization",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/1/29722\">",
"           Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/10/30890\">",
"           Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/60/16329\">",
"           Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/11/4282\">",
"           Conduction abnormalities after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/4/25673\">",
"           Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/23/5497\">",
"           Left ventricular thrombus after acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/19/39225\">",
"           Mechanical complications of acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/17/12570\">",
"           Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/17/20759\">",
"           Predictors of coronary artery reocclusion following fibrinolysis (thrombolysis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/37/35418\">",
"           Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/53/16217\">",
"           Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/14/16615\">",
"           Supraventricular arrhythmias after myocardial infarction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coronary artery bypass grafting",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/22/6505\">",
"           Coronary artery bypass graft surgery after acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/6/11369\">",
"           Role of echocardiography in acute myocardial infarction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/28/28101\">",
"           Biomarkers of cardiac injury other than troponins and creatine kinase",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/53/28505\">",
"           Classification of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/60/16329\">",
"           Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/39/25209\">",
"           Criteria for the diagnosis of acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/13/31961\">",
"           Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/38/39530\">",
"           Troponins and creatine kinase as biomarkers of cardiac injury",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myocardial infarction",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/14/30950\">",
"           Acute coronary syndromes in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/30/26088\">",
"           Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/55/13175\">",
"           Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/48/1799\">",
"           Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/57/5018\">",
"           Anticoagulant therapy in acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/2/5162\">",
"           Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/49/35610\">",
"           Antiplatelet agents in acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/20/39242\">",
"           Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/53/11098\">",
"           Beta blockers in the management of acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/28/28101\">",
"           Biomarkers of cardiac injury other than troponins and creatine kinase",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/33/40469\">",
"           Calcium channel blockers in the management of acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/27/14778\">",
"           Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/55/33656\">",
"           Cholesterol lowering after an acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/10/30890\">",
"           Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/11/4282\">",
"           Conduction abnormalities after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/1/29722\">",
"           Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/22/6505\">",
"           Coronary artery bypass graft surgery after acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/50/5930\">",
"           Coronary artery patency and outcome after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/35/28217\">",
"           Coronary heart disease and myocardial infarction in young men and women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/59/16314\">",
"           Coronary reperfusion for acute myocardial infarction in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/39/25209\">",
"           Criteria for the diagnosis of acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/38/7786\">",
"           Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/43/1721\">",
"           Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/33/44567\">",
"           Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/29/469\">",
"           Intravenous magnesium sulfate in acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/4/25673\">",
"           Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/23/5497\">",
"           Left ventricular thrombus after acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/27/8634\">",
"           Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/19/39225\">",
"           Mechanical complications of acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/63/24566\">",
"           Nitrates in the management of acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/41/44697\">",
"           Overview of the acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/20/37193\">",
"           Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/59/7098\">",
"           Overview of the non-acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/33/44569\">",
"           Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/17/12570\">",
"           Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/42/34473\">",
"           Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/17/29975\">",
"           Perioperative myocardial infarction after noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/17/20759\">",
"           Predictors of coronary artery reocclusion following fibrinolysis (thrombolysis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/14/25830\">",
"           Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/46/16106\">",
"           Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/62/31721\">",
"           Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/16/29961\">",
"           Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/37/35418\">",
"           Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/55/16250\">",
"           Psychosocial and other social factors in acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/57/922\">",
"           Right ventricular myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/43/2746\">",
"           Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/52/35658\">",
"           Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/53/16217\">",
"           Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/6/11369\">",
"           Role of echocardiography in acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/31/37369\">",
"           Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/1/30745\">",
"           Stress-induced (takotsubo) cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/14/16615\">",
"           Supraventricular arrhythmias after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/20/41289\">",
"           Treatment of acute myocardial infarction in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/38/39530\">",
"           Troponins and creatine kinase as biomarkers of cardiac injury",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Percutaneous coronary intervention and stenting",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/27/8634\">",
"           Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/46/16106\">",
"           Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/62/31721\">",
"           Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/16/29961\">",
"           Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/31/37369\">",
"           Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/48/9994\">",
"           Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Risk stratification",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/43/2746\">",
"           Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/52/35658\">",
"           Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/31/37369\">",
"           Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/27/14778\">",
"           Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/60/20425\">",
"           Chronic anticoagulation after acute coronary syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/41/44697\">",
"           Overview of the acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/20/37193\">",
"           Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/59/7098\">",
"           Overview of the non-acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/33/44569\">",
"           Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/42/34473\">",
"           Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/37/35418\">",
"           Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Unstable angina pectoris",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/2/5162\">",
"           Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/20/39242\">",
"           Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/53/28505\">",
"           Classification of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/1/29722\">",
"           Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/57/22421\">",
"           Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/20/37193\">",
"           Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/33/44569\">",
"           Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/9/25754\">",
"           Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/43/2746\">",
"           Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/36/29257\">",
"           Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-5EE4C82E5E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f41_17_42256=[""].join("\n");
var outline_f41_17_42256=null;
var title_f41_17_42257="CT and MRI showing pericardial thickening";
var content_f41_17_42257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal and abnormal pericardium seen on computed tomography (CT) and magnetic resonance imaging (MRI) studies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) CT scan showing normal pericardium.",
"    <br>",
"     (B) CT scan showing thickened pericardium.",
"     <br>",
"      (C) MRI scan showing normal pericardium (arrows).",
"      <br>",
"       (D) MRI scan showing thickened pericardium.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Breen JF. Imaging of the pericardium. J Thorac Imaging 2001; 16:47. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42257=[""].join("\n");
var outline_f41_17_42257=null;
var title_f41_17_42258="Patient information: Ulcerative colitis in adults (The Basics)";
var content_f41_17_42258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15613\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/60/13250\">",
"         Diagram of the colon and rectum",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/22/9579\">",
"           List of foods that can make ulcerative colitis symptoms worse",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/29/42450\">",
"         Patient information: Bloody stools (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/9/38034\">",
"         Patient information: Colectomy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/11/18611\">",
"         Patient information: Colonoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/38/11875\">",
"         Patient information: Colostomy care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/20/5443\">",
"         Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/11/17586\">",
"         Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/39/10869\">",
"         Patient information: Ulcerative colitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ulcerative colitis in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ulcerative-colitis-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H214239029\">",
"      <span class=\"h1\">",
"       What is ulcerative colitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ulcerative colitis is a condition that causes diarrhea, belly pain, and bloody bowel movements. These symptoms happen because the large intestine becomes inflamed and gets sores, called &ldquo;ulcers.&rdquo; The large intestine is also called the colon (",
"      <a class=\"graphic graphic_figure graphicRef58531 \" href=\"mobipreview.htm?12/60/13250\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214239036\">",
"      <span class=\"h1\">",
"       What are the symptoms of ulcerative colitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can be mild or severe. They might happen just once. Or they might go away and come back over and over again. Possible symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Diarrhea that might happen 10 or more times a day",
"       </li>",
"       <li>",
"        Bloody bowel movements",
"       </li>",
"       <li>",
"        Bleeding from the anus",
"       </li>",
"       <li>",
"        Mucus coming out of the anus",
"       </li>",
"       <li>",
"        Belly cramps",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Swelling and pain in the hips and knees",
"       </li>",
"       <li>",
"        Swelling and pain in the eyes, skin, or lungs",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214239043\">",
"      <span class=\"h1\">",
"       Is there a test for ulcerative colitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are a few tests that can help doctors diagnose ulcerative colitis. Doctors usually use a test called a &ldquo;sigmoidoscopy&rdquo; or a similar test called a &ldquo;colonoscopy&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef52258 \" href=\"mobipreview.htm?4/46/4834\">",
"       figure 2",
"      </a>",
"      ). For these tests, the doctor puts a thin tube into your rectum (the lower part of the large intestine) and threads it up into your colon. The tube has a camera attached to it, so the doctor can look inside your colon. The tube also has tools attached, so the doctor can take samples of tissue to look at under the microscope. Other tests might include X-rays or scans.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214239050\">",
"      <span class=\"h1\">",
"       Can I do anything on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your symptoms might improve if you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cut down on foods that make your symptoms worse (",
"        <a class=\"graphic graphic_table graphicRef78463 \" href=\"mobipreview.htm?9/22/9579\">",
"         table 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Avoid pain medicines such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sold as Motrin&reg; or Advil&reg;) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sold as Aleve&reg;). If you need a pain medicine,",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (Tylenol) is OK to use.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you start cutting foods out of your diet, your doctor might suggest that you take a multivitamin and a",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      supplement. If you stop eating dairy, you should take calcium and vitamin D. These supplements will make up for nutrients you might be missing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214239057\">",
"      <span class=\"h1\">",
"       How is ulcerative colitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Depending on your symptoms, your doctor might prescribe:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines that you put directly into your rectum. These reduce swelling in mild cases. It takes about 3 weeks before they start working.",
"       </li>",
"       <li>",
"        Medicines that you take in a pill. A common one is called &ldquo;5-ASA.&rdquo;",
"       </li>",
"       <li>",
"        A brief course of medicines called steroids to reduce swelling. (These are not the same steroids that athletes use to build muscle.)",
"       </li>",
"       <li>",
"        Stronger medicines for severe cases. These medicines work on your immune system to protect your colon from damage. Common ones are &ldquo;6-mercaptopurine&rdquo;&nbsp;and &ldquo;",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/31/28149?source=see_link\">",
"         azathioprine",
"        </a>",
"        .&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For most people, symptoms go away after just a few weeks of treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214239064\">",
"      <span class=\"h1\">",
"       Is surgery an option?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When medicines and changes in diet don&rsquo;t work, surgery can help. There are two types:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery to remove the colon, rectum, and anus. People who have this surgery can no longer have bowel movements in the normal way. Instead, their bowel movements come out through a hole in their belly. A plastic bag catches the waste.",
"       </li>",
"       <li>",
"        Surgery to remove just the colon and rectum. After this surgery, the doctor reconnects the intestine to the anus. People who have this surgery can have bowel movements in the normal way.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214239071\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In most cases, ulcerative colitis does not affect a woman's ability to get pregnant. If you want to have a baby, talk to your doctor or nurse before you start trying to get pregnant. He or she can make sure you get all the tests you need before and during your pregnancy. Your doctor or nurse might also want to switch your medicines. That&rsquo;s because some of the medicines used to treat ulcerative colitis may not be safe for a baby.",
"     </p>",
"     <p>",
"      Conditions like ulcerative colitis run in families. So, if you have a child, he or she might have it too.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214239078\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/29/42450?source=see_link\">",
"       Patient information: Bloody stools (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/11/18611?source=see_link\">",
"       Patient information: Colonoscopy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/38/11875?source=see_link\">",
"       Patient information: Colostomy care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/9/38034?source=see_link\">",
"       Patient information: Colectomy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/39/10869?source=see_link\">",
"       Patient information: Ulcerative colitis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/20/5443?source=see_link\">",
"       Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/11/17586?source=see_link\">",
"       Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/17/42258?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15613 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42258=[""].join("\n");
var outline_f41_17_42258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214239029\">",
"      What is ulcerative colitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214239036\">",
"      What are the symptoms of ulcerative colitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214239043\">",
"      Is there a test for ulcerative colitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214239050\">",
"      Can I do anything on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214239057\">",
"      How is ulcerative colitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214239064\">",
"      Is surgery an option?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214239071\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214239078\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15613\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/60/13250\">",
"      Diagram of the colon and rectum",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/22/9579\">",
"        List of foods that can make ulcerative colitis symptoms worse",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/29/42450?source=related_link\">",
"      Patient information: Bloody stools (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/9/38034?source=related_link\">",
"      Patient information: Colectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/38/11875?source=related_link\">",
"      Patient information: Colostomy care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/20/5443?source=related_link\">",
"      Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/11/17586?source=related_link\">",
"      Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_17_42259="Doxylamine and pyridoxine: Patient drug information";
var content_f41_17_42259=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Doxylamine and pyridoxine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/1/34836?source=see_link\">",
"     see \"Doxylamine and pyridoxine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F163442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diclectin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat upset stomach and throwing up caused by pregnancy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to doxylamine, pyridoxine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12018 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42259=[""].join("\n");
var outline_f41_17_42259=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163442\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012023\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012022\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012027\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012028\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012030\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012025\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012026\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012031\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012032\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/1/34836?source=related_link\">",
"      Doxylamine and pyridoxine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_17_42260="Endovascular stent aortic dissection PI";
var content_f41_17_42260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F84002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F84002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Endovascular stent graft for an aortic dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 720px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     An endovascular stent graft is one way to treat an aortic dissection. A &ldquo;graft&rdquo; is a tube made from manmade materials. For this procedure, the doctor makes a cut in a blood vessel at the top of the thigh. He or she puts a folded graft in the blood vessel and threads it up to the damaged part of the aorta. Then the doctor unfolds the graft. This graft does not need to be sewn into place. Blood flows through the graft.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42260=[""].join("\n");
var outline_f41_17_42260=null;
var title_f41_17_42261="Shoe modifications";
var content_f41_17_42261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F65017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F65017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shoe modifications",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shoe modifications. Left) An external metatarsal bar distributes weight posterior to the metatarsal region. Right) The Thomas heel provides support for patients with symptomatic pes planus, valgus heel deformity, or plantar fascia strain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd Edition, Williams and Wilkins, Baltimore 1996. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42261=[""].join("\n");
var outline_f41_17_42261=null;
var title_f41_17_42262="ECG atrial tachycardia with block";
var content_f41_17_42262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1054px;\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Single-lead electrocardiogram (ECG) showing atrial tachycardia with 2:1 atrioventricular (AV) block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 99px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrial tachycardia with 2:1 atrioventricular (AV) block. The atrial rate is about 160 beats/min while the ventricular rate is about 80 beats/min. The nonconducted P waves (arrows) are superimposed on the ST-T segments. The P waves have a similar morphology to normal P waves suggesting that the ectopic site is near or even in the sinoatrial node. This arrhythmia may be an important sign of digoxin toxicity, but can also occur in other settings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42262=[""].join("\n");
var outline_f41_17_42262=null;
var title_f41_17_42263="Vaccine schedule based on medical conditions";
var content_f41_17_42263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 783px\">",
"   <div class=\"ttl\">",
"    Recommended vaccinations indicated for adults based on medical and other indications* - United States, 2013",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 763px; height: 711px; background-image: url(data:image/gif;base64,R0lGODlh+wLHAtUAAP/////MAMyZzAAAAP8AAIiIiLu7u0RERCIiIpmZmd3d3WZmZjMzMxEREe7u7szMzFVVVYhtAEQ2AHd3d7uWACIbAKqqqt2xAJl6AGZSABEOADMpAMyjAO6+AFVEAIgAAHdfAEQAAKqIACIAALsAAG1SbZkAAN0AADMAAJZwljYpNmYAACkfKXpcehEAALGFsQ4KDkQzRFUAAO4AAL6PvqN6oxsUG1I9UrKysuXl5cwAAHcAAF9HX6oAAIhmiAAAACH5BAAAAAAALAAAAAD7AscCAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz9DR0tPU1dbX1gPa29zd3t/g4eLj5OXm5+jp6uvs7e7v8PHy8/T19vf4+ePYZwP8/wBZ+QsoZiDBgwg9GUzIZSHDhxAhOYxoZSLFixgFWcwIZSPHjyDpeAypZCTJkyjNmExJZCXLSBa0OXig7UEVCAMgvNTk8mXP/516GHAr0CTmgJk1oeCcIASnTqCXfqaUCvVOgQENnhh1QGVp1U1UT4b9OudqVgA0ByxAMOAAVwATtAk96iApTm0HEgCYi5Vo3G0F4j5NwLatzbRr274lG2hsSMeM35gVkpYo2wVwBzAAsLXugAcOGgwgagHzkNADDADwmllnTAQODGBFOhrA5ciNcbfUDWgyWm0WABzIabt255pXERRR8FcbUdaChasVwrZA2uDDn/LmA/lj9+1ofF9fndNz8OOf424+LVqn6OcDmLbeG1+I0AnjnYLnDv77/jLiAUeeewPohd4DyRGxFQDvkSdfdMOZVl1+xP2Xh38YYWhhGAEOEP+cfjgdAMBVdNWEGmkLyPaZAg0uoJkQ0b0W2wCwUajdhnVoSJGOOHLB12g2AuDAcG3J5JlNEIjWll4kMtCgAnMFViFheB0moH495thfllySxCNEX3YpJjNhMlTmmGgacyZCa6bpJjBtEhTnm3TqMidAd9apJy158tPnnoC68uc1gwZqKCqO6aPooow26uijkEYq6aSUVmrppZhmWg8VhcKpJSGd9vNGqEuQekWepu4WR6pCJOrdp4OwWtCod8g6Bapy2CqrqxzZOoSvUgDrRarCtgqqSrkmCwevGQlb7BPPbkFsrceWoauytN76qkiFRKvFtHZ4Wyqyq2LrBrMZwqr/kSTgqgsIruXGm22w284h7riRtMttrOQua24b6F7kbLfszrvvutb+C7C8Udz7ysBN4HXwI/raWy0Z1zK8sLa9upuEbB4zUrHCfsDrr8ZsBLxjyEeArACNmgkFG5VttQfAAkQlIKJmLzowl14NF3wutfwmjHLKR0dcL8kt+/OyAaHphYAFhClgQAMPvOwAzgDoDEBqDBowwWYWZLWNEw5XZLDFRWPMtBq7crp00ka4PBACCgiXgNcKKPe1Alx7PdABBnD9d9D5rv32HiYrjvTJ9HY8sRJ2U5d3Xnz7PQBzmC2wsxCEj83ZWR0JvTHL/BkNueNwyy0520zg9bLlemfe/6oCD4jGwOfCQf1z5BKxLjzj/Q6PRtwcN4t66mb4XGDxazyb9hGND0338a4rP/m7THguRAHK4QWBdgioJsQCphFRgIhOIAB0FSNfr0f1pxsPPbRzr57bEt6PqBzIZePKA/ymhAIQhXLsy0L89PcH+j2OgdHLXrq218DusQ98AAAZg4IzAfl8jyg8Y8DLZEIk1bioLYVZn++0oZcDCKUBecNX/WC3P7fJT1QQVNrrFjeGl8VwCO5DW/e48b+BLMA9NhmCAb+mmgYYYInry6ATYSgEA7AvdGTLygGec8CS2C+CbRtDxnKYBpVFBGJhREL/MKjBslmAgB/8GuieSJQTsv8wgVaco+E2R7gRdTEJC/wi0WxIxjLeEAnTEwisBqgNAyRALg6g2QFstoDfechDv0MAWxpAJJv445FY6Z0BECAapjByOsbi3wWLOIQGIOCPfpRj75Y4Ae1cLYYGWA8WR9e7WMrwgRTMQh/D4EAwFhKHwJsg7A4gn7oEhwEFqNrVsnaUI3bNbH7Jom2IcoDOMcUfUxsC4UaJO38ws2vpW8kaw9cWGH2mCEscHB2FRCTlnNAt1SGc857XxyX+0pjBTIKTmjDMJBAGfvcDpvUEaYRErgKN5RPC7Ea0ANv9jWuzM+IBNxfRilJUjgm4jyjZB07VJCCdplMoD4uQOwYEZwn/Bf1CMVt3SEIiTnvLbKaH9hJNEfXtdlwrwGYGIrqy2caETMLMQvhogDzKEZpwQWniFhrQIxQAZ5jZZzRJOR19lvBrQtlMHomUQB3alKpoVakQdyivUzoSkhbd3AmdKMt9Sg2pH/XHXEQ0TpJmUBsIkGrw0lpT6lggd5FcT9dg87IHEC6KV2Ni2JwqJLqu9awzzCxAS8fWY/IPlmNYgAcdmszNrnQIaQHO1jTjSPaVj3B29Ic880gisF1WjKdVHWHNqszcqhG0XwClCH+lBZotYIQ0et9eykqE2G4OC4Hc7REmYJoCaOeqXqPJkMR2o9kewIdhw59upWtIzyIyfwyF/4JHcYsF2RAFSk8b0U7JU1a8EWGU0kovMpnQgJfmzihOBGVtvApYWfZVOg2wLG9nVVj26pe4nX1wEyp60CFU+FtZmEBZ43sznQg1ikD8YQbheCoJY5YKXtsvg807XrUueGVVrcJ6ezmsLKCPCBxeX9kUANluHBC/GCavZqeQ4oTK1Ar2VaBvV3zT3t4QlA1Y7XSEKiABJ8CKAs6jcGPDVaZAOXYZ3rBtaxnbBCa5iiRWm5BdzDwHW9U00LywbUSsZha7mbM45WFoXrpjFiFIROvb882uzFfVWNGZPCUnTWzzUjC3tzbwBdtVzDei+ooYyEpes2mP8EY6I8GfRzhpkP9PrETMQMCDRDhziRtMTAkKbHkAmGjXrpiAJVpxohUdq6G/O5CrOvWTIv1nFRKgpONuI4hKZG4RMA1dE98ZCR1N36eBKwRRIxuhLVafaE2TRztarctokZkCIPDeKANyya1OnpOPKejRKcDPtnbLOxlAaOEE59A7heavW+LpIpC2yZv27AMUywRQG0HUmSb190SDS8JREW+KNidRrIvfDnqR1WAwI5hg3TVtRPmEmIm3fDVTbxJpGZL73qujBztk+wUmjiEUUpQMONHynRIz4wT3zVf+bPVBEzYZzItrrebXwrTTfVQ8N8aPrO5Xx3h+KQ24/SZwwHg28YmKpfndrOj/ZZw3FW+LPifCL67wj0JARFZ8owNYRHRjQVWJnBQ2m7HXdBjTsIZMoGwU9K5imnKc6jDXYxe1Tp1RmtTr+47o2JVe9qvaJ0V8pREM9z1wbWR1vox3dkNcbXd0P30IfH9C6LNNd46/PJbyFKoSC1AX3DkRqtQdqdv9Iu3zkp4LA+S5pstO9nXbj0WUJmjwizDjOudd2U4Y/YvxPPeWo3Y98ZyjVpfoIlI2VS6I96uKAqv7dIvBcL3ffc+Xv/Gng98JMSV+AsCL7SZYEcTlS0xOnGObFz5glKVEC1sQYJN7kjvWDXBPladqcld6nxdRZiBa3ZdxnseAduZv6LVm5gYF/+nXXMrVfscXGgpgAZvhPUKVWNvUYRG3F0xRS7eEZnDxTaAzcTdSgH1nUAMhG/02akrQaWMgXDOoKmX3SGmWSjQofkzGfE53d0YwcEPwFwXQN5dzWIVhRa0Va5+0DXrhD1S2U97mgnUjIqKVFzeTM5iBX4pHOEVnaO5TX8SWN3ezDchne85XBI9URc+FfsOHhcfXfPmVBAo2BDfGI2MEhDroe0JmAU9BTqHxAA+QItzkQYTDN0fRX4MmR1GkQg+Xgz5Yh1djboHzhcoRUaeWciUIASe4cCTFFW8nhH7HBG/4V7gjbl9Df3nRALUlXlSgfEbAfgk3fpXYUJu3dDVWd/9nBGuCWG3coBoTcBYI2DuMiGtTGEtYNnR0eF/swwDykYkjVhya0XZyxEj8dzMSg2j0VXmoRH4viAQCpg0KsEUjYkvm9BQVGH57t4arx3QKd0K1NXEg1IWz9jUxITb0t4BSZ4Cm+IsxZoScAXSUUQBiIxyKaABv1HF1YRP0BolEkXaMlXSZ9wQWCW1z6AS5d4v/6IYxyFFq6AB3YU7m044XyQQD2HbE1k5atQ0gQ1c6MySNBHDeRz33RYX3GDg7M5F4U4j+eIptmJICSYRGMIHNASVcMTVupU9hRYVysYwiNxwJRomyBAVFlgTHGAXnZ3wfSQSpKIOleFBhd5KNJo7/SICOFOcWdLVFqhdHkIhzFgBZpHNbQQiBJHk20ceTslSOGwmBvNgFGvcQaJQEXUkGWvOMhhBdIAmHq2h5fQMzNEYistg+anhrQwF+/uQ0WJMVsWWTDnheZKmTchR73jMQajcERkWUX3l7iiknHAd8ZpBCQZkIjGmHRVCK+JZEI5J18jE4sNeClXmXuxGZbIF6aKE7vJMZ5gh4rCmUuImTEeaHn0cw1OmaRwCOkHdNLKRVaaFBj5Q3NEkjoCmPYzBcz1leJvZviMJxLQOP46gGtIiBrQmdJWNk9lmfuPiaAVGYogef+IliHidlmNFRIBRW1khtnKeeSfBTAFlB2Bmf/ww6lGwIiBSahQ/IBO3WZ1hjoJLlRPO5oA9ai/ZUezfJPRGqfuZ5nb1YWp23dPhXHwb6MmzBADIzIzXpQlhhlRWKBbKWYnnhod7VonbooBJqBAbHoi7KPxf4gxe6n+5YlA04gjOaGlHDaMkmHFzki1WwoTDkZ/TmM/coSgTnpBNKBPukHAbknawIGNxIHEiIlkiqoGcamk5QfPBEp1Gqn8Qpp2zinhgqR1VKO3kBjoXmS+U5bAMKch2nGWOqT9Wxiy2nej9lQCElTiwIeptzFGimAEDJn4g6BSi5pPIYp1UYHFZGBLlTEzDppjsXp7n4pH1amwnhn8nnV2EKTTV3Of8nFXKHmqR22QiBhFFqynouwgCjNJIlOSKuFE3D2H0nBAEvE1YOQEv0d6rcKSKnJGB2ZRub1En/xyKLEasOSIhYE4lsGRwVRSJX5UEGBzJilyI/iTXkyqcnOpwvmqFV5FfClYR3w6vb96t62qPCKjy1VJCIelVjqRyLhmapKQQPeZGJCYU28UoGZK5/VmmhoRpbdE5zBBfa9ErC4U0Vh2r12ot+GW/KqKrZwWNEkZfacFTo5JcnW6f5Sat/Wp2DRDHCE5kMUKwAZgDaaZxH4aZJaQHwOREF0Ky4ZkDOCpMqOxTH2Ed71Dd45XhI52nw8rDMKG8Q2aR683KjyVNRxbX/NTuiNwuq/2CrEKoFT6SzdnoGEwC2EFY3eOMPDjA1BsS18RaxoKOIHBSyVxtycaeLqpOUItckyvUXIpQWVHKc24cZSXm2Rxqge0qYgLqzTSCuerNsA4sEUGJ5UsRC9Jm2M+QZo4FcgOYX2+CyQcedBeJWJNKtHZVUQoJ5fzirX6CA0qmvK4qvUhqY+oozzIZctqVEwads1kUE6LhqsiqhsrYGHWm4vFdccjGDffi8dWuh0SlnGMciEem5y8EA4yMiOiON0jZADLAAXPFI/1e6NosEIWqmQxC9anCYlEu/bgug26ukkpqoZpK54TIFa9EyoEWjFhaO39M5OgEBCSCm//CLtvLLv0dwbX6KBzOVBfObvylavQQbvCyWR5qEFZ1EozFDI5HkU1Q4F6gKSaRaEjApvjhGvmc3a+hLBGMTSZixvo8oopULjR1cbSYanc0WBht8lZp3hy8cwNUpwtzkTU9zpVPDiJWmsfm2PjV5wQeXPm/3trebRAjJvKp5FrVEV4Bjo3lTwwAcofcUo0zxik/LAFyWf07Zj+m5xVfgvT4smOhHbNEkGoDGwtLRTkecvUQMmHlWUyI8uLtaOyrctRPleGtMjqYRGuMqBEjbBM65wMyrF3kYrPFbRUk3ggegE4imb2Bnkm+Js2A5xEW8BKCWwcxrym1pQICWQBtbyP8NSKQBWX5G+Z4y61FX1ch50ZBv2LdXvMRFMcRz2wTDBUrbeEJynMnKzHtFtm99FMnbKUew9bmyRCIQp3OFIW0IYH/MyU1+HCXdpg0QIIDi5sbIpRqyLE6qYbxO+7q11VQUjMT+q8STfBBsC8y1S1HE/MBP2bWNKsfVvJjGE4rYrBqnjJB+9VhlepFbRMpdl2p1BIrz6lg6can7OrEGxoIjGMuWS89fHI+YmTcgus+GbK/9m69J3M/Es2ZtPNHms2UPrVX4QjMSbSyKR84mlRfD2Eerhay01ayyZHRiaCwm3cHD1JIFMpVY0dKgDNO/e9WYC7cCjGMK7CI/9DKufNL/UPo4QURuKUd7qaYap8a1MeVreBQ+pNhF+3Z6/Hyvh6y7P9y73IvVu7w+ExgazVtpE+jX/sw24PzTcqQiPAxE18ucTMUZHqfPqAsfB6CdlFeT80zWQazXd5yzv3wERtpcCszZRvBaQKMzmIbaR1BJ40psvClzY83KVDCqMV1w3hzB7fOXHuyR2hu3eX3bvuxbo00ZUWaL1EG3vt0EuZOOTUEU9Nrcy1sEF80AYPxd4QslWHfJt4VKccGjSmDbHKw+ub3HTLCVEszHhqnc6u27vAy8w11Yxf26WG1xdeEA952C+p3fQ9DOcFitBLRTDQA0q8x8s8EgcVjbvC3cBVTe/1zaZrpbUcid1Yb9v7281aF9GnPBsOLWhP7QlELbpgiqVZg4sGNBr6thQE/R3Cj+fwerpbl03VACNNr9geqWEwkgiJsznvKMoKp5I9ato1TEqAyeBIR3VG6sf6L7z1IArO29n3iK1xV+2PCN4StFqcqhlqA40Qup5R+KdeL0wJyqtn/FDQdAJK1q5ntBaa4NligOsY1940gLATHBY2hnNlfHHqvBvlrERRzKm2Fx5OWD0ei00E3u4Ib+ymAphSDlcec8cmCnJIbIip9t2p79wfHtWcRqjW2ReJRGOExtYIXTRSElyWROBXl7iv6QYBfFDaJOBC7lOQmgE/3UU6DzPv+B7q+F5+mFzuRR4ORcSj+C5lHg9FIYi6m8q6XOXemdLeW03Z9/5xrKoZtcTs+lKOqrHBqfjOmKsFT6vTkvnkoxVYxzCYu9tLdf+ua53nq5o8+zF1VLKoD7R001eqOEIRohx7q1McKclBRxKuSAIzGI/GwrC2zx4Zc+7Vg5EZkCz+2hvNfU29emG2s1yuGWR3lNSDjaKeo8LTpafDFIvOP19OpjnNK1/qbSluvcaH37FrkuGorSCBfSaqUDzmiEsXafcbEdLbLddDMTgLHo+H8bIezztoy/Aj6LcdZdlBfXHu65+9vvrdVMnOFr4MBSjwi3eQXJjq9FFlHk9K+OXHj/ljqMA41dRa0a0cfXxKm4TyUxiAtYUnKNG4+sag/1T37hU7/LYMC5H59GEy+g1/jySRfztVTQ2XUUe2uQwZxUbo32IMTddw3cYpDqdR/cFP7seNLV6hWzUXAbN+bwWD/TWS3vNEJNhLo3bmqt5lj2ktu6Jx8iEX/pze7s6X25eX9In69eQLNOrVjK5HN4lRXbTy8yzLvgl1+/PSj7S5CVt8eHen/3lh/5mS76arT7q/RXoyNAfoNwFkc9e/P94B/+4j/+5F/+5n/+6B/+CyHeUb8cJWrpBrXPSmxc0r/8PRgqPFjktT+c7A8EAOFAWDQekUTkktl0PqFR6ZRatUaV/1ctNGt8NByARYEMGFgGiQNAQUwMBg3jIiFcrAEFBMCgbFgAJiaEEhaELBiY0hIYGx0fISMlJykrLRu7Dgy2tLqYFPY4rTxFS6mU+grYEkk5W6kSQqsaNoteTate74T0uI40p26fhHGLjY+RO5NdmQ4SHMDKBlTV2IgQAI/o7ODg9vrsIAAaHggN2WSPiJEZl5cyGeIU+uAMvsLGHuIRFIoc4qc5OFDPwB4H/Gw1+ectT4GF0/QNQNhN1QI44ibAUeXLXUclE/DYipfIwIGMDxBILDdgJJ81b+KEWXel5DB1HU8x2ZUnnaKGQoBJmfkOZ1GjR0sNRfpKTQJx0gitaf8DIEG8QUW2icHTCxwAC39kFRICyidSAA/KHc2kCsLGPGucQROoqoA4Qol4rTEgp0CCArWGNCmQiCyZqkUO0LXLZ0CbMHz4QUvrRKlZLHbO2dpEq+AmBoMmiBuw2UBJaNkCFyHDwFmDAWtQ1kvgWu8aBPHIpZxWJDaCBxZ3p7ZMdMnOXrNfM65npk29A7j72bxSeXh166aoF30FjcEmqF73vDHSGGsdrby+ZWmAwK1Yr3iTXDeayXuBiMmbitOdXIgDi92Bg0MIBhYTDokx0GnIP5YK6uYAByDoJo/1+upmNI7kawYw4kC6CQBNagIAgU0KMgOo0g6YajwjBlMAmk3/EjOpP1o+/Mu2iiAIsYjPAhHNwwxNLM5CBF6sUbU1iCjDyLYK0KisUYCMUkpRssPplgVC+W6heAAAKCQxzDNuDzjwOKkI9wR5ckpj6GtoAUMKWIM7z9xCooAFQmPRgAJQC3KJPC3YQ8k8FmCgvT0eyKKgQB8DwIEBJouPidhGg4kBB2Ih0zVxCoWjDksdGAwOQJDTCwHXJoDpFlR2U4CVE0PkMU8lQHzwjxVVU6U5jUYcy0IbRdxEDR2F6LVET6pMRpet+Pn1PiR/+rA+DHNZ09prpZsy2SiyskIsydTElkojgCGDHgTwwFKI+zJDIw4DBPKmJgUaiM5PJEBhSVA+/+Gghd18U3rUyYzgUMCCLyVdQkZHz+iyL372esCxBcSZ7VFADI3zrSITK0iBRKWl7EzXBjCEVhTXTcm3IGulql+ZWFTl0ckWnrmImnqFYAID4BsQNB9xBXJZ9GzG7C0TC7iq3DrDDUbcp5/edhmpnwDOipQMebMJqqG+tzqur0hVZCZ6tYYXOqQKpTEE21DxzjJK2nWaEIkIqumpYyaE5AQoNQC5NHCGgwEXU3Krt5V+zHBonqja+1xoEx1taWpz6tpyKcFm8/K7N79MvsyPuaXmhg2thizmEBzsYofhfhDSm/Gou8+ErcSlbGWiBJ2Z6Trv/WtrdeeDaXeChwIHHP+WUhzbW/oG1XS1FQCORlBbb9xTuvMQkHNkMr+d99zB/9738ecD3gp6w3DmiD3Vsqyd9qcYFJfKiCXeGATL37qY4nEXOnwoyRdAj5jPCmMoURHktqE8bAhh4oOCqzy1ijiUYy8saRQS3hcFCKZBguTgg2suRRydZCZa+6NC/aSAAPMI5X7Dw5v+tDausWkHc/+rlgBxyD0CVoFeDFjhzZjmKghA4CXPmQAJAegEPczjKXKYQCKe2KVB8IgJGVyfoYxggCYGAoqJ4BEVE6e/Es7vhA1UVhNOp42SGeUL9gqaCJOSrdrZ8DrJ4l8OA3jHLSRLXUhg3xHaEJY17m4J/mH/zxG+4jDGPMo7ZiTED49gyKsUIZFY7AMjjyYpaBhhAmS4E5lE1TCs6CZCuylVHgCCmnUARxOnGsAgWlMhCxYEVdJ6iAvfCMienAUMsQAkeaagwifUBY7x8SQeRnTK1TjSa7QbIB2tY0c8ThM7OzxFNxT4RwQSiIhUMSISb+jHQRrhH3U4ZB/a4J1dngmSCgNmOUWkCnReqBcJY8ADBtMlfKpCCRrTGFbWoLqqcIwMAQ0JMfYSHY+B7ADiWJ2hFlq3PfVshvjaJQo78qgLGsiYDqkXzwjaooq+oyXxuhACUtKAgbwOOOAUo/+k0LeV1uYk+3CjHCtHTZ06EJpScI8i/4XXn9ctkFyUlEMSkWBIt/xjI5YcACb/uQS0KARLk2TqgOT5VHqaMQudTMxsftJPeX4JQWLx2K+qx1EMhgR7wHDbAtpqAPxRzlEACQ9tROQcl8WECBGBmCsHIVN4rRReAGnq7Jq5ojKMYQxy8yROk0Aaje0lnh/K2gS+ogB6RY4YegwnFBbmD870KjF5KBBkWbhT1ea0hldwj1yQcLAodJKnS1giSlYYxSh+cZInxCJvhCkE3Xpxir1NyCEaMIEvPIWfYUirHahhiIIU7Sc6Qmi9hBBXhmEMWCbSRD49xyLCEIlGHavNaRJS2rpE9EOT/K5eGnCYObRTGEmSJ0odQP9d+RVTUpoI0DU2sY07VeND7dyeZZRyuyYRBJkOclptVxth/ipPFBZwqdigMDgIV9FCBoAgjSqoYSvQoxsKUNVoPkwiEN5UODbDYhkilJixziG6kLFeGp67SjJpd6+XiustIcu2ZlGkJnHrwjUchL3b+ddCC+qOHegrMiUh4Bx/8wsujytGTeSpCL0S8AIyu9nUwjQKC2vbOFAGVNau2R2Ri5SEo2lN33mWzHG+FikARaShusQl6A3Mb/nsXfcagMssOgcDEEvnLJdFEybdg5frcCcxwMGlBzaLUmQaB87ggV0PRmoRXOOWeJy2Cm6GM4W1JUBFfw7VayJFvhhw1+v/1WavYOgrQOAau7PopiSD9Ya7aKRRZ9qvp7+rM5snHYrmIPbU41s1sjf3bDvXcXldI+awX3hsamt7zEZwVzmaJAeBCS4bpXxNHcwdFziUY1MDWdl7yPTmZsfR1aqOwneQcE8pHO/e/GSCvlFLSYRoAZ4v9SMzeYFljIYXW23k78A1V+zhSHuknj5C4bo0zkPEwVGh9soCoLEbCwuM3QMQR4TSQ6QmrXPeezwTRbY9hZXuYYOVfuYw/Y0vilpDgVQxsJ1yDsidpzOXF/cOeR4lXZLt4QChQEMdKGvw9SF8jFM/M7TRiOvsFQwJKDXCG37o9U+LKHo23/B8mbDwsfuU/+qfNYt1+6fGIdfCAuaG1MpZJBFyrnscr8yeHAYyiOb0vOX9Ew8a5A0/KUSdF6ROHhTwnbdf9tyKggm65I1A9EUfQR+82E2TDNEAaqhiIJuIkHkQLfUsUn2/q4/7vQu05/WhFDAHsP3NaD92iJuwaoy4KNWDi9NdCfPqZ2o71nEC9w3TA+Ubh8i6M9Kz6O/9dbUMd8YtJMrCy9BlQzjYbJLmJFXVgSUsUc6Fyp+IW07voFT4B5XLgRIGgBwJuCXn/I8wm8Rnq3l4hQpMjkrDlkbzvm6F+i85/q9fBqQfBvBCNo9FrqIu9oBAQo+EGgrkVMo80kRNFgxiXuJlWgqVRv+lxxygJtxAAVEqDlYqUqhD/ujPIroFK8jgHOilBqFL0sIpQBSADG7JpDYB5gDQetqv99Lu+BiO57KH2bypCdTO0txB+dauWLrhKqbPzfBONfTOH/jO+jhuIMxu+8Tn8BqjoSDDRcjhVrbhQmgkL8xAsuBD0lJPrZwAJRqHUMTgtHhGAQ6ABrtDdfLCVX7upWqmvB7rGlCj80KGDAiQnRDjKkLK37CBN/CiATfkFmirIQzFUKTLsD7kK5JGfajC5lrBvPwszMjBn1yHu0xQRFDjkPZQDHqLOiSNYg7iY94N1NDiqIipLYSAHL4AgBKK7AzjDeHrZgxxRmBkI25h/Gr/YqZc4h7EQJYAz28UMFw0j2KQxhtMzJUMwa/yBSJs6gv4LmhuY4J8sMBEz7Aegvxagpb8zhuh0O3ybhzxDiYeIORUYeQ8buS20O+uDw08SA/3Dww9bfxC5sTEA0xYxh68ZCHnqg0CpeicIFAkZg+eCFNIKFGiQ0biixcSoZ7MQAmfpGwc6/+sIlooEYNWiCTRyt+qwh83IiUfsAgu0ZOmAQfXBVI0IUIeABR/inYyZW5SJAsIzBla561W8SUHAdLscCad4CIL4VHMyY0QYUAwBhCqsiq7RCTLgsD4gQf/Q66azNyowiocSw47DhDoQEdepBmf4aki8UTiUuo0T2PW/yIWHKANelIxQkS9IABPRhJHJgvwKgY+oiiR1LA0+IGh+HIIo/AsGAIxBIfvIIBk1KcyyeQtq88fOc4rVuo1NoogwykhTwQ8HsPFyO9EtMYuTwS8gEL0JFKJLGIjQoNGCgAM+GBwXnEVJuox4gQQw2l0JiPyGoNIgIItCmARhSAHcqARhWo4L684H6O02mIRbyFpEk6j7sRVKEgnDaAqQXED4UiY2sI0bsUr6mWzWuehgOXIQCHAIo2EsqM2SQRL8KCbeNG0frEXHyA/r+3BGKUGB+VOCs2XQMYWEuXNXkFF1jKgsKkmqkLSlFJaJtQaHXBWqEI3+gKZGmTHGizeBv8CAm4qC3pFDf4rZJxMrpRRRVrGRPZDExxTHkWTmoiyTQKhxDowNaXlcRYSyNDggqrkgM4GAPJz137oH5BI/5LoAHHM37ykJxHDNURPbn6OSa/MRJ40JA5ASpPTQnRUqvBiQEHO3Eiv9lBPJLugA4EFABdkjaoHVFaxIZkSJxPr3uSzH2gh5LpB9LLvNi0ENz3N3eqFDIDN1yQCYIigIa0MLVHTyPAUZaBhDYdADwEDmJyJ6JrkB0UE3TYUMq8qu/AC0BADkkjU9AShQOyGUA5TDk4GewAtHpFvRu1NC+ZSC+i0Tj+hGz7FG+4RUPNHCzAsZHAiWFMV27qM8E7oqJz/0NimACZWRjcMQbZ+dY5sS3ASoBk1Lc2iCPvggmfIhC67IbiSxBtkaTfY5SDAkdIIRsSyTDcGx9FCplDXcSGxh11g1eJklUYL6FtFwXtw1XJAp1iLQmBj8xB2rwoKblknLo8UTxQgIBCPMOb89fEeM18Ztt4uVsIobsK47XKeDWzQh5BQbWIbNlYtds7krHc2FsFaLdXI52Nbq2NZ9uxO1tlStnM2tvJubtow1manldUk7tJer2Zn1WVf1n0gNnRaNmZR9mdjbmmZNReyb2qptmqt9mqxNmu1dmu5tmu99mvBNmzFdmzJtmzN9mzRNm3Vdm3Ztm3d9m3hNm7ldm6x/7YT6PZu8TZv9XZv+bZv/fZvATdwBXdwCXdwh5Zoj7ZnfRYpdJbYntZom5aGglZoZTbgEFdlbzbakJZieRZyMddpO/dxQ7fbLjdxPfdzkYI5OTcXkNVkoxZ1qRVqX5d1q4lmSxdgM9djT80SEc4BRfZ0NRd0Z3d0abJ3W9d1OfZ2dVdxIzfCXoFfFeF4SZdpYXdngVZmofcdpHd6uVd5lxd4g1djBaOBNuhCZsoB7uMpeDV5r7d5rVd0iZcNhQ6bPoRM0Bcg1FclFNZYvbdrVtZycRfOrrOBuqkN9SC/MgY+vqAcCq1g27d6HVd2F3Z8kaCAR+OAmco1F7hH9jeM+v/3e6kXgndqgLvOPEYjhrYzQnzoxNbpf+kqfGP3geH3SEp4COTqHFKYJRhhSDrYgT+42phXhDuicbPNTghYHBJlT4jkINxCDzZY9SY3akp2hieYCaKqCIYIMpU4vw4JPZ4YiiP2h6HGhcEYhI2CiM/oHUrMC1IiHmDEfheMg+LYpci44mD4feN3ZtWY64Cr/N4YNOM40rqh0qRJjO+4cv13c6dYj4P4kItYhvN4dfHVkKW4cC35kunWRCRELQSECDD5k0E5lNVWkzd5PiSkkCk5kQcgAFi5lV35lWE5lmV5lmm5lm35lnE5l3V5l3m5l23Zk83Al4WZlYF5lYf5mJH/OZmVeZmZuZmdWZmL+ZlxGZhtN5XBx5ilOZu1eZu52ZmjuZtf+ZvBeZzJuZzN+Zx1WZzNmZor1pqvGZ3hOZ7l2ZfVeZzreZ7xOZ/1eZ9h+Z7t+V/t2J1TDZv5uaANupv9OQLgIAMoAA4qAAQkoJUxQAOE2Z8P+qIxOqOR2aIVegAY2qEhWqIpuqIBuowF2n8IWqNVeqVzmaMjOgAaOgA4YAAugJUlAARI2pNZeqd5uqdb2aIDIAJeOqZnuqYD4KaHmZ1l9KTf2aeduqddmpVjOgA2IAIC4AIGgANc+QI2AA5wWqgV2qhdGaifuqzNep01eZaFWqqNuaqvOqu3uqsH/+CrJSCsY1mpkZepWTalz7qv9zmqYdqYI2ADgvqlW9kDPECmNYACIqACKECWydqvJXuyoTmtZXmtA5uVB7uwXxmxFZuxHXuW8XqSpyQlbqq0lFenKXu14xmwp7oDsroCMOCVZdumMQCz79qyWXu3ebuXgRqzXzu2Z9uVa/uob9uwcxuVrWUvulgIiCj4Lle1d3oAHrus6zoAqBujXRubPWADNKADOjuxZ5qxkTucdbu3aRm3nTqm1Ru9sfu8Xxm4udu7wduVPXu829u8lXvxNMIIr+BNQHIX3vN2pVufRYCvx7q6e1kC4OC2FzqkWXmit/m6s/uiE3qhG3oAKoCVD/88A2CZq72asyEbvlnbrS+7vHU5wze8G8a7lSvAqrOZvVG8tzkawx2awz36w+Warml5tLl3pQzsxfwbYUdjddDg5ULTYgscnxkcwX9awRccxte6qG0ap7WZwqG8oCNbmre8rDMcxmM5v1Mcm7PbAzw8sOtbmmXcvceaxP95vxEDl2xzyKmgnnZCwElWyYOZn6c6rrvhsZtcAjqgA5qcoju6ArTala9bxN0aqxOdlTOgG2ZbAuTawxu6qzWAA7D6sTFgwyO9wY/aqqk7A14aqfW5y73ZzSl70V25owcgoilAAwZAA2Z7ouEgAkA8x125z7NbBL47ADIgsVsZq+FgAzr/4NJnXaspfaGB/aVlm9gHwNhlfNPRnLdR/Zl9PIyNpA9w4zfI9UasQbO0Tg/aGFMsJHp0tVg2Ap2cu+mSdkaXHJ/7/LBfmrobe9CruqHrmwMyPQBAQNhbedExe7PFHNgJWwJgnaYbGtAzgNo73ZUz4OBFnQKw+gIq/q9VfZuv/alZnZVbfK01wKonmtCtPADM/Kr7vZV5vbo1QAQ6YLFjGatFYOGP2sMRPrAvgNRZubjfeuZXea0zwMODnsYznpuz/YW33XxNppEqq23+kg1OMTI6EihIqFDOD+aA4t3hfc/3ed53frhH/cwjwMNBYNYjAAMsZMMVXcpfGrY5gOc1/1vWNTzU3/oCpjroHX7DI0DuNxzLQx0EzvzUiz6bN96pOz4AHr6wLx677b6rJeDtLWS42frJWfnfE7+VOaDJBwAD7t7mrbridT4AZDvzJX3NY33xd7vwmfnoA660ukJrtqrpi9NL/0mYkJQXlk6vB/+cvd7kxdveK2DQXxzzszrlYVngDbu7f33YB0AE/L3vP1/hjXnoN/+oK0Dmn5/us5sCKsD481n1kxn8efrwZ1qrPSCiQz6ol9/kgz3wX3nlPT7awRzSCRu2OX/6Pb/uGxumaR0IMptAZ4ChDAIRSSAg2Xia0im1ar1is9ptdQDwJrnicRMMOKPTarV3DTgUAP+G9mLxNQAKh7e9MFBA2KHpnSEkODDEASgMWABMILhJTlJWWl5iZmqegZF5fjZJDIxiTHFUDGwMUDiNSnQgjWYojQ7MSokaRcg2idhW5VZUOEUEXAxcIDVlzO6mDgdDF682bTCBYouZhV1hDE/53sZWiGh0NB1zYG1nt7uTxQ58S2WMWgdQaAxolAZzXKgadUHKuAC1BgZQhZCgPlRHwjAjZgzZBVQb+OWTZ0TZkl7U3oEMaYVdFm9UwjUZV+7cRHXrvmxC00bNgVEJ5pypcyfPnjkDGPxRAHSUAkIADPmpZaDmAASRYkKNKnWqpk4ir2LNmrWDBlZa25HsNi+UBHP/KcPwaxJhyEurX9/CjStXSse5dq+EFUtFQlmWygKkVcK2bdSZVA8jTqx4MSa3dx9DbgdicOQseauYlJKuQil8YUBcq1CMMLfKpk/fvaBBBGq7lzGP3dz5L+gmorWYgWqYMe/evn9Xctx6OPHiU15Pyax2SN2/HAbAMkvaOPXq1o0jTz52rZJrzqHnY0lYN/Dy5s8vFn59PXus2ZsoD4DqoGcpGyJEtAyzdPv+/v+D8h58Y80nUH3V4HeLfrtlwiB6D0IY4RrqAVihhSPtV9I8SLAkAQgHKlFBV7hleKGJJwIoYADKcRjKh3+FOCKJDl5Co4Q34vgbhSjy2J6AGNQy/0oU8HU1yjdFjIVXiT0y2SRqKgIZ5JArFilPE0hykVtMNubYpZdU7eikmK2p+FWZY6KZZjZnmgkTeV/CGedUYapZp1xsureknXvyOQaeWWm5CZdyElpoGnT2mShIf4rEqKKPOuloo25uaaill7LxRZCbctqpp5+CGqqoo5JaqqmnoppqqvuN8mAtrKoaq6yz0lqrrbfimqupsA6a3qu9SgIspsNKKKyrxFJiLLJuKLulATgFa2mzck5bWJzV9oZtg89yia22y4Kb2LfZhjthuZXqyO0k4/rGLo7u1nitvMANoO661p6bL3rwKsZvsfo2SK+9zEoLsL/JzvvlwRMOTP/wmwBDTC6hCx8bcXBoIDAKAg98MVQCeTj1kwMJ0GFHxk1xXC9OCMThQAOOUDqxwfsm7KVhJ2/csU0gZ8zAyCUfpXHK6rIMgMswx1yVxUv3WyjFNDMdrRoITPBFHAVEgrUCLidAck6CFFK1yl4kEEnZMhWs79Pmwrm2oG5QbTXIIG/dQNdAYyy2umefjfbDUQOOLrUQu+3GAxxD7cACtdhRLwBnG2WI1wDUoTjjd+DksgEMfMxJ2vkW7rfCCVs+SuN4QL7HUXd/XfoAp2fewOade/534LfHK/PMEHZdMckOAMDA6Y9nrbohcygg1AK/Bw97GwUw0MChn58beu2jt43/BvPC75R6ITcFJfz2zp8BvfTT2467+lIPvvuDvUMtlMbDe7/6GwM0ILz8TZFv9ACKXE93oIMa9gq4PwTQr3jfu1/+FnDA/jngf5lK3/oqKLqaVS9C8DuP9dBggAYA74LtGyAHMZijDnoQhBMUnAVbGMDsuQ89GzQPCoNXNfQ5LYb0MuG7IsSAG+LwbS4cYg1zpzYN0o6GNqNeuTpYxHvBcIkUHCLunngxHZoHBzio2AmZGC4n8vBGVmTblnRlxjOiMY1qXCMb2+jGN8IxjnKcIx3raMc7eouKLhwjFI9YQT6+MIzIAmMUpWhIIerxj4dxnLgIZ0FAJk2QxCJkAQ/Z/8UpJjJqvZqA6oKFh0ZiMXCQhCT7MljCQnaJlJFsTCYVmawBdJJZn0SMKvG1vlF6EVyUtOQlecnKVqqvV0ZJw/4cx5QDOOABQ4FAHoSGsFAC53Bc7KGhasnCHaKyl6m0JTBFaYlhogECqqsX1hyAiAJADw0PaADHJsDMPpLwfUksDy6rCU3e1DKf2fxlN71ZCXAu8A46yYMDIfCTu9XiKaU0pTynKcZcLmuX29znvzDZz3sOIpZngAAzH0BOBJizaOXbGDuNGE8ZzhOb2hwhQ+kpSQipMo8XBdyggqSANDygZ8YcBTKTMoCP+RRsDvNjQwlIzRwS1aUUragvTTpTi/9ZM5BfRKJDmSrAlqq0qVZdacCeyjQwcMpVQeIVHstq1rOiNa1qXStb0bhKp3p1ZvwxjaQgZde74jWvwwmU0i7FSDdAS5aZRJRr9KTXwyI2sYotrEzTQLJNqQGg7WqYB3fDyL/+U6NybUdd3FHXxYI2tKIFLV+76gY4uEGy2ZrlGgLLiU9ilohf2EKBRjGa7izKsKPdLW97u9jS8nMNqN2fAxn32NfxTGST08kEaoE4NRRTXVhrgMjmABR2Lo4oP9mZAU72MTgcgGV7yO5PjzjXK8CILtfwrG596973wtdOwIUrGlAbiEWwE6C/0xrXlts4pLlBnK/FSTkdwLI54OH/AMOTG9YAYDcAWEB6B2DATcG5AAaYVwwwcsYAmFAPUjghIApa0Gzja+ITo5hH87WEjVB7MpsYJQFD+UPkWEe5PmRsASGcWufGxpMzKBhaOrks6hDACJui9scFoG5TMsyF77CiswEQghOi8ByXkPi8Kd4yl7tMpreyeBL2FWo6j1I1C9DYeOBLHvfQYDePspajAIAzgfegALsJ+b+vJZ6Dk5hkPTDCEZCYc2yHRdizDEgtTIiAPqwkgdEYYQuf9TKlK21pT6z4iqeNQzEVsM7XJSVjRVEzA4XnslH4DKA53a50a8HMPFNOu0WWA87eoAhCMMUpP56qlqvwHXV4QALH/2ANCKQRAF8sZDoV+oiaHn0VZ3BBytEexTuYLREyeeUT1n7Mtrcg7UtLIdPPxBEDWEsJ1f6m3E0s8RZg9OF7RKMVts1Se02DgUZLAMvHyXYV6tIRZ1vh21bwhRX+kl5sABwkRcj2MTaVbYFjYeFi+HAt1msQfif8Ewcnw0e6rQ1+ewLiwJiGV7rd8CA93OJvUU22czFiNYkbnsNCd1wP/YmMS7rekSkCazrggc5QweOK3sttqSByXFDb170GBc7b8ZyAqxy3Y3g6pkF+8Sk0fQwb91PJrf7xbBx9JF3HwrfDDhJneCUCFeiAalgjXzBrOq6OXHo2sq7s4RSh6EBaxv8sUgFiENTiObJYQpSMQA1vnDwDAOEFFbY+nwpwZD4bCAhrKDAfoDfBA7UoRi5e0YFcaAAfl5/C4gfwofm8vLMcZsLj1eH3SEsB9aX/0BJ2keyrGyMg1n4CLzKSltlTybaPD4DmU9GB2iMDCfym+DECUgrLg5j3vziO8/Ghj7T4vhT3tm0tFFQOU0Dn0cx/PeaHrpaKU6H4G+hABobkodI349EdvoaHuuAVD3zo2hNhBYegH2mK98MScEajFd2TwN24yd1m7ZXORQYGuFwH7N2U9V0xMJpBuJ3U/VsxHAMrmERdeMAsqIa+gcjlGVwSqN0FHEMxZAATpMX30UUFDMT/o6ldB3TAfbRIE7Rg6EmBB1hZV2xdXTxHlFlcBXzIAFCgDiIa8fUgBaid131EsJUBxlnZAHCABhTDvfncEtZfEq7FOdxHE54FyHUcBQ5DDjoBEyBBshmhEoSeFVIJV1yhOWyh1ElBEXAA4kVAFDjbGIZIv11DENKhYHhhBKThc1zABxqDBnAAGB4DCiKD/YXCaEjAiEVERJghPQzBE8Rg/mHHAcpcAjoWcp1BAjCZUG0T3TEWuxlHDYJABEYENaSh2tnC8V1DBu7figxDXdRW+W1dCUodNSzByRkI30VifuBHAACeFQrjI9pGZ0jAQ0BdonUH+3Xf1aUhQYQBZ4QC/wZA3EdoI+5FYhkACUIgwzc+IwWoQr79BcXZQth1HAfC4KZcgLM14r55Rj0aBD4mXzouYtTdxwZgQPtxHslFIS76oTRKGTvOwqOBwCzsYmcx5MsVJPHlX8blQyMu4wUwmpFcGzp2mAieRswtFCjWV/SEkEgNDipqnEoeBwM+BgXkGxHYIEVsQN+xQrFNAT9wB25tYaRJQC6yBSKi13m1CEdcAzCyYPmpxdp1gGjMYFPeliEGRvpNIQX84B9SIfE9I3QkhE0i41j8BQ8GQBB24/1VJdYVA7K5IaNl4Vgy2we2SBeqVx3CXri53eGVIebRIzMWJE6upTn8pXh84E5OAf+jzYIGKKJEDMBdwuNBuiWwWZxcSsG9jYhQmp/oJSYkhgjbrcZeQAEOAt2wfaX+ZZ5E0pUnjqScTIDPUEKSvUFKpYFrnhuGoQEj3Fnn+EEg7NgSsSQ89GYZuGRqFN8AuN8+1KRBGAkFcIU9dEAVtiMTRAk32sMwOKfi6V6y5UJdXokqQJ4JHqUQih5H1qEqaMBtdB4sVKP/xUZAvMh5dda7CVtAVEDfJecU/AXwlWUTnILfYdzmWd8+lALw+UMNWslwcuN6iUCSTJlA4GV4OpoG8iVyygP/Xd/zVai8VQAHVCf43eQ3ONuHbaBBGt16wWf61UJnVMA1lB4ySNk9GF3/NcqbRPqCV6gnhhobhoLkaTaWVBSaJbjWGtxZ8nDKLCXZnfnUq9QXAFWCa3LSI9CmITjAhMnLb2oYlU4auLGH0DEJCBTgpXGF15GB2aUIag4Vj5obYiwAEO1abN4a2MgmkCkpJVjAU3DNItSLy/TBO42OSsLfilRj6XkAEpBnjnZBcGKpiWjpoYrJZLhD24mJSJbpICAAdbGmQVVXvWwKI8xac43CA5DiKBQATnyqBGEMgA2TpZIqAhApAKFqHOBMynjMGUQQx5BifdmBAlyY7EwpFyBiCE4mdEBhGDqBaRaqzSnqsSKrpUEqGaVBgbEM9ABPIsyBIjiOpvJZI9QX/xDhxAGoqUzcVEaN1E2hlgXQJpyGq62lQdxI0JJhTIJtigqdQZNmj0ruIgZc5zceSH7MiComa7/666Ut6wo1q+ooGHm9TmBVq+NATo45wObA0gPghMMewHN9wbeWj+oMlH0paZJlbAG4zvAgTyGcaX2hGsWeIq+OGBEeGzIEa74Sa9AZ6r/K7MzyVsAGEbjeJrRWlkzATHmFVxo82EYtgGvdV6kO7EiFlMcOwG7+GUgZWAGMz04Mmv+Y7CTx6xWsqEYaCU0KyTq+bEsaK82K7djqlc2KUPm42kbVAvigQXYVBaqBFJP5TK5BrBfQbRqk6dEazXU9q56a697iD8s8kP+mNMUnzWkGUWmbhC3ZMm7j8onZShXNoUeQXgIDAJiz0EScDtLVVsaVOu7ngi6ikimzgquXrOZuTlazliuvEYfnhu7rwu56QO7okmQOdYpY/QrhttXu8m7v+u7vAm/wrsqO1u5UXRVW3U49IdVJZdVEVRJXBVfx6tLyMm/yapXzIm+7vFRVPZRFSS9EQe/0ulL4Xq+hGRX2ou9RIdL3RpTO+KweGNlQ3OqMcct1ccyruu/HdBeoFs3RRNX6nscMKRX5pq/4KtFSRUhMcRP7Wu26ShiFAcB93dkDQABtjk2CCZW6Xk0kNAAA8U0k/G9fFdUpEXAJY4pEmfD5qq8IM3D/A+MB8iTZi/2UIQxYyXxs9xjZH6CB5nAO7VJvAMOm9hbw8xrvARPxCiNx9LawX0ltJCRZ0W5UR/nYjUWtwnKwkpqPVBkwSnEvTIGv1ZJw+XZxAi/wEhdMQiWYInTaqmWMvdTB4FqxHDBZy5BqCJsWF6swGdtTUjVvCoexH5OuGdtTj1KCR1nsVHxQCNmxEpeHAPexHv9wEQ+wGOfxVt2xIA/yyAJWLWhuVPzQ2UryeeRADoxxJVPyF6fH9pqyF3svJg8xIO/xLZ0yJGevxBxx984yGwjvLvNyL/vyLwNzMAvzMLNRGbuyKrMyH1vvKzOz+f4xLD+yJTPyMd8yNB/v/zJb8zNvcTRLMy438ydS854S8zh/yqGQ8zmjczqrsw+DcjifIgHAczzL8zzTcz3b8z3jcz7r8z7zcz/78z/bM9l8TOLGbkHb1ewusiuDAUAzdEM79ENDdETzs0BzrkFbdGIhtDvLzABIdEd79EeDdEdTNEFfdEnXSUZr9JSG9EqzdEu7NAGMtEnLNGKhdErv6UvjdE7rdD/H9Ez79F3VtE2/804TdVETdU//dFInSlALdQ9xtFFDdVSvtGGQtFJb9ZgSr5csTudEGPAMlPQutFSL9Vg/NFVf9VnDHDtr8Y24DAN0EhzYJvuGNVnnNAk8tUcPAAkUtVmjtVbYXV8rrv8xr9aPOtbG6LAcQ0Ang+Jc77QOoMAojMAH7HMISHY+UzY+2zUBfEAI6PNm63Ne7/WhALYnAJ48EOpfj3aeZHUEzRJKClZwUFYaJIINhRO8fi9j5/QJuMAKwPMHyMBkV/ZDZzY/e3Y+g/ZRi3Zqi4EHANuUEJ1y34lar1LRzgHq6kZsn0HIkmLDBokpkiRu4/QHoAA9h8AohMAMwPRjD4AJmEAtmABlh8AIrIB7E8BlD4B6mwABkMAI1IJmc/Z+j8IHtPcorMAJ1EKBqzdvn4B6H/dOe8EoVzR0XwEIODfx+aczbIA6lDYV+l8pbDihSni4SbeDdDXlQMCRXeockAz/Hliq9ITa0Ijq5Zi4rAat5ModeL/0B/C2PH/ACMzADKCAZA+AZPd4fVd2CKDACcjzCoy3fRP5CBCAC0h2Znu2lNNze89AccuAgruADsgAZ8O0XiN371Q1Wl9kYcIgMVzZlDHBYkqBGbp5iOdcVp/By2hObTbCtL6W1pzBOrUTM03xKC7tqQWJ6th4zX1BURf5ku+4joc5AZgAlF+2kfe2C0A2pYN2pBu4klN5CGx6PJsAg59AcfO3e49Afj/6mA+0nGuBN4hgfjxaZlheiNiC4B2ELGaAeLA6zNL5I0DA2TwAU/wUwhrAVx9Xk/mYjNXCIYczjru0bv+2ZstAj/94/2Q/eqTX9w7A82UbeA8QwA5IupDrNbZb+QdwdJUH9whoew8MwKiPNwFsuTzLwG/rQIPrNFLvumfq+lLSoGisecsCxr0pZcDne7EKtkfN9oX5D9vuuZH1eUnJBNGc2WFrtLO7NAmod5DXt3mjd6ZD+YC/95FDdrhf+8ePwmP7t35b+pCb+wDw9wnogKUjeC3APH8/tpg7+OOsesGTnjyO5z7cBoZzwHIan3oS/frxPNgKdvDo8Ac1xbDPxE7hTzOZDuZ4QahRvDtbPF1zfdfDM74nfdhz24g3NW96/dmj/dfrfISLfdtrBVOXPRnfddrT/VjztdvjPVzAfdwfy9zX/f/fG/Xd5/3gq/bS871L+T3gK35OCz7hO361kf3h/0viL37ls3TjP37mB0jkS74XU77lgz5eJ7fmk762cX7n08znh/7qlzUAQHiZl77j7z3q60iis/7tSzTYx/7uj8c10f4OqXM6r33wE3/xG//vnv7vc3MSb7N5OHLtf7M3r5s2S38245PhK3/TXHMoO38Q2zLz5/L2f3/0Uz8ts3D2CzFL1fJvPH/6gz/5x/Ikw7/8v/8rHf/943/+6//+8z8QDIRDYtF4RCaVS2bTaQREpVMqdVDFZrVbbtf7BYfF4++VfPaa0Ws2QN2Gx6dveZheX9/xe6me7+fjAgzUGiSsMiz/PFxkbKxLdOyL3IOcxKskxJzUtBR05MzszAL9OyMVRU0lOw1VzXNdZI2TbYUdowXDnbV1sz3V5Q1GBZa7ejpGTlZeZm4W6lU1dp6mrra+xs7W3uYmgr4VDhf3FDYOOEdPV19nb3d/h4+Xn6evjzd2Nbff5+/3/wcYUOBAggUNwsO3alwaAwaILcwVTt9BihUt9kuYauJFjh09fgQZUmS7jGL0FEAgBUGBYAdYDmj4EIBLiFtkttk4MoCECBQHUCDI02NJUTl1HkWaVOlSi0QjVkGpkqXEmDU3SXRzUYIQDUDZCR3485zYgWA5OrVklOlatm3drkWbBkvUKCsVwASQ/yDlAQRC+A5ooABA3wEIHrhhICSBlcQDFi8YsvhA4wUzX1ZV0HgCAId9G0AQsjnBkAV3Dzt0QNMxggUrAdxVkKCBkKm+sA7wCGJDO7MByZIV2Lvpt2FZ3x5Hnlz5wbhdThYpcNdA3r0H8uJ1rXLzAJZ0+3RvMGUBg5kQADwY8EB1VQjmHzSIOR2B9dFTRqeuDKGyavODWcI+YDOsyjGOIw8yUMeDIXqKQIgNOAgAhCE4oKACITCIcEJ0MhjiggE2uHCnCCSo4AIQBwAhAAxwCyADBBsUQoKdTkRwuJtMKnA5HXfksUd0miOHCu/swksvyzgzwyUHIBOisiJTmmM6h/8UKGC2wo50I4H1HBpssZkS4PJILhNobAAFDAjMzCPx8u81Mw1I7IDDeLnxFRYtWrHEdCLQkycOBoAwAxkHEAEdDTAUQYMACGXnNwYrmPGCADzwIAAOulrxHBf/LHTEnWSkYABJKwKyEbV8RDVVVUcqVRGooGzTsZn2YilMl+4DgAEnpzMySgAmQOAuC36lFQALzNzyivbOg8nWWq9AYLNjBUNgvijWu7ayAtSMQr9g6kTjVIP4TMfFc3jCANIAKgyAzwEy+JOIC9zNoIN0fgMqXRHPqQDDnTDItMUM9G1XRqE8HNUn4orKcVWHH4bYoFZHmQtW17YdgIFinc1MCNb/3OAV1iiGQGC6AzzeawiWkn1NMySvfRYAjPsSbLTp1rzZoYyR9XhO2wi88yATJQVBUXT47KCDCiL4E0IPZDQUg0PZmfrHQhfNF1KwKLX0p1AvMBFeQCc1uCeEbcyn4Yjt8ZQ5r4LraW251ZkYC3DLuDkLmqz6+Vu1CepAwQEqeDuADkDUYOl2HeSgAw0c7KBCISpwHPJyhfAw630DMFGIFHcaQIMNEORw8LI5FxXtaP6We6vQC98TarjHgv0f4QSScHAI231c9rkvqhuRfPLGYm++0wb694MODCn4QMSdW7d22p4d66DiLsgDpytd0V/lz1r4qePH1+i274NzMOGh/8JPi/Xfmd9zCFAfnzp3QDt/V8XHB8B+xQs/DNGIGnQB10mgAwEzF4wGYDAaqaN0A8CQ5ITAuQayAwSV2gD20iE1e0VgNzCqAIQspLtFpSsD9tvd95w3B1ccQDDkg8jdFBK086FqhZRw39rypL4/AcVTGugJBxl1DuZdQAMckMDn1AEW/rULUnzyIeUOFwEEiq1TBgNV6taRgd1oIEWhmhSCjJhCdFBAA5IKXYzU0a8A9OtSELpgOiqQogFUalFXq+Gi2CcXR9xFZDN5IQzHIUNw0DCPPLrhJXIoN3Khg2AjOtui5mWheo3wQhQAkQTIyETNtc1c7RoYi1z0yNNF8v8cEdhfiVIHRktCUB3p2l1XOFe1U0pABJDy3+Q68EAEkYVe9jpfIvfIhwIk5mYnG0IgBem35B3ShsP8xCIdNrQIGe0cTSNbAIDIO2BqEwPwS1CNzvU5seirbUhTWgS+FjZsPm1fpvRQoUAAqW02KIy82UA3i6gBPBpOdD15oyMHYK/RWS8dtFSeMP2ggAZ4iQxoUiYCEuAtKbhwCxjLA/GWWQbz8agDrsvnKXu3NmEWQ5qrCtzkYFe6DcwvdBio3Ic6gD9RuS6EG/xfJ2VXQHttRXSkm1wptXiuyeFycrihacI8JC/8KREdRQOmAjOAvwr0EigxDWkwoWmTLCxAQLL/uo7MhgABB7CpTQWwThQs0AAHHMsBMyGCMqVQVo3eoq4bDRKdTroWAiZNcd2bW0l3YUhn+gicbFNXWTRY2HooFAt3eWuWolCfqChgJRRFDQDK+sIDVKZN15LrFNCDk7vi1VV+IyxHHhhBS1JQCOJURwYDINt1cLBdH5wcB5Yq0xJWFYUiESwcoMfY44BUffKAkSwHIoKBEncfjq0CmfrgJcpCST9rfesC+pOr/6QnCt6xaBYIswADEEYyhPlLYAbTM5ABADQZi6xp7dZRnXBRm1/EzT7JeMrdLGp/vmsjhtx4xAjZEXWFquNY+tm8rTJiuM6FcIQ7Al0hedYNRZBZ/0res5gGWMAB8JHCArpjhNJSIUwNNVZ4DkAf7NRmMNsxQDHfygAXy5eFzQwJKid3NlYSwXuayqosjfjjEd1SRUQIoetc6UtKdvMjwcXJXiU8ZSr7psEUg4qFwUpZ0kRhAhDoVRREvAYu3SWuNHHWkroMEyY1ycbzxfFH4hkhejIov7BFR9jSsc9+Ok62AQWy4ZYMO4Suj5CeSG2VFb1of1DYPuQZGXWv4J0ooIfGU7g0GBrg4hM7VExJKgCudAUyGb/5tHpNtEVsatTBIfVEQ83l4FyLonVA9ZRDyIAZW40hsWDVyYZOW6oZPWxiv8PRUoBspCc76T/miluafXYX3v8T35dxhjAbA3XHCrMr90bG1Fag71IaqdhnHpqrwi52utV97BALCA1oDcMEavztaMb5KMmtnT+Y+2sdQZkND1Z3wBnN7igw1NNigCi9+WbuiKBb4Korn8MfPvEIE1zhF+cq0LqxcY53/AhXPoQ0PD5ykpfc5CdH+TRALjyMt9w5A9oowyd78JAjD+aCNLfMMw4LnWMZHC4Hus/1iledJ4DmtSiOOHq+C1MNned9w1HQpX5jZsbcEkaPxNKpTiCrNx3qq3v6KlI+drKX3exnR3va1b52trfd7W9nhimmPveV17vrkcC63ZN+cxjm3Ok2B/vP6R50rZ8a55Z4gM8cDPj/qh/e62GHfOCjPnigF17ojne55euedaLrXfKf3/vkKd9yzQsP7qdHfTJ6kXrWt971cN+8JEaf+XBTnLj4kLjtdX9Iiy+8KrOHM2p371zcD9/4Eib4kOadCpbVwXh9r/3xtQpw6VcfYsm32PKHFybgg9ve1v9d8cE//oTGfmQVk4p0qDMrv3iGWuzdGVj70JjHeHsybmaZtjfTGcC8VzSkMQ0kSY2X0IvW6K7YsBLtY5jvI7+IEb8GhMCHST7oUD8jWbHrkA8XixY36I4/4g6ZCY8QI48DcI/0YJlleY/4GAwWs48BwA/32o+X6A/XABB3azzbyL0I7LfV08EeTBXs/0u/J/k0mFEzNxNCX5mSKvEYLHEMlpGoawETUHsZMkkmiFITbGkT2ICTAZCTG3y6HPRB5HjAMCTD5ADCuiDAWRlCyxA1bguzkZkOYBEWYjmSaTnBEvw9NIMWaVGTakkrLOwssQokivq6LyxDhxnDQ1REuDA/9lE+scoYbIMZbfuYI+wDjzEZlIEr2sCZMnMZZ3mZmVETm4GZ9kKSnVEAZDIMLwy2ocg3gKCegACjRUvECItFggCOgLidRbSH3vuEEsOS7hMfVAOIUFEjknjFfZjFW/yHWSwIDqggAhKCZESKWpwb11GudWBGf+Ck6zmI3Lmpc6At4/NFUwHG5xPGl/9jQH4wogX7EWqsh2UEsGYEQ3nAgBTBpgrIqrewRuWRHnbYxn7oRnIzCO2ZlEoxxsXSvXJMR8wjRoH4E/WhKaDgKWgUgkoBocbBRjmaHD6xkJCCoKrStalRHISZyFBBHDLarZASnCbKSHboAEBJFH5ro55wHBHAHwTJpRfhCUA5EQPDCB50psNaHDUaSQxBoZzUHyHonyFYkRPBEAGqqRg5IFF6EfmZkddyIKdcl9ZSSgsyMOGwLQ8qypsaoZsKyRPSkOmTO1UIr4aMsnW0BwtZLHfCGnTKILK8JgK7oFDht2UsEcfhNTvaJg4qSVHxgP7yGrGQADw7h3hCJUnxE77/BEp0SCLe4YrC0Rd90S+B6gAouq2wEMoa2qF06KGC0aYg0oCYxCP9usx1YKJHcaIoSpoMqiJOQU0JyKLjCjQvWpc7m6X9WpczskyFZKMBgyOgnKNFsaMhyiOGlAM/ooK3hMtXkEt7UJofYyOs+aQImCoF2QCAQbIM2aYyYpG2YSOxiCRROcwL2M7F1BTYQiKn/CR0Gc90OJwaaZt5ws+uCM828jEMeLV5gZoLAM8f44d+/J1xUxF1gSQtEpVfaiUMwKQF2qS4KacngpruDKX4JKV3GirMHBwew40JfaVwPBeFLDJW0yVeMqhfqiHojINiYhNkEoLQqk47iD57yACz/ylPIqqUHkInxTmlECIwdYhI8+wgqElPr6in1WzMxTHQIIVPgSmX3YhJDBhSpjlSdTAj7wmofzyaDTCaw1pO5iJQdWDQBB1N5aGmojHNsXGnJ+2mQyFKIoKt18xQ1HQiv1InUWEnORUqpWIU/qwn4PyKfUzRdfAzgOrSFSEoq1KHQgusRlwoFDuDhFOJibIwQIIDeBPG0gO3ejzRi0TSj2RMqlSgqMQ1Y8wfdDicwUFPXvOKo/xNALoADrAQC6GAWfykc9A1C4GpE1EcqbocXCvKB1GHmIybpAKhCIWaVQUIBYWYlBqclXIQlzoUX0sqmyIj/1kRnbJMqgSdn2qRoP8CUfVZtSNrtVkbqt3CHFdNrKdazVt7LaqSVF+LUUvtqq+SNEgcALIyq4tJqxRrKxfcxBtlA1DtPlFlIVL9nSTdh+wkCDOiSZCgVl6MhzudhzUFiF0cNoJLNskKq8q6LM/KrM3KFjSsKBwdA4YFPoeVBIiNGFdVyHs4xoHYAKfSiYzV2K9IH7bJTILYt4cjOOlStpK1rgXALgDQLim4tADMsJbVAv77jNC4DjeDt/JSDMqT2fOj2Z9llTYV27J9Mn7Nskv0hqjYMADosA/LmzHDGCIARilwCPlgQSm4D3hDsbXy2h01W7fw2cAlXCv7hbnQsn+dW8/6sjccMzQAxTH/KRMqcaEicFnSA9zCZYrB1dzO7UW0pQKkJdnqogJLc7FM+4JNm4LI3UNjMRO+Pbqp+1qy9dzNpd3axd3nAt0pGNktY7YqSIxAUtkvmLbVlUIuEUXKtbYlHLzZpb7cBbawhd7atTivWtiC9QJ5y1GFuM7pxdjb9d7wbZTd5V1MfSj12t5YyFzxjV72dV+SIN/0dUgcfL36bb3Vs9/81d/97Yb4lV/ycV7Tml1FAr1CHB+/M+AFZLxh/F/o47q7c4S8e7zQY8XjQeDIK+BOONwGXqYA7rxJkODFy+AFPmDPK58Ebh+x498VZuEWduEXhuEYlmG3a0sOduAKtuCri91S/xjhHq6JCyZhBfZhw7PhheO7G47gHcahIRZiJK45FE7hIFbHIi7hB+5gHeY8JtbgDxZhDD5hKc4rKrYKkZvhGN7iMkbjNFZja/BfMR4kNyCAOJbjOabjOrbjO8bjPNbjPebjPvbjPwbkO+65533fQgY27nXjMYbjQGbkRnbkR4bkSObjQZYyQ7ZkiBO9RF4IY5DkTvbkTwblTqZk6b3kUm60NtZk1ArlVWblVnZlAhhlU5ZlBtvgVN7kRX7lXNblXZ5kAMiBHOA8Up7lYb4HVLblL+TlZFZmZb6CEFZfYSbmaB7fWo6EBlC8Y6aYAVjmbeZmVm5mJVYkaJbmcR4LY/8OBGvGZkTr5nVmZ0j+5mAm53g23BpuhLm1wXQe1XbmZRLQ5k8eABJg5rwA50eo5FnORXmeZnp2BHTG52xeZh1AASEYgQ/g4xCgaD226DzmZwL4gBDY447e438OaGeuOXEmXBCYx3uBR3kmuDZT2C1Axy1g6IY2PWU+ARdYgTj+ABmo6It+5I3uY5DWY5FO5neOJpM225xtlJWOZ190gFHjgpjWgpmm6YdV5g9AgToOASEIgRmA5YgeABMwgSEwAYsOgRFYAbImgIweALA2AQIggREYAo726LgWgg8YayFYgRMYgr0G65w+AbAmal6O5WhmxokEnQXqAItMsJccZl//vEBIZIAHSA0haKjI4FpZcQm+kAKqrmqwveqcnuMPGIEZmAEUoOgBoGjSXuuLDgEUOIE5XoGsZuvVHgECcAGK3miQzu06HusZEGoZAGwX0AEZ8GhYBuiiPmNpZka7/Am8jAC9tBTKJObeG4+3Qo/DWIADyKxSdNvF8NvJuNzPBu1kZm3ZFu0PyGmRNoHbzujW1mkXkGj4Zu8R4OvY3u0QuG85NgHBPgGhlmuyHoG3Ru6Abh+kNltmfE8K4FAD/RDxHIJ5NWWLQ4kX6pXy+hXAWJnuOjMFJO/y5uWb5mmOlgHSNu2JLvD2XusdiOOM5useIIAdcO/UBmgV7+0P0Gbe//bpEWDxHhiA/85qAhDuOZYBntaBwd7lwibm5qZSCtjSozFS4ZTlo53p7HavgkWPVBQQ8w3GD5+vfk5mEgBr1F5rrvbq+iaAvC5r15boGU/x287riKZruJZv1cbxAZDrE9AB+fbrIdBzuY7o5Cbs5a7uDjFNVKVIVeVKY31s/7VRIYgxIZhsnRmAyhgNx8jsYvFyh9bnTvf0PL6CX4ZnhCb1z6XmTT/wT1f1VY9jo246BC/1S5ZRVMchMGf1W2dnV188WI91Q551WidoW8f1YV9mXX/mXkd2YzNnYC8FYSf2Z9dlYy/pZKf2dfh1ZhcuXIb2bX9laQ8FXq/28L12bP//N23n9nMP5SvAARwY9XCv9nEn93Axd3Snd0lWcndPdniP9xmq934XZULH93xf9n3P9jV+4TM2+IRX+IWHglMneB7GYSOuPDD+4vlFOi3uYoz3voe/eC8GYMKjeAr++AnW+CcO+cvjeAKOeEWehMTL4opf+RgyYZGn+S1WYYbH+ZzX+Z3n+Z4vY4VOeYK2YotfBJLu+Cge+pHP+JI/epsXvKBX+b8j+kMw+uc5eaef+iX2+Cau+SmGeqGPeZkH4YE2KaYneaVXXyi+iq33+q8fLJ+/X6yD+7mne7ofeLfXUWf3973/Y3Vnd3AP+MDXI4cvhrr1ck7m+8QH5DcAfMH/x/cJ9JJtIXsrMPwPR3zFx/yQngPH5/yCmEBI64vJ9xWCv/zMN307ZvzOV/15RuQpQImSsYCTWYyZeQAzg6/KBoz2ei8GcIAHaIztmk70cr8K3AvhBwzBiL/FmIAhuOZvK/3Th/5W3/zVp342JXyUKADtGo0EeI/D+DJkGwAL6G5S433uKqaoZrEMJP6ZSP9YAQ83GJaJ1/voz/zUr/77pwfsu4vwcAwgSAyGA8TjQEwAJoNGATAwLIiDhQIyYCgB3C7g8DQMuGBFFJBAfMPjNdQAECsKiKrDi8/r9/y+/683NkBAWGh4iJiouMjY6PgIGSk5qTj28AAVoLnJ2en5/wkaKjpKWmp6ipqqusra6voKGys72yoIGKhHBwDxNJDw0IDJtcAA4ODb9TBgZlDAcIenW9AATcZmDaV0oAYW19Z9NqHW1aDkdIuern4rSOn+Dh8vPw85lqA0QKu/z9/v/w8woMCBAW2tg5JrHBdkBYgsMNCgiC8xQxa82ZWk4RAlvPB0E4NNIwNu19wQQWDAQcQsDoBVOwgzJqB29GraVERi0M0BJG4+soePoNChRIsGkBDBqNKlTEMZXNdGpkyVL6V6ObNnwhOrXLsi1OmzkQ4UQ0Z8eBTibKO0jHIS+BDCEVxHPMM2Apqpqd69ri5ooLCqg4QhGzqAQso3sWKAT//VRfUKWSbWyJS90rSr6ISLFYQ+yECrNp5bSHPv9sRcCU3Qxaxbb4owBLCqCxI6dKiQ9BNi17x7o2qc7nHl4cSLG/+KWtEHFIhCDAkxg8AAsgNMmCBiIm2IESuwE2A7fYgJAiRGEHkbt/yQD9eHrDhB5D11zieo102OCG8+3/z1DpDNCWwDbMBBAANgUEEGn2yQ2yYeEJGUgAQKNoQGAVBQwRAYBAACEQX2ByJRwKEj3HEm3qIQFwVscSJll+FXyAecGfLBCDPMgMJZA5xV43dqhYDCCYaswBx4PI5AgAtnuTWXkohcN0NpMtDngg4yxCXdaTAWYgkm+4UIplD/dcL/wQAFZiCBgR6AEsEGnURQwQVHRVDmmRJQMIBhmmiwoQgWDiBCmIIONCI7LR7KRR0K5MEAHQtYZAEDEBCzKKJdvbhlj0POKGOWBJiAJFs+duZCWaPWBSp8QjIZgqqFmGDfCaWZh90I43m6JZdXDcrrP2NygqAmGBoIICcZFNZJBgrOGeyFFXA4gAYRXEDFABfAOUAGevbKbSyFzmTpiRAhsBUeU5RrRonhxoQpjJp99pYMNd5olqegfrcDIWzB1wMBO4SqY0/3OvnBIE2GNkK+PQwgK3METGmIDJ/pcF+u0u3abcbeFhtAnQF4kOavm1ywwbJvVmAbbh6DvEmZfm3o/wmfGs+8yrd/qOvHZHqAA0cfFhhhlQIIWODFo7rg0WgDjwIQKQQHMFDpupJBYXEhJFCX43fPRYcqku1l92NZANvr9RBkoUdeqTsWPIB5J+hQqnxEvG0eWVrm+tiXNO9dioDZvklYgSJrggEVz27SwQbR4haAhBzgOYSCGA6BsgaEbct35qDYnDNUPe/Bsx9De2MR6V8sQ8YyFBXRM0TQHJPSAETnkSIAK0rNVbtV7847ZnlrDnzwwmfMeR84G//5zr0kn0cCxXgzwB1TWITEBACkq4AcSzwPgBYqjrPAAbi3qHvv5p8fz+/Dr89++60Vz4e6BYDhSxtLZ7FRHHUgw/9zuiwVbT1vgEElDKDeAagxASRkD3UQgEAXJuBAAJCLC9o7x/iIUz70aXCDdAEADnCQF/eJcIQkJAj89iA/lKDBfhYZwBOmAYByMK0BJvmcGWZHhi2IIQ0FCB/1wpeAcqiOCAeIWgLEtzoiFMAlF8Qg1TgIxSgyQj8lrKIVr+gthBxEfuJb4TBaCAc5VEsBPDtCErxwAB0uow5H+KEQICAHOQTRiF3Ug1aa6ESwSHGPe6QiFv8IyEBuTotQyUUX5aCAAl5EHDFkUQ2JYQxkdGEBAZTD/L7wwxgaII6om8AzuABBPIYrg3wsZe/8KMhUqtKKJ8RFHi6ZugYo8iRh3B//Sd4AEYk40nkURB0ZMtnLBVbqAF30nigRRUpTKhNvqgnhKp8JzeG1Mg/HM9HouOK6YyLzicvsJu9QGc1winNm08RDNY/zM2HIRGg41OaJkunNePqkS84cpz3vCaZyXsWd/OynOaFQrYAKdKAELahBD4rQhCp0oQxtaN4cCtGISnSiFK2oRS+K0YxqdKMc7WhBCekYf4qUn+e0VEn9edKRGm98Kd2mSl15nJYaR6bFoelwbLqQl+qUpdrEKR59qlOgXoqkO/2niYQKGaRapok+VWpRnxrSYzp1XVPtZ1VhctWlQhWkNf2pVy/YVI+KdaxkLatZz4rWtKp1rWxtq1vf/wrXuGIUq1ut60x7ates/uGD5OOpO/X6zsAy9at+LaRdD+sivNYVsH24R19xx1ipRPauRyVsYSFLV8RqdqhSzSuiHCtYqU2WXYsN7WUxC9bMbna1pJWra18L29jKdra0ra1tEcpVErF2t1uEggB+C9zgCne4xC2ucYmLT6Ecd7nMbS5wkwtdgjh3utT9rT67MNpDgYS3uh1Adb9b3egKBLzkPa54z+uP8qo3uNfN6SuJEMGXbpe74PLueu8bXPT+A7/31a9/Z8Hf8rY3t7ZTg9DKNdL50rdz9g3wev/LDweXF8IUboWEvzvgFHJhUnSowyexwBIhfPEL+9tGExaFhP8BHOAOGhnAA3IpQwPsrwCJHAIE/PcMBS84fr698IQrDGAfhxfIRDaFkKeb4YQAABgJoIMCVNLkTzZKxABYGjFXCAdy0cEBDmiUMj53jiCqpFxOy8MNdbxjXDT4yNQtcizYPF03yzkUcGZukt9bEdt1EQEJmIJDqGzlkoBhabZbQBq6YIZKLcOXEmSRGTeC5jT/c811Zu6cXVFpS19605rItHHvHI0UwZLPzqgGIhX5kW8UYMsOINeXyfFCalhwF3WE5DESEGlJY7fHnl4up1fRa+P+etPBHi6ovXA0Fe2ZI2dEgiypJ+gnpHjFtiPCiyMS45XQmAE2zmUdcJ1dlPL/utjIHTYqyD3cgODJ3CVEN3CPres0C8Ld5WZ3Kej9XBCkaRUYsNyBQLFue4sQ3/CO94Lnje/8CpwUCRfAEPatChBsKAIW+kTAF84+ghMYXAaXNMIbLgCMj6LhjYP4yBQ3ABCUHDZy6oSfOjG5IQSAZENQeb+HkJQHDagDHED5mkTeH403teMeH3fCgU7no0fA5JrwwJo48Bc4cUwTF6hAoDghrQvlw+kd+4sEVK6JNhmGQW1CeoiErlqir0sIpeOCGWqH7Ph2QcZV+TjJze4Jki/dExWAmQQwsHdPQB1mI7OW1gPQd038nQKKkwAHMkCFDFzgQRsgPN5bg/beql1q/0+jRhecobPPM+AAbV9yAyDwyV1TGt+X74Temf6xp/8n8AGqwIc6kXXYxL5jIvNABsTuCTi13jWZN6w6cs0u5gVH+XhIZ4sOEEC3L0OGiUrApJqHABRvBRhwgGVOV0/v4W+i4VRoOdVRrnLabyJDRLB84QaUD5qn/CiUK5DOD+Q3y4ufL8WP6vGzGnp8oGMBiAejszpQc4CLwgQVATtd4GrcVgXGsBJQI4Gfk0DbwwUWQA0WED1e0IDXIzvdUy4IEH12d3T7d3f7l1z9FxwHgXxYxXzsEINcwEvegGJwhDoHAAEauCgPADXX5w0OkADWowzq1D0BNAGlA2UgCAekl/8oCIYG2ecGptd9dfQVIPdbKpiCKnhPLKhbr4QAEfFJ0+YAIDFBKmEBQTQENEYEHzYENNRiygCBSiAEeTY/DSFiNTYEcABiqTcMlYQ6dKA9dKCByaOB0iN3x6BOrbYFGkiDNPRLZiAMuvBqtjN6pQcMqPcSJsh6KHiCXNiF9FZwBcZlWoYAXNYoIHFohwZ9ZiY7TsYFlQgFL5QiQuAAgugNtLYQzSBlCJZGwdRlD7EMwWiJTbAVDWABKpE8rTgMKoZo31AtThBQzWCFPZQHBuCH34eFIeeJnQiK9uSFhvJKXUR6hNZDIKGM3oONKnYJKeYLhBaFVwEHqwiBywBLZrj/BVHgZ3nWBb8IPSxxgC8BDEQDQYfGBcSIB0BoBurAADPIYNuohZ/4jeIUjhwXDeKjAOXAauSyXc4AiV0wKbbmC7C4ZJNxBodGgkxjj4c0Bg1UkrxYFX8YTHPHaD10B9xXko1CQdSHBhEkKRn4kTFldN44fFs4kdFUkTeTC/CVOipWhm1wDFuRYkbgbfzzhtU2BK92aBqhKPdoCR52BiAmSTT4PNozkxRUj+XCbZWyj1Xgg0NAgUtQencFfu4WkUR5lNCUlJ0zjreQTSN1TSeijH1Vl+h2l+GXl+G0lyvVl4DAANEnUs53IswYWIVJbodpl4mJlKK4cUq5efQlCLcl/5qjSZqlaZqniZpy1Zl8+Zm8FW4tWFo79po89lexKZSDhZun9YWtuVuzKY5b5ZsmpZu5+VSvGZy0mVrJaXy8uVrHyZpQ5ZyPJVpEBZymhVrKeZ2OkZrbyZ3d6Z3fCZ7hKZ7jKVBpx5yaFZ3ICZ3yNpzYWVTGaVnZOZ2ad56blZ4o5FmHkgM5IJ1URZ3rWVnEKZ/+SZ/1iVj3CVMA2iKgFaDzqVgKSlnu6aAD+psGelgISk0ARZ4byqEd6qEfOlGryZgWeqF4pTeXt40QOSiexn8pim6jWFcvKBUy2p7TeaJ456Igxyssuhc5Sm6j2GJyl2AlkpE902JQ+Ac0movC2f9ZN2p2PiqRYMKjegGlwQakBjZB8iUcGsE8HBiTfaCkSppYTdqNVXqZK5ppLWqmlXalG7YAHfY/fSiELERiQ2BiDYBidspi1gZjSiBja6iHN9aGTxkIzJNsj6giUDOoIKGHFgGnz2BLLiVKglCma9prO5qmPWqpddamTOZkUFZqIghoBoRlErRqp9hlSzQZYSZrZGaF0mcBkTYZ6QIHfrYAS8iTZ9aSFpGRD/Cp5SCmkYGhk1apm1ppmHqsmmqsRwakDqFn1deWhkanqWYN5mhoCpFoC5Gt1ZcM7ghuhYoHyhA1yvYzS+atZkgFTbZswZpUJlqsy8pmyFpnagqvF9b/pp+3bKEaTIkEbUsKBhupqmAWa2MGkrVWDLcmqz1zAHDAgUYIghMkkt8KhMpWfWLwpRHqVU6KdPWaqYIypU3BsT52rxTbaBiRP86GatF2Ok6JlS7Wp3GgbYFald+KbM56pHqwAJ43s4xaj3OwbF1WBJKase8asgFWAiogr3BGr0WLXzBKojs1rPuksUDHtOT1AjCQAsZ1tEkbr8patffltE/7UlGrekT7tVo7BFlbXFuLpslKpWcLtiKqnmJbnO4qfnBbXQOgtsFVAkSAtBRgOTLTIUPAAfJnMm/rtiCLt+oVtnQrUmT7fWa7uMa2t79VA3orAFubdf3WAYDiIAri/xe3p7iJyxSTK2Byi590+5ZB6wDuOK6TardFabp2VrkC0AI28FtHSy0tZy3Yoi3spyFL27WIO7vU1bituQByF0QjBblfIbnF63C1e7k1IAAxgLS5pwHbwie+xxofW7rQa7yom6D+lJGOFBkQETUyVkCYkEgIYGhWFbutB77E1bdDcAPCdQNDwAJ/G7gY0AH+VhjyZ3heq7QEPL/HdbyAQGWe8weUtBBDoEIOIJYTcIGIej0NYKRKRLJVZhFMIIRqEETtBLtkercHDF5ce2TCa8LElcA15ZAgCA0MQUMM8EnYKK5kYD1c2nwdeAzDlGOnSAcPoBIOG5+pNbUit8Lfhf/CQqbCScxe4puhZgaBDkSGYsBtwVCHVbZsJutCEgTBD7CPc/DFXlCD2VCSylAVOimJ2GWoCqGToIQFW9FDzvifQ1vCTuxcS+xjTYzHDgfFRpWQdcRqqXgGTggS4VN906B9XpCSZwAMmBBKn9d2yLAAKAF3zvCsbPyMk/GmO+yBBCihPHXEGNfHedy282rApezHQ0c7LGKt27U0h7xshDZA+whGK3QSyDbJX3zDn/wAfCaP4epLnYyVMUYEkNlZJCy7qmxep1zAxMvMq2yeGybIqMqRdAoSugARTWbNK9KBs0Q0j6wHZTyW3UOB2LhhDOB5mvwFDOtiXPDG1anM8hv/zcLmzMM7uvU8ioG6sisGyxbBqB5WDkBbBNsGwRbhZ2LMj9IXw45ERm8YQBzYdi3mqBocSa/7nvGLovVcXHp8YXyMxy3sBzDEB4wYEw5cHN4nz7A7ygvH0R19zymcyqUs0nuQLkj6wHQME+VLHOhbovO80S8tXB4tYSDtxDXtuCPM0iDK1E3t1E89nn+8T0ldt8m80ifCoLc5oUpd1Vpdo0K71btJ1UH1oBBqInxlnUxa1hndoF99KMPKymNN1lZt1q7p1gRa1zdVxHhNoTMB1X8N2IEt2INN2H89zXItbnTd1aB516Nkmxjb12od2c+J2I+71mx9cI0t2ZgN2WHN/9eebZGVbdmKzdnchaDN6155XRlRy9oCKtaiDb+FLduzTdu17Z1SvWuwbdmWKdS97dtZGNO/XbxIrdvbxNvCjdzMTNTJfbbEXdyEydzRLdTLLd1F69zPXVnHXd3bXbzUzd3wet3YTZffTd4r7N3lbanhLd55hN7t3d3B7d7Lqt7rvdpDGd/3HbLnjd8uOt8j9XZmhsHxqMaMBrX2vd8Hbqn6jeAg198iBXrKd0nA7DrwmNHaveAX7mlHC9Mei+Gb2uDH1A3VN7FdoBKI/EvrXLcW3uHJ7QMqnmkaXm9hsuLpjdupXbNbgIeAEOKctxWH6KXv9TnKgNNja+AzLt0qMP8EKQrj6QbfRs7gNU5gDfE836ZTIe6EpmpOueyOBE7WLu7kQp0C4IfkA6ACNBDmYd4CwFUCNqC/LDAEPiAAKQADAwADaa4CR2sDL+DmA3C/fOu3cT7ndS4APOAhhhsANzcADWLUX86ZcY1sCIASFoAESsCVL4Y/wWASc6g/RHA9EGg9/EyGJguH1raP2vAEa1xgL9lL5vTC4ubljF7PYT5ca04DNMACJRDmJSBca/4CLzAAun4DKiAAMKDrLQADNKACLPAC1Xu/V0u9lou5Gk7stnvsntt0oKsBHPB1xAfr/A3lKdRDECAEv4DpECQGTdivXawLDWA9IOGS3Fdm34P/iqdaKbI4ScXQDS1GBNRIk6xeWq/e7aos6/jb5yVwAwPPt8IevZmrAr6+7A73Anf+W2xOBGn+W7ebuw0/AA+/8SWQIb9LBRjAeAPgeIsR8Cl6pWZAQ75QhxD8zzUUhdmKjzkEzCNWaPBokCqyEre0Bw2Z2QB/8niM8GpuA7VuA7i+ejAe7cI+7SVw7BLP7MQ1vdXL9Lru9DTAjdt7uJ9r8kH/5I7+eWrQEb4gzqvOwTB/aOfQELvgQF8W76TYavQei1hxQ0vA82rHiV7f22M+ABYPXGNe5kOf8daVtRou53Ru57ouAHpOBA//W/k7APsL6IhPA3O+cwJMG/XX9Xq//5hz+z1XQekO8fKhs4oQPAZ6+OlT3M93kGKjnpVTefdEl/ecT/s/xuG1/6LffiiHSt8ZCvS4D/zAffvB32sfPtJv2OriPfvEz/wbLuPN72nG3/tWsfzQb/3cOPzXz6y6P/2D9fvaf/IKDv4Yxv3dL8rjj/7ij/5IVv7mb6PrD/7qD/921v7u79jfP/9GLv/5/2lAABgAiEXj8ThELplN5xMalU6pVWt0OBBsuV3vFxwWj8ll8xmdVq/ZbfcbHhcH6HX7HZ/X7/n9uhwwUHCQEC7rSghRcZGx0fGxKWtgkrLS8hIzU3OTs9PzEzRUdJS01PQUNVV1lbXV9RU2VvYy8f9KCRI3V3eX8ZbXyveXN1iYKCGh2Ig4OYkZ2Fl3eVcauoi6uhYb6dqJW/sbPDqcyXv8qRz3GBr9l73a3byZGb49noh+GhHfnr8/m3+fvYCI1Dkb6OjgMH9UEkppiBCgQH2zKFa0eBFjRo0bOXb0+BFkSJEjW+lbeBIluYUPv7FE6dLWy5RQYEaKKDHevpozeUL0t9Ngz17mgA4VuqSovJw3iZo8+nRc0phQlVKdIpWmTKv3guJc+vXZVrHJJJE0exZtWrVr2bZ1y+kfw7Fz62kpdBdvXr17ufjx+3cPX8GDyQA2rIdwYsWADk2l+xhSlsWTKVcOdBizX8ubCWX2zBn/NOjGYSGXHmo3dGrVlj23zrMadhrXh2PX3ju6ClbTQiXb9v378mzhwIlvEQ64ePI3uOXudv4MtXLp07scn029tnXN2LmLYX71eXjw0buXt629tfnU6Puod//doXMERwogE79NiHv9q9ln3r+5v8D+4w4+LKxCYAAFmJjPiPruw4+8ASVMLEDaJlyswtculK7ArKAyoAEECtiGkvkKqMS+BxOJcMMW78oQOThSYNFFMGC8o8biOjyHqgUWKIBBJIIkwkEVrckvxyQHuXE7MWpgYZIbwphRyTGY/KNK23bsZgkgixDxigNGBEBMIQwAwABuHBhgyDUNWNOCJEoE4ERK/1J8sLcs9WzjyvbGaIEHAWoYoAYwqNzTiz4DQBS2LW1CwksiwLSiTGXOjKIABhq4lE4GFzhgiSHpvFPFPBk9tTBFETODBkK7SMEGSgR4AcoBAn1ykhgEiGESFmjAdQBd3VMU1dQcVQnSIMGsE4EHhGBgEmQWsDMBO8WcNtohEmhgkjG/LMDHb4lIU8EGvBW1SCNXLJbdMFRdtQwVAu0ChhIEoDIGXWuAIYUSWODCXxoEYKEEfwcktt3NjkWqS0sKeKABZyeAQIgRC2jAiAUYIHPMMgc4M00yJ1giTQdAdADNSx5uAGV1s6Ix4VPf1XAMGliQsosXBnjhXi1saGELFf9aeIFXFlq4oZIbiB7AaP0QjpmyhfFL9ttq5/w4ZQUunmS+Sj0GeQgDoD3A2SKwjbaJCbx1mUuYod5zZjzISAEGoL+oV4AStMhX0AFSANiGgL8owQan+3w76rjAo1rSlcu+58wJEFBggDglF5kIj+MMuQgIFijCgQbipHNjthcxFXGZ47aDDKQpwXmLFnrVgtZJAtV7EqB5zR33AexW7+nUCZO6qiIiBWBZSj4v8cwDuJ7P6gTKxLZaMrl+fNsiKH/cdOiEL3Z11r+X7fDxByNeGUWw7p4n1M2vMnws3y8j+PnxQv9IfThlXya37b8wfnT4X6quNMC84I8r/BOP+wz/uKEALqqBNipfBAeBQMUpsDQMpODBArjBRE3Qg3KwoG4wiA0NhnBYHUShAOq3wjaMsITPOaELu/NAF7aQhmqAYQx3M8McUseGK8ThD8+wQx5mEElEBJ4KUThEJZLBiEd8TFneUkUrXhGLWdTiFkVyQQNJETIkXJxYxGgMUgmjjAw7SRoj0xWwNOWNzQEjXdjIo7GksSDzgONK7ujGPf4xHDqZ4xT52Mdq5JEsgGSKVUhYRzXGERw64eIkKVlJS14Sk5nU5CYx4ZRBGrIfjvQJNBBZDFEmsJBbaeQio+KV3HxyLqd8pCpLpUhXUmWVtwykLuMDSzKmkpZ4siUkn5JL/2K2hJdf9CUjhcBJZz4TmtGU5ia96KFl4jKJFHzgNmF0Q25+E5wwiuI1j+LD94UTncMRYjrZ2c7MjJOcPTGn+dxZz79405751Gcd4BnPmcxzfPsUqPiaOFCDsrOf/uxfCA8qUHw2FKIPTKhC+ei/c0bUng/F6EbfNVGxmOsIEKCYugD6PY66U6MnVak4q2lHqCBIQUtgwNoAMDGXlVR4K01nSnXaU+149CQgmpQRIFAJZ9WpW0bCaep8Cs44HApVTZXqT1vKJaj46HhHmOkRbErSbEZwqtucGyVUMCWL5iisaW1NP483VCp4bURY4xwTnDcJBsTUTXCSKU27qtSvNv9QrfE7wwtg4ANDnbVGgVUsYNiqLJpKoVLW2F8TDvC50I0pUp9aAkiJOlK/Itaki53ZGQbFMy7ASla1s5WgaqWr3fkKWMJaomhpm4fGiotZzhoAtAYgLWpZC1x20ha3BrC2ygJAARFr3LgSBADOOpemIr3pXw1YW1WZIVb2ope98KUvfhlsC4IjGHj3Y13z8rOqj6KPwyAmMYoVl04YM9vG4GqmlGEOCXXdLTLSxF6WSXGpiDtvAVn1My7ojGdUMrAAhLY0o7kuSg7+nXkGbN7bNs5qXLMvubbGJo5lLq5gQ9PYuHdcOg2gZUhQGxgD/LYK36h19iKsdreAN73tSl//fgOc4LxAOMO9WLQXRp7jLFXTyVXOyPjV3H0797kimPhiKb5mi6EG5AyRoQWxCpYXZMc02tXqdpTQnZh7N+HyWDnI6UUWfRx74kksj2vNex4Aoje9bFmPTSUu0Rl9SeWYoTlAPAV0U4HajclSVCGgzemg0SNoRuu00JE4NKLFoWimPto6jsb0SSNN6V1aWsCbVmdBRe3TTnsamaB2caldo2lWQ/TUqDYhdQf46vSs09YqjbWs10Hr/+XaP7gG9kZ3zWs9qrrKwzaMq5Wtz2Ib25S+tl+zY0Rqajf02dCuyzS53W1vfxvcG1HzLLU9zF2C0hkP4F60W7lGdKORlec2/7dLyz1vZL47GaWEd7uBiU09JlMbskTlK+t9THkHk5R8Vgi/f4LvhRt81hDvRrgpXnGLXxzjGZdmwTnecY9/HOQhF/nISV5yk58c5SlX+cpZ3nKXvxzmMZf5zGlec5vfHOc51/nOed5zn/8c6EEX+tCJXnSjHx3pSVf60pnedKc/HepRl/rUqV51q18d61nX+ta53nWvwxwWXxf72IE+APYkJWQFABVU1jeXyILj7dBuO2UfS9e6HyHu+b37Y/o76bnMdSZqF4YCELT3NZ69CUiFrxXSvvZwCN4JlZo75G3hd2HkPReAB/HmA+94XVC+EXO3O2QNz3m6VwP0DVp76v+tsNVHYF7vpoeE5u3xdtbjYgKeLyfimZDVKzReKJK3PDCGzwvYz54Y9cXg7fUHhePjvfQfjnz0ccF85l9hU9p4fiNof5LrOwIC1P8J77s0pDoxQLcJQICTkUsJBphsCKBPE7Sa5eb693b9E6DEAxTA25EBCUHe7wF4y7PoBFQOgLfYj86Ei7eQQfD0bxK4B6keAEHy7Gy05nrcbABABUQGoAGQQUwOAAHAJHRGBwAsQL6I4AFQDAHfDLn8LwkqEFtKp6h2C2Vq8P0qMEgyTHoS8AVd0Ah08KgogQMr8E7SJE0SILcAoAaLi3LORP0MkGNEsP9cEEjsirfiZAl3K1r/KOfNIHAAuEcInwVtqnASOGVNuEd0WnAAnKyuDkDKymQMJ3B67oqoKGFE3hBlJhBMKEdrKpABshBNjJBMEtAL2zDDFuAQfwRUzs9Z2FAB3Qz9sCVItidlVtCubnASMIYO46oBAeBsjgG4JFG3PrFB7Cr91q8I5s8DnSUUs4d07K/EfBDP4NAIDMAILbFkygSpihBtuLC3fnAAKAYHpcwRMyymdg89qEHxVtAVQWUYmYByLAD4VjEMmRAC2qum3mukkIwIpAtiDABIFCB0lLB06OMAObC5nmxM4MtLBM8bjWAFDw0BRgZrtHFiVlALQQWktsUBEFBBojAKQScM1U9r/yjmANRRAcAx+6xhRBZgcp4wU1BmpiYSAGaK9rxGIT0HuZRLSCZAH6XwA08wBVNmRPAx/CaHY56QzkzkAO2QI5PrAcaRch6SbJTLptzRJe/BBEPFHi1mPiBg7eZupggvASCGTBQSSBzAAVxP9upxHtlRsxpEJcVkKZvyYdquDxOEJuFLs0YSBZMya1KvWhwA8tTOGUExHbOmCNJSs0TvuDiSCKZxHFWw7TwGKDOGvjomK5+xYjpFHq/xLQswZZpHATWmHJ3rKHGyABNyLBGAKZ1SMUmSTD6HI8UkKgUPLDFGJ5nQ8SzSKd3yAMUvlMiPcVpyXOZD9B5AvxKgGpmLSP8QIMM8bH2ucAEcQDYzRwnXTjYXcr9U78P80AiEDzUFzzZTbCABwAHOZnmgsBJkk0HUTjiFQAEqJXTEhlRmigESYAHCLzgTJDfJ5E6wBvI+5mza8DwXICP5sv0ID0VAhzkHUjotIRk5ZzbXzw0LgCWjUPAqpQKjpTzPRO3u0774c/UQ5DbhU3kKdD7Cc+4mZgEsQEQQckT8MFzoRAHFZDmVJznJpAEaIBmJ4EKvxcnApUO3UmuGUkAP4BAnoTorlCvXLgF4K0aJ5AAGEhe/MxlxVDUnC0T8kDXt5EJRkx0ZNL40DK541EiLQElFj3PCpcNcUkIXcE6K1EJLlP1aNEH/frS5xEQ+WZQ+sSYKwxMUK4H9lHT7Dm8ZEy9I0lIo7UsvlbO3XpPJGGABtFGyjuADwfFjII9Ms6o/YTRED2BkjBT0RtIuL6UsL3J54gRPAcBN+dFiWCayMqUkiaQBPudDH1FQ+XR/yFNFLZJI3s8apUzJOjUSjQHFGDVSJxMJOOdRrxJMglEEpbBS5NJGIccAH9VQz5EIEHUBKbI5UdNT5TFEmBCkysQPZdW46mNV7TQqM2cCIDJEmZVZo7UyTyxFdVUz70RZubJ06vEEwdVGW/Vbk7FVRQ95EABUNEZOlVAlIfUuQ6wlpzHJCBXE0hUKh0Rfj+BJFRHJLodywIRX/62UKyETN9cGWCWFXfP1Gt90YcU0KD+TVI/AXEkTIEyTzU5xt3TLR7kFQVwz/jyvv3ZLQZBqWEMnE83w/3hTCe0EOM/VCKJHYg1QZW2QY8OQt1QRWzDQBSmRA7llJCNrTR4rKi9HR1k2CVZUV5sQGZy2KT2MSaPlXM1wHYWRZ7nGF6UWNolEeaKWTSzGrnayUqx2W+3LOBe0ZiGmDYmrYrF2WKOQArlwskDKArpUUGsxDvVzZz+nE0Gx/oggakMkDyfBFiewv6DlbEF1EJFUUNn2R7gmQSA3bTtWRzkW/eB0ZuUKZGl1EzWQNek1CutqBKlUesTWcmsWcz3WX5UgXP9I11P+SwMzNG/18BZ1UFUvxc52a2t7FDXNkBhh1nhQUfrYTmOdoftKCFeb4GS6Z3kRIU3JTnpf4niZIXnZp67s8AkYoFDVJXtDFHoxdnrHlyiql3zPF31JzuzWNH3b131Dbn2piirqZOmeL3oVgU4ZwT3FtyWK7wj29309Ln6tYyeuNwq6z02gAPLuN/T81xEMmCrsl3+pIH8XIfemAIKp4Pu2wYGL4IIRIYMDWIEG+DgEjgpWEFN0bx46eI4kWBgqWBG8s5xYmAknuGtFeJBIWDiYEQG45f2QsLdyqzulNWSUdipl8x8/1xo7JQBx881wEW2guLiUhxeJFxIzR/f//vNz9HAAJ8FzKMFn70/92G+IRSYRhTF4PTDtRhBnl9B4xCRBihF49VYIZNCuOgULJ2FzCPGKmRAP/Rhnm3Bt1O5EfDOQ/3gM8U89/1MKpRgZwPABtiWpVlFoRdFFn8wHCbm3hkBpNbk++TiTQQWSldZqz6QYb7GSkXEuUURpu3gYcbcYgVjhcPg+dHg2eJgpRSRNTpIxyWUFFSBkGNIAjlhkTfW+xrEcOWczoeuNHdYvHZNcxPJVI+YqK9JX75ExhYAwfflqy/JNYzOm1pgcPxAlqVJASXWmvrlTIjOuHjIi+/SdbXIywxKaD1ZBrBKdC6AubQ8Bzpki9RlEixd5/+xxpEAK+JY5HvEVCfqRUmnqACjGGYFExIRZovUUGegZosMQHk1QmL+5T/PZCBj6H+tuIin6HDkHNAtgl2mZfWzZNZhx7SrLPp+TY6b1vsLzRom5pjxwbapRNos4TJNxgeuDQXJUZplA/VwRS31zOwuUptVVTGx6RsGYTIfUpy1Zw5q5TJWnqrEUbUNVRQ1QS1+0PUc0uJTHrIFzq9/MrDfUBbFGOBtvrI9TbDbwcaYzQeJO8nYTNnGar41grPfaOBEUN+3jRh10mM1Ue9Yxrx8LMZHHsBOAqUVWRM00hFnaOVx6rRIPVJKLsiHVI43hQyc6o8VxPkAkRX55if30s/8X9rkyxZk983KRlknjlVmNRzUdNbQ1l0lHe6DHdSE/M16vumBzlXRSTJ1vm3HNJEBF0lsF1Vrf9ra1WlTXOWEX1U7hFKROxLk3K0WWd7sbGvqAG/KCubRZb2HL5G7P9lcTwFM9tbpDelJH+gimEhvllVMkelWr+7Ix2zTCrvcogWLmCmUlZe2KGAbdU1NEFghhk7U5R4pPm7hWpg2r2HJltqmVgQj1Fql8iyvVdtIa1v4SZI7ralNGVlIccEG1GpB7q8QNF2WWu0/DWvAiXEcHF0ygFloIV61bPAHAVkTMUBXXx2qgpZF18Gbfj3S5pwOH1qH/uLw5GQZZz8b1y2L/4NBtHaCVAxBrnBaVPRAEe7oS+HYS/s9OojYo7aS//ZvSNtg5QseYh66wF4KB38qG2dzq3BzPh8FwT6LOp+DP91zQB53QC93QDx3RE13RF53RG93RHx3SI13SJ53SK93SLx3TM32KXkHTO93Tr6KCxuL7kpd+vyHQFViFmUtdncOzq+F+V/0R+m4R7nfNV2LSAA+Af4+E9PzokM07Es/9wDceRj0YPiaBXZ09FYH1mE8ymWDNeT0aDm0Buvfykp0mWBjaL/LOixTWl1gbIFwnbh3FP/gcxF0YzjLVm87Xw4CHiYB7F4LYlwCFsUH5qi/dG9IJaj2QJoty4lwX6r3c/38B3xWB1utI3zmYZHxBhgP+VZMC3alu3cGg3RNWFkG3yUGwAkXQAxWETd7sjgH5h7lQuXqxcYNRiotditnPlSnGEevY43frGzPxyz+QB6/YDP0WjpMxBEVElPdP8NSPUyjxjIEXd/VQlpsZkpXhE3f+5ulswkEe/nb8AS6QSc9xCUmeZCq5EBucSnvL5mnRGj4xFHc6Ah9w/4YTxilRGewY5qG+xUMMeA8x5CkLxgGZE/cPRYHEh7Xc/ZyYTRC8zJnYBuU+xs19QMG4GFf+bBxTZAC/DaURBo9+Lv1vEQHwkG1Q8ocu4r+AGRcUJbFVpB2zWs5kVt1ZASQyn5GwMv8zkx8vGmMMGuU1D7bt0i+98p3FEaSLIPQ7ZiM/RyYrejjtcKPfeEbBd+682fFQGmExcvGaOR6VYVILUUFiMmIU+ri1XfWPS/TARQUZMySZL/QVcjh5P2uon3vcsSTdNR6Hn83Ymbf/klpR/5/3OcTUebGpURqqWZ/jFVuBAFEAKAaKAsLhEAKaRYth0IwCIBDAo2FAKhyNRJM4sAAGhjCaWjgADsMCwwFgFOBos1hRVFAhC2LDA1qYFZZW1BBaYdYWGwCXVwKcHB3i4CVmpuYmZ6fnJ2io6OjggMApaqrqKquAVCYSwAIDQMLA7QBCAkLYXpORGwBV2xDe2q/BAu7/wMLwwsJu01rRsu9wmNm1E8QAQ0K0MK+xo5ky7p+T0a9CMHEewrKkI1r7MRKzQ0HD2CVeAgMuBbrCOENXoNkrNPbgLZCD7UwUdong4UpgAOCBB+ZuIWzyrMwZhehs4dLF69E8NL7KSMxDL1GwPRRvgXkozIi+W7zuNVyIL8zHR3/w3DlzDORGZkGDmRnY5MGBitrQBD0YtNbJJkz2HD2wAKrUV1ScHpCnNQFYmiAxqWETLOkCBdy8rSU24c/YeJjIWkwYhu/Ro7rgTiVl+DDixIoXZzLV6jFkV5pizfkaKMwDogAavGngINgwpkbJbYlD8NWzzIIgsPmChvMjvyAL/0tDoLoKm3HIJmGCre/zhCYxjfhRmFJ4oqNNvsCxFdImguAWiM+LIgeJEiGFlW+uiQzABF7til/yw3sK6qFk0Px7evnpgNVsMj/f3PnzkJXCg7vbQ77fGeE9AV5W3XHnWm3ZFVPfWkeZcd4jSSyxIGtA0eLAAH0tl0iCE3IB33NexXYEGwp8MQsAGPYlRx9X0CdYAiiquBZsp6HkDoRhxMJPOJf1gU4YNTaxSDayVeHig7TcCIAuENLGGJRRSjmlYY5FdmUqRup4kkB1nBPbLQ8YsI9roL0i2pJ4cENTQbLcwgAbBlDEC0kAlWLAVAVUBCYDgui21poZpkEmGCQlMP+cHgDdQuIl9RzgxZv5sGGLdw3qZIQCikLgAEDi3fLodo/u041Dv+h0RjuZBhRVLquF5dEf5ijQywAO6cmRm7mwwZ0whPanThiGIqrqonec2oZOSYwaxxqQkkrPp3Jo9p2DZwSaAKcDNMCEGcRCMGYuGVKRRanCRYustmDGF0U3OOFyBbjwYNspFcQGB2O8gppBbhpSHDNeRbcKKuscjtSrqBH89qJocIXZawgzMFbxKpUVW3wxxmVgufEpWmb8Mcghi8zYtBkvwJ8mxTHA4MgtWzwBh4vx+nLMjHnB8iAwu7wzzz1XbCXHkXnsM9FFG31YyRibWGkYrDIw69FRGz3/s9ScTKBk1VlrvTXQQT829NZhiz022WWbfTbaaas9ctdeswL22nHLPTfdddt9N952t+22KnBzkrTFB6CcN+GFG3444okrXiXfkA1NdVFP9ivNcZ/cvDjmmWu+OeedG7134x0jBjhbfndyl+epq7466627rnHob0/mlqJ/EFskEZpSQ+qcx4DrGhLwxPGApk1Y0MDrySu/PPPNcx277LC4FSd1yPRR+RPDHANbAp5BwhzW6Tg/Pvnlm38+0tCv8rhb+RnhFO5OYcGquK9MAyxOjugiVzc1FYE+AAMowAEqD3ShY9+v5IIkPEmhQh65UP2u05r7SKw2xkMeATOowQ1y//Buy/ggCEMoQgQi6gHCw5238jWvXPjOVzASWE1Q18EZ0rCGNrzhKC6Hwx3ysIc+FKDgfijEIRKxiEY8IhKTqMQlMrGJTnwiFKMoxSlSsYpWvCIWs6jFLXKxi178IhjDKMYxkrGMZjzjBkeoxjWaDo1ufCMcpdRGUMxxbe2IIx7zmME6euJxA7gCk2pWtjsW5Tt6PCQiWcfHTjyuAa5hQtoIaZNEUrKSnVvk3yYjBM8w4VZ9Mo6e+PesNSHPk36iiDloEQV4NGBNwSHWH4I3SlwMYU4aCQgeWAWqdr3Hkr78JdowuYnHKWsBQrjNAlKCBKOYhg4fwkJ8ZJGbIRhTD/9FOgMCJtVA2wXie5JAwKwIGZ26PEhClcglkICpznVmTZiaICaYCgAOORnHI8t4BpDmKY7RWO9MQ8hLwPQXI3S4wQEbGUpIymGQjsginex8KER55s7GaFIrAyjAbRxIOWmYpjZQy2hu+Dkbf96kCul8oYSEYAtKqGc3KS1AmyIq05mGbKKYgGctLsonQehoHtdCVynf5CeR4s4dBwsIjLK1rQIQCwGxWlQuoxVTmlK1qnK8qlWzqlUf2rQfW/0qWGnY1VKEtaxmFeBY73DWtbLVeWnFRlvjKldFYnWudr3r4t76C7zyta+E02sZ/CrYwcYNsIAlLGITSyXDKraxjj1QGmMfK9nJso2Nlv0gZTOr2c1ytrOe/SxoQyva0ZK2tKY9LWpTq9rVsra1rn0tbGMr29nStra2vS1uc6vb3fK2t779LXCDK9zhEre4xiVjEAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     NOTE:",
"    </strong>",
"    The recommendations above",
"    <strong>",
"     must",
"    </strong>",
"    be read along with the footnotes.",
"    <br/>",
"    The recommendations in this schedule were approved by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP), the American Academy of Family Physicians (AAFP), the American College of Physicians (ACP), American College of Obstetricians and Gynecologists and American College of Nurse-Midwives (ACNM).",
"    <div class=\"footnotes\">",
"     *",
"     <strong>",
"      Additional information",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly indicated for adults ages 19 years and older, as of January 1, 2013. For all vaccines being recommended on the Adult Immunization Schedule: a vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine's other components are not contraindicated.",
"      </li>",
"      <li>",
"       Additional guidance for the use of the vaccines described in this supplement is available at file://www.cdc.gov/vaccines/pubs/acip-list.htm.",
"      </li>",
"      <li>",
"       Information on vaccination recommendations when vaccination status is unknown and other general immunization information can be found in the General Recommendations on Immunization at file://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.",
"      </li>",
"      <li>",
"       Information on travel vaccine requirements and recommendations (eg, for hepatitis A and B, meningococcal, and other vaccines) are available at file://wwwnc.cdc.gov/travel/page/vaccinations.htm.",
"      </li>",
"      <li>",
"       Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available at www.vaers.hhs.gov or by telephone, 800-822-7967.",
"       <br/>",
"       Information on how to file a Vaccine Injury Compensation Program claim is available at www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. To file a claim for vaccine injury, contact the US Court of Federal Claims, 717 Madison Place, NW, Washington, DC 20005; telephone, 202-357-6400.",
"      </li>",
"     </ul>",
"     &Delta; Covered by the Vaccine Injury Compensation Program.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     <strong>",
"      Influenza vaccination",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       Annual vaccination against influenza is recommended for all persons aged six months and older.",
"      </li>",
"      <li>",
"       Persons aged six months and older, including pregnant women, can receive the inactivated influenza vaccine (IIV).",
"      </li>",
"      <li>",
"       Healthy, nonpregnant persons aged 2 to 49 years without high-risk medical conditions can receive either intranasally administered live, attenuated influenza vaccine (LAIV) (FluMist), or IIV. Healthcare personnel who care for severely immunocompromised persons (ie, those who require care in a protected environment) should receive IIV rather than LAIV.",
"      </li>",
"      <li>",
"       The intramuscularly or intradermally administered IIV are options for adults aged 18 to 64 years.",
"      </li>",
"      <li>",
"       Adults aged 65 years and older can receive the standard dose IIV or the high-dose IIV (Fluzone High-Dose).",
"      </li>",
"     </ul>",
"     &sect;",
"     <strong>",
"      Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       Administer one dose of Tdap vaccine to pregnant women during each pregnancy (preferred during 27 to 36 weeks' gestation), regardless of number of years since prior Td or Tdap vaccination.",
"      </li>",
"      <li>",
"       Administer Tdap to all other adults who have not previously received Tdap or for whom vaccine status is unknown. Tdap can be administered regardless of interval since the most recent tetanus or diphtheria-toxoid containing vaccine.",
"      </li>",
"      <li>",
"       Adults with an unknown or incomplete history of completing a three-dose primary vaccination series with Td-containing vaccines should begin or complete a primary vaccination series including a Tdap dose.",
"      </li>",
"      <li>",
"       For unvaccinated adults, administer the first two doses at least 4 weeks apart and the third dose 6 to 12 months after the second.",
"      </li>",
"      <li>",
"       For incompletely vaccinated (ie, less than three doses) adults, administer remaining doses.",
"      </li>",
"      <li>",
"       Refer to the Advisory Committee on Immunization Practices (ACIP) statement for recommendations for administering Td/Tdap as prophylaxis in wound management (see footnote *).",
"      </li>",
"     </ul>",
"     &yen;",
"     <strong>",
"      Varicella vaccination",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       All adults without evidence of immunity to varicella (as defined below) should receive two doses of single-antigen varicella vaccine or a second dose if they have received only one dose.",
"      </li>",
"      <li>",
"       Special consideration for vaccination should be given to those who have close contact with persons at high risk for severe disease (eg, healthcare personnel and family contacts of persons with immunocompromising conditions) or are at high risk for exposure or transmission (eg, teachers; child care employees; residents and staff members of institutional settings, including correctional institutions; college students; military personnel; adolescents and adults living in households with children; nonpregnant women of childbearing age; and international travelers).",
"      </li>",
"      <li>",
"       Pregnant women should be assessed for evidence of varicella immunity. Women who do not have evidence of immunity should receive the first dose of varicella vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility. The second dose should be administered four to eight weeks after the first dose.",
"      </li>",
"      <li>",
"       Evidence of immunity to varicella in adults includes any of the following:",
"       <br/>",
"       &mdash; Documentation of two doses of varicella vaccine at least four weeks apart;",
"       <br/>",
"       &mdash; US-born before 1980 except healthcare personnel and pregnant women;",
"       <br/>",
"       &mdash; History of varicella based on diagnosis or verification of varicella disease by a healthcare provider;",
"       <br/>",
"       &mdash; History of herpes zoster based on diagnosis or verification of herpes zoster disease by a healthcare provider; or",
"       <br/>",
"       &mdash; Laboratory evidence of immunity or laboratory confirmation of disease.",
"      </li>",
"     </ul>",
"     &Dagger;",
"     <strong>",
"      Human papillomavirus (HPV) vaccination",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       Two vaccines are licensed for use in females, bivalent HPV vaccine (HPV2) and quadrivalent HPV vaccine (HPV4), and one HPV vaccine for use in males (HPV4).",
"      </li>",
"      <li>",
"       For females, either HPV4 or HPV2 is recommended in a three-dose series for routine vaccination at age 11 or 12 years, and for those aged 13 through 26 years, if not previously vaccinated.",
"      </li>",
"      <li>",
"       For males, HPV4 is recommended in a three-dose series for routine vaccination at age 11 or 12 years, and for those aged 13 through 21 years, if not previously vaccinated. Males aged 22 through 26 years may be vaccinated.",
"      </li>",
"      <li>",
"       HPV4 is recommended for men who have sex with men (MSM) through age 26 years for those who did not get any or all doses when they were younger.",
"      </li>",
"      <li>",
"       Vaccination is recommended for immunocompromised persons (including those with HIV infection) through age 26 years for those who did not get any or all doses when they were younger.",
"      </li>",
"      <li>",
"       A complete series for either HPV4 or HPV2 consists of three doses. The second dose should be administered 1 to 2 months after the first dose; the third dose should be administered 6 months after the first dose (at least 24 weeks after the first dose).",
"      </li>",
"      <li>",
"       HPV vaccines are not recommended for use in pregnant women. However, pregnancy testing is not needed before vaccination. If a woman is found to be pregnant after initiating the vaccination series, no intervention is needed; the remainder of the three-dose series should be delayed until completion of pregnancy.",
"      </li>",
"      <li>",
"       Although HPV vaccination is not specifically recommended for healthcare personnel (HCP) based on their occupation, HCP should receive the HPV vaccine as recommended (see above).",
"      </li>",
"     </ul>",
"     &dagger;",
"     <strong>",
"      Zoster vaccination",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       A single dose of zoster vaccine is recommended for adults aged 60 years and older regardless of whether they report a prior episode of herpes zoster. Although the vaccine is licensed by the Food and Drug Administration (FDA) for use among and can be administered to persons aged 50 years and older, ACIP recommends that vaccination begins at age 60 years.",
"      </li>",
"      <li>",
"       Persons aged 60 years and older with chronic medical conditions may be vaccinated unless their condition constitutes a contraindication, such as pregnancy or severe immunodeficiency.",
"      </li>",
"      <li>",
"       Although zoster vaccination is not specifically recommended for HCP, they should receive the vaccine if they are in the recommended age group.",
"      </li>",
"     </ul>",
"     **",
"     <strong>",
"      Measles-mumps-rubella (MMR) vaccination",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       Adults born before 1957 generally are considered immune to measles and mumps. All adults born in 1957 or later should have documentation of one or more doses of MMR vaccine unless they have a medical contraindication to the vaccine, or laboratory evidence of immunity to each of the three diseases. Documentation of provider-diagnosed disease is not considered acceptable evidence of immunity for measles, mumps, or rubella.",
"      </li>",
"     </ul>",
"     <em>",
"      Measles component:",
"     </em>",
"     <br/>",
"     <ul>",
"      <li>",
"       A routine second dose of MMR vaccine, administered a minimum of 28 days after the first dose, is recommended for adults who",
"       <br/>",
"       &mdash; Are students in postsecondary educational institutions;",
"       <br/>",
"       &mdash; Work in a healthcare facility; or",
"       <br/>",
"       &mdash; Plan to travel internationally.",
"      </li>",
"      <li>",
"       Persons who received inactivated (killed) measles vaccine or measles vaccine of unknown type during 1963 to 1967 should be revaccinated with two doses of MMR vaccine.",
"      </li>",
"     </ul>",
"     <em>",
"      Mumps component:",
"     </em>",
"     <br/>",
"     <ul>",
"      <li>",
"       A routine second dose of MMR vaccine, administered a minimum of 28 days after the first dose, is recommended for adults who",
"       <br/>",
"       &mdash; Are students in a postsecondary educational institution;",
"       <br/>",
"       &mdash; Work in a healthcare facility; or",
"       <br/>",
"       &mdash; Plan to travel internationally.",
"      </li>",
"      <li>",
"       Persons vaccinated before 1979 with either killed mumps vaccine or mumps vaccine of unknown type who are at high risk for mumps infection (eg, persons who are working in a healthcare facility) should be considered for revaccination with two doses of MMR vaccine.",
"      </li>",
"     </ul>",
"     <em>",
"      Rubella component:",
"     </em>",
"     <br/>",
"     <ul>",
"      <li>",
"       For women of childbearing age, regardless of birth year, rubella immunity should be determined. If there is no evidence of immunity, women who are not pregnant should be vaccinated. Pregnant women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility.",
"      </li>",
"     </ul>",
"     <em>",
"      HCP born before 1957:",
"     </em>",
"     <br/>",
"     <ul>",
"      <li>",
"       For unvaccinated healthcare personnel born before 1957 who lack laboratory evidence of measles, mumps, and/or rubella immunity or laboratory confirmation of disease, healthcare facilities should consider vaccinating personnel with two doses of MMR vaccine at the appropriate interval for measles and mumps or one dose of MMR vaccine for rubella.",
"      </li>",
"     </ul>",
"     &Delta;&Delta;",
"     <strong>",
"      Pneumococcal polysaccharide (PPSV23) vaccination",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       Vaccinate all persons with the following indications:",
"       <br/>",
"       &mdash; All adults aged 65 years and older;",
"       <br/>",
"       &mdash; Adults younger than age 65 years with chronic lung disease (including chronic obstructive pulmonary disease, emphysema, and asthma); chronic cardiovascular diseases; diabetes mellitus; chronic renal failure; nephrotic syndrome; chronic liver disease (including cirrhosis); alcoholism; cochlear implants; cerebrospinal fluid leaks; immunocompromising conditions; and functional or anatomic asplenia (eg, sickle cell disease and other hemoglobinopathies, congenital or acquired asplenia, splenic dysfunction, or splenectomy [if elective splenectomy is planned, vaccinate at least two weeks before surgery]);",
"       <br/>",
"       &mdash; Residents of nursing homes or long-term care facilities; and",
"       <br/>",
"       &mdash; Adults who smoke cigarettes.",
"      </li>",
"      <li>",
"       Persons with immunocompromising conditions and other selected conditions are recommended to receive PCV13 and PPSV23 vaccines. See footnote &sect;&sect; for information on timing of PCV13 and PPSV23 vaccinations.",
"      </li>",
"      <li>",
"       Persons with asymptomatic or symptomatic HIV infection should be vaccinated as soon as possible after their diagnosis.",
"      </li>",
"      <li>",
"       When cancer chemotherapy or other immunosuppressive therapy is being considered, the interval between vaccination and initiation of immunosuppressive therapy should be at least two weeks. Vaccination during chemotherapy or radiation therapy should be avoided.",
"      </li>",
"      <li>",
"       Routine use of PPSV23 is not recommended for American Indians/Alaska Natives or other persons younger than age 65 years unless they have underlying medical conditions that are PPSV23 indications. However, public health authorities may consider recommending PPSV23 for American Indians/Alaska Natives who are living in areas where the risk for invasive pneumococcal disease is increased.",
"      </li>",
"      <li>",
"       When indicated, PPSV23 should be administered to patients who are uncertain of their vaccination status and there is no record of previous vaccination. When PCV13 is also indicated, a dose of PCV13 should be given first (see footnote &sect;&sect;).",
"      </li>",
"     </ul>",
"     <span class=\"double_lozenge\">",
"      &loz;&loz;",
"     </span>",
"     <strong>",
"      Revaccination with PPSV23",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       One-time revaccination 5 years after the first dose is recommended for persons aged 19 through 64 years with chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (eg, sickle cell disease or splenectomy); and for persons with immunocompromising conditions.",
"      </li>",
"      <li>",
"       Persons who received 1 or 2 doses of PPSV23 before age 65 years for any indication should receive another dose of the vaccine at age 65 years or later if at least 5 years have passed since their previous dose.",
"      </li>",
"      <li>",
"       No further doses are needed for persons vaccinated with PPSV23 at or after age 65 years.",
"      </li>",
"     </ul>",
"     &sect;&sect;",
"     <strong>",
"      Pneumococcal conjugate 13-valent vaccination (PCV13)",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       Adults aged 19 years or older with immunocompromising conditions (including chronic renal failure and nephrotic syndrome), functional or anatomic asplenia, CSF leaks or cochlear implants, and who have not previously received PCV13 or PPSV23 should receive a single dose of PCV13 followed by a dose of PPSV23 at least 8 weeks later.",
"      </li>",
"      <li>",
"       Adults aged 19 years or older with the aforementioned conditions who have previously received one or more doses of PPSV23 should receive a dose of PCV13 one or more years after the last PPSV23 dose was received. For those that require additional doses of PPSV23, the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years since the most recent dose of PPSV23.",
"      </li>",
"      <li>",
"       When indicated, PCV13 should be administered to patients who are uncertain of their vaccination status history and there is no record of previous vaccination.",
"      </li>",
"      <li>",
"       Although PCV13 is licensed by the FDA for use among and can be administered to persons aged 50 years and older, ACIP recommends PCV13 for adults aged 19 years and older with the specific medical conditions noted above.",
"      </li>",
"     </ul>",
"     &yen;&yen;",
"     <strong>",
"      Meningococcal vaccination",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       Administer two doses of meningococcal conjugate vaccine quadrivalent (MCV4) at least two months apart to adults with functional asplenia or persistent complement component deficiencies.",
"      </li>",
"      <li>",
"       HIV-infected persons who are vaccinated also should receive two doses.",
"      </li>",
"      <li>",
"       Administer a single dose of meningococcal vaccine to microbiologists routinely exposed to isolates of Neisseria meningitidis, military recruits, and persons who travel to or live in countries in which meningococcal disease is hyperendemic or epidemic.",
"      </li>",
"      <li>",
"       First-year college students up through age 21 years who are living in residence halls should be vaccinated if they have not received a dose on or after their 16th birthday.",
"      </li>",
"      <li>",
"       MCV4 is preferred for adults with any of the preceding indications who are aged 55 years and younger; meningococcal polysaccharide vaccine (MPSV4) is preferred for adults aged 56 years and older.",
"      </li>",
"      <li>",
"       Revaccination with MCV4 every five years is recommended for adults previously vaccinated with MCV4 or MPSV4 who remain at increased risk for infection (eg, adults with anatomic or functional asplenia or persistent complement component deficiencies).",
"      </li>",
"     </ul>",
"     &Dagger;&Dagger;",
"     <strong>",
"      Hepatitis A vaccination",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       Vaccinate any person seeking protection from hepatitis A virus (HAV) infection and persons with any of the following indications:",
"       <br/>",
"       &mdash; Men who have sex with men and persons who use injection or noninjection illicit drugs;",
"       <br/>",
"       &mdash; Persons working with HAV-infected primates or with HAV in a research laboratory setting;",
"       <br/>",
"       &mdash; Persons with chronic liver disease and persons who receive clotting factor concentrates;",
"       <br/>",
"       &mdash; Persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A; and",
"       <br/>",
"       &mdash; Unvaccinated persons who anticipate close personal contact (eg, household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity. (See footnote * for more information on travel recommendations). The first dose of the two-dose hepatitis A vaccine series should be administered as soon as adoption is planned, ideally two or more weeks before the arrival of the adoptee.",
"      </li>",
"      <li>",
"       Single-antigen vaccine formulations should be administered in a two-dose schedule at either 0 and 6 to 12 months (Havrix), or 0 and 6 to 18 months (Vaqta). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, administer three doses at 0, 1, and 6 months; alternatively, a four-dose schedule may be used, administered on days 0, 7, and 21 to 30, followed by a booster dose at month 12.",
"      </li>",
"     </ul>",
"     &dagger;&dagger;",
"     <strong>",
"      Hepatitis B vaccination",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       Vaccinate persons with any of the following indications and any person seeking protection from hepatitis B virus (HBV) infection:",
"       <br/>",
"       &mdash; Sexually active persons who are not in a long-term, mutually monogamous relationship (eg, persons with more than one sex partner during the previous six months); persons seeking evaluation or treatment for a sexually transmitted disease (STD); current or recent injection-drug users; and men who have sex with men;",
"       <br/>",
"       &mdash; Healthcare personnel and public-safety workers who are potentially exposed to blood or other infectious body fluids;",
"       <br/>",
"       &mdash; Persons with diabetes younger than age 60 years as soon as feasible after diagnosis; persons with diabetes who are age 60 years or older at the discretion of the treating clinician based on increased need for assisted blood glucose monitoring in long-term care facilities, likelihood of acquiring hepatitis B infection, its complications or chronic sequelae, and likelihood of immune response to vaccination;",
"       <br/>",
"       &mdash; Persons with end-stage renal disease, including patients receiving hemodialysis; persons with HIV infection; and persons with chronic liver disease;",
"       <br/>",
"       &mdash; Household contacts and sex partners of hepatitis B surface antigenpositive persons; clients and staff members of institutions for persons with developmental disabilities; and international travelers to countries with high or intermediate prevalence of chronic HBV infection; and",
"       <br/>",
"       &mdash; All adults in the following settings: STD treatment facilities; HIV testing and treatment facilities; facilities providing drug-abuse treatment and prevention services; healthcare settings targeting services to injection-drug users or men who have sex with men; correctional facilities; end-stage renal disease programs and facilities for chronic hemodialysis patients; and institutions and nonresidential daycare facilities for persons with developmental disabilities.",
"      </li>",
"      <li>",
"       Administer missing doses to complete a three-dose series of hepatitis B vaccine to those persons not vaccinated or not completely vaccinated. The second dose should be administered one month after the first dose; the third dose should be given at least two months after the second dose (and at least 4 months after the first dose). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, give three doses at 0, 1, and 6 months; alternatively, a four-dose Twinrix schedule, administered on days 0, 7, and 21 to 30 followed by a booster dose at month 12 may be used.",
"      </li>",
"      <li>",
"       Adult patients receiving hemodialysis or with other immunocompromising conditions should receive 1 dose of 40 mcg/mL (Recombivax HB) administered on a three-dose schedule at 0, 1, and 6 months or two doses of 20 mcg/mL (Engerix-B) administered simultaneously on a four-dose schedule at 0, 1, 2, and 6 months.",
"      </li>",
"     </ul>",
"     &Delta;&Delta;&Delta;",
"     <strong>",
"      Selected conditions for which Haemophilus influenzae type b (Hib) vaccine may be used",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       1 dose of Hib vaccine should be considered for persons who have sickle cell disease, leukemia, or HIV infection, or who have anatomic or functional asplenia if they have not previously received Hib vaccine.",
"      </li>",
"     </ul>",
"     &loz;&loz;&loz;",
"     <strong>",
"      Immunocompromising conditions",
"     </strong>",
"     <br/>",
"     <ul>",
"      <li>",
"       Inactivated vaccines generally are acceptable (eg, pneumococcal, meningococcal, and influenza [inactivated influenza vaccine]), and live vaccines generally are avoided in persons with immune deficiencies or immunocompromising conditions. Information on specific conditions is available at file://www.cdc.gov/vaccines/pubs/acip-list.htm.",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bridges CB, Woods L, Coyne-Beasley T, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Adults Aged 19 Years and Older - United States, 2013. MMWR Surveill Summ 2013; 62:9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42263=[""].join("\n");
var outline_f41_17_42263=null;
var title_f41_17_42264="Approach to the child with in-toeing";
var content_f41_17_42264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the child with in-toeing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/17/42264/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/17/42264/contributors\">",
"     Scott B Rosenfeld, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/17/42264/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/17/42264/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/17/42264/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/17/42264/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/17/42264/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21546632\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In-toeing (&ldquo;pigeon-toeing&rdquo;) is a rotational variation of the lower extremity where the feet or toes point toward the midline during gait (",
"    <a class=\"graphic graphic_figure graphicRef75796 \" href=\"mobipreview.htm?17/13/17616\">",
"     figure 1",
"    </a>",
"    ). Out-toeing is a rotational variation of the lower extremity where the feet or toes point away from the midline during gait (",
"    <a class=\"graphic graphic_figure graphicRef75796 \" href=\"mobipreview.htm?17/13/17616\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In-toeing and out-toeing are among the most common anatomic musculoskeletal variations encountered by pediatric primary care providers and a frequent reason for referral to a pediatric orthopedic surgeon. However, most children with in-toeing or out-toeing have variations of normal lower-extremity development that will improve spontaneously and can be monitored by the primary care provider.",
"   </p>",
"   <p>",
"    An understanding of the normal growth and development of the lower extremity is essential in evaluating a child&rsquo;s rotational alignment and helps to elucidate the mechanism of in-toeing. The most common causes of in-toeing in children are metatarsus adductus, internal tibial torsion, and increased femoral anteversion. These rotational variations are seen in normal, healthy children, and rarely persist into adolescence. Even when persistent, intoeing rarely causes dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/1\">",
"     1",
"    </a>",
"    ]. History and examination generally are sufficient to distinguish common rotational variations from less common pathologic causes of in-toeing and out-toeing (eg, hemiplegic cerebral palsy). (See",
"    <a class=\"local\" href=\"#H21546688\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic will provide an overview of lower-extremity rotational development, common causes of in-toeing, pathologic causes of in-toeing that must be excluded, and an approach to the evaluation and management of the child with in-toeing. Out-toeing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30823?source=see_link\">",
"     \"Approach to the child with out-toeing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546639\">",
"    <span class=\"h1\">",
"     NORMAL PHYSIOLOGIC ALIGNMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotational alignment of the lower extremity is determined by the alignment of the foot, the rotation of the tibia in relation to the transcondylar axis of the femur (tibial torsion), and the rotation of the neck of the femur in relation to the transcondylar axis of the femur (femoral anteversion) (",
"    <a class=\"graphic graphic_figure graphicRef56825 \" href=\"mobipreview.htm?25/33/26129\">",
"     figure 2",
"    </a>",
"    ). Intoeing and out-toeing may be accentuated between six months and five years, when children are developing their walking and coordination skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/2\">",
"     2",
"    </a>",
"    ]. Normal growth and improved coordination typically lead to spontaneous resolution of rotational variations (",
"    <a class=\"graphic graphic_table graphicRef64901 \" href=\"mobipreview.htm?13/4/13387\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Intrauterine positioning has an important influence on the rotational alignment of the legs. At the seventh week of gestation, the lower limb rotates medially (internally), followed by external (lateral) rotation of the upper leg. For the remainder of gestation, the tibiae and feet are medially (internally) rotated, and the hips and femora are laterally (externally) rotated, resulting in an external rotation contracture at the hip joint (",
"    <a class=\"graphic graphic_figure graphicRef79381 \" href=\"mobipreview.htm?36/62/37858\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal newborn posture reflects intrauterine positioning. The hips are flexed and externally rotated, with the patellae pointing outward. The tibiae and feet remain relatively internally rotated, but this is overshadowed by the external rotation contracture at the hip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/4\">",
"     4",
"    </a>",
"    ]. Out-toeing due to external rotation contracture of the hip usually resolves by the time the child begins walking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546646\">",
"    <span class=\"h1\">",
"     COMMON CAUSES OF IN-TOEING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of in-toeing originate from the foot (metatarsus adductus), lower leg (internal tibial torsion), and hip (increased femoral anteversion) (",
"    <a class=\"graphic graphic_table graphicRef68100 \" href=\"mobipreview.htm?4/27/4541\">",
"     table 2",
"    </a>",
"    ). These conditions may occur in combination, which increases the severity of in-toeing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. They generally do not cause pain or interfere with development or stability of gait, although children with in-toeing may stumble or trip more frequently than other children, particularly when they are tired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546653\">",
"    <span class=\"h2\">",
"     Metatarsus adductus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metatarsus adductus is characterized by angulation at the midfoot, with the metatarsals pointing toward the midline relative to the hindfoot. This gives the foot a &ldquo;kidney bean&rdquo; or &ldquo;C&rdquo; shape (",
"    <a class=\"graphic graphic_picture graphicRef57425 \" href=\"mobipreview.htm?29/44/30414\">",
"     picture 1",
"    </a>",
"    ). Metatarsus adductus is the most common cause of in-toeing in infants younger than one year of age.",
"   </p>",
"   <p>",
"    Metatarsus adductus is thought to result from intrauterine molding. It may be associated with other &ldquo;packaging problems,&rdquo; such as torticollis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/9\">",
"     9",
"    </a>",
"    ]. An association between metatarsus adductus and developmental dysplasia of the hip (DDH) has been noted in some, but not all, studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The neck and hips of children with metatarsus adductus should be examined to exclude torticollis and DDH, but isolated metatarsus adductus is not an indication for hip imaging to exclude DDH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43798?source=see_link&amp;anchor=H4#H4\">",
"     \"Congenital muscular torticollis\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27113?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of developmental dysplasia of the hip\", section on 'Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metatarsus adductus is estimated to occur in 0.1 to 1 percent of births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The true incidence is difficult to determine because mild variations generally are not reported. Metatarsus adductus is most commonly diagnosed in children younger than two years of age and is more frequent in girls than boys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metatarsus adductus is often bilateral; when unilateral, it occurs more often on the left than on the right (for unknown reasons) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/8\">",
"     8",
"    </a>",
"    ]. On examination of the foot, the heel bisector line is lateral to the second toe (",
"    <a class=\"graphic graphic_figure graphicRef60426 \" href=\"mobipreview.htm?24/19/24882\">",
"     figure 4",
"    </a>",
"    ). The hindfoot is in the neutral or valgus position, and the range of motion of the ankle and subtalar joint are normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25515563\">",
"     'Focused examination of the lower extremities'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Classification of metatarsus adductus also should be made according to the degree of flexibility (",
"    <a class=\"graphic graphic_figure graphicRef60426 \" href=\"mobipreview.htm?24/19/24882\">",
"     figure 4",
"    </a>",
"    ), which has implications for management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7639?source=see_link&amp;anchor=H4#H4\">",
"     \"Lower extremity positional deformations\", section on 'Metatarsus adductus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Mild/flexible",
"      </span>",
"      &ndash; Spontaneous active correction when the lateral border of the foot is stimulated",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Moderate/less",
"      </span>",
"      flexible &ndash; Will not correct actively but can be passively corrected to neutral",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Severe/rigid",
"      </span>",
"      &ndash; Unable to be passively corrected to neutral; may have a medial skin crease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most cases of metatarsus adductus are",
"    <span class=\"nowrap\">",
"     mild/flexible",
"    </span>",
"    and resolve spontaneously by two years of age. The most important aspect of treatment is parental reassurance. Even when it persists, metatarsus adductus rarely causes pain or dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of metatarsus adductus is discussed below. (See",
"    <a class=\"local\" href=\"#H21546674\">",
"     'Uncommon pathologic causes of in-toeing'",
"    </a>",
"    below.) The treatment of metatarsus adductus is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7639?source=see_link&amp;anchor=H6#H6\">",
"     \"Lower extremity positional deformations\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546660\">",
"    <span class=\"h2\">",
"     Internal tibial torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Internal tibial torsion is characterized by internal (medial) rotation of the tibia. It is the most common cause of in-toeing in children between one and three to four years of age and typically noticed when children begin to walk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Internal tibial torsion affects boys and girls equally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/8\">",
"     8",
"    </a>",
"    ]. It does not occur in premature infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. External tibial torsion is more likely in premature infants. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30823?source=see_link&amp;anchor=H141829715#H141829715\">",
"     \"Approach to the child with out-toeing\", section on 'External tibial torsion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Internal tibial torsion is bilateral in approximately two-thirds of cases; in unilateral cases, the left side is more commonly involved for unknown reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/16,19,21\">",
"     16,19,21",
"    </a>",
"    ]. Internal tibial torsion is associated with metatarsus adductus in about one-third of cases. It is often associated with, and may accentuate the appearance of, physiologic tibia vara and bow legs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/55/27511?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to the child with bow-legs\", section on 'Physiologic varus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Characteristic examination features of internal tibial torsion include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When standing or walking, the foot points inward, and the patella points straight ahead or outward (an internal foot progression angle and a neutral or external patellar progression angle) (see",
"      <a class=\"local\" href=\"#H25515547\">",
"       'Observation of gait'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      The medial malleolus is level with or posterior to the lateral malleolus (with the child seated with the thigh directly in front of the hip joint and the knee pointed straight ahead)",
"     </li>",
"     <li>",
"      In the prone position, the thigh-foot angle is neutral or internal (",
"      <a class=\"graphic graphic_figure graphicRef68556 \" href=\"mobipreview.htm?34/22/35169\">",
"       figure 5",
"      </a>",
"      ) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Internal tibial torsion typically resolves by five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/23\">",
"     23",
"    </a>",
"    ]. As the child grows, the tibia spontaneously rotates laterally. The average thigh-foot angle changes from 5 degrees lateral at birth to 15 degrees lateral at maturity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/23\">",
"     23",
"    </a>",
"    ]. However, wide variation of tibial rotation is common. An internal thigh-foot angle of 30 degrees falls within 2 SD of the mean in infants and toddlers (",
"    <a class=\"graphic graphic_figure graphicRef67096 \" href=\"mobipreview.htm?19/1/19487\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Management of internal tibial torsion is discussed below. (See",
"    <a class=\"local\" href=\"#H21546758\">",
"     'Internal tibial torsion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546667\">",
"    <span class=\"h2\">",
"     Increased femoral anteversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoral version is the angular difference between the axis of the femoral neck and the transcondylar axis of the femur (",
"    <a class=\"graphic graphic_figure graphicRef68562 \" href=\"mobipreview.htm?36/56/37760\">",
"     figure 7",
"    </a>",
"    ). Increased femoral anteversion (",
"    <a class=\"graphic graphic_picture graphicRef50912 \" href=\"mobipreview.htm?32/34/33314\">",
"     picture 2",
"    </a>",
"    ) (also called medial femoral torsion) is associated with increased internal rotation and decreased external rotation at the hip.",
"   </p>",
"   <p>",
"    Increased femoral anteversion is the result of intrauterine molding and genetic inheritance. It is twice as common in females as in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased femoral anteversion usually is diagnosed between three and six years of age; before three years, it is masked by the physiologic external rotation contracture of the hip. (See",
"    <a class=\"local\" href=\"#H21546639\">",
"     'Normal physiologic alignment'",
"    </a>",
"    above.) In-toeing due to increased femoral anteversion may increase until five to six years of age and then gradually decreases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/19\">",
"     19",
"    </a>",
"    ]. Increased femoral anteversion does not cause pain.",
"   </p>",
"   <p>",
"    Characteristic clinical features of increased femoral anteversion include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/4,6-8,19\">",
"     4,6-8,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When standing, the patellae face medially",
"     </li>",
"     <li>",
"      When walking, the toes",
"      <strong>",
"       and patella",
"      </strong>",
"      point toward the midline (internal foot progression angle and internal patellar progression angle) (see",
"      <a class=\"local\" href=\"#H25515547\">",
"       'Observation of gait'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      &ldquo;Egg-beater&rdquo; or &ldquo;windmill&rdquo; pattern during running (the legs flip laterally during the swing phase, when the foot is off the ground)",
"     </li>",
"     <li>",
"      Increased internal rotation and decreased external rotation of both hips (symmetric) (see",
"      <a class=\"local\" href=\"#H25515563\">",
"       'Focused examination of the lower extremities'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Preference for sitting in the &ldquo;W&rdquo; position (",
"      <a class=\"graphic graphic_figure graphicRef81940 \" href=\"mobipreview.htm?28/4/28736\">",
"       figure 8",
"      </a>",
"      ); uncomfortable sitting cross-legged until lateral rotation of the hip improves",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The natural history and management of increased femoral anteversion is discussed below. (See",
"    <a class=\"local\" href=\"#H21546765\">",
"     'Increased femoral anteversion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546674\">",
"    <span class=\"h1\">",
"     UNCOMMON PATHOLOGIC CAUSES OF IN-TOEING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncommon, pathologic causes of in-toeing in children include neuromuscular diseases (eg, cerebral palsy), disorders of the hip (eg, developmental dysplasia), and lower leg deformities (eg, clubfoot, skewfoot). Although these etiologies are uncommon, they must be considered in the evaluation of a child with in-toeing because they do not resolve spontaneously. They can generally be excluded through history and physical examination.",
"   </p>",
"   <p>",
"    Mild hemiplegic cerebral palsy rarely may present with an in-toeing gait [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/24\">",
"     24",
"    </a>",
"    ]. Spasticity secondary to cerebral palsy may result in over-pull of the internal rotators of the hip or the adductors and inverters of the foot, which may cause an asymmetric, unilateral in-toeing gait. Asymmetry is a red flag. The history may reveal perinatal problems or abnormal developmental milestones. Examination may demonstrate spasticity of the gastro-soleus, hamstrings, and hip adductors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/19\">",
"     19",
"    </a>",
"    ]. Such findings should prompt referral to a specialist (eg, neurologist, physical medicine and rehabilitation specialist) for evaluation for cerebral palsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29209?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features of cerebral palsy\", section on 'Spastic hemiplegia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4104?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis and classification of cerebral palsy\", section on 'Summary and recommendations'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Developmental dysplasia or dislocation of the hip may present with in-toeing related to limitation of hip abduction, leg-length discrepancy, or persistent increased femoral anteversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/4,7,25\">",
"     4,7,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/199?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and pathogenesis of developmental dysplasia of the hip\", section on 'Embryology and pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27113?source=see_link&amp;anchor=H119602789#H119602789\">",
"     \"Clinical features and diagnosis of developmental dysplasia of the hip\", section on 'Age-specific findings of DDH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clubfoot is a foot deformity in which medial deviation of the forefoot is combined with excessive supination (the sole of the foot faces inward), cavus (high midfoot arch), and ankle plantar flexion (equinus). It is distinguished from metatarsus adductus by the presence of these additional deformities and inability to dorsiflex the foot.",
"   </p>",
"   <p>",
"    Skewfoot is a rare foot deformity in which medial deviation of the forefoot is combined with lateral translation of the midfoot and valgus position of the hindfoot. The possibility of skewfoot should be considered in infants with unilateral metatarsus adductus. In infants with skewfoot, the head of the talus may be visible and palpable medially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546681\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting complaints for a child with in-toeing may include concerns about appearance of the legs or foot, excessive falling, awkward running style, uneven shoe wear,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bowed legs (which is often associated with in-toeing). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/55/27511?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the child with bow-legs\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546688\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The objectives of the evaluation are to identify parental concerns (eg, cosmesis, frequent falling, permanent disability, interference with sports performance), identify the cause of in-toeing, and exclude pathologic etiologies. The history and physical examination usually are sufficient to achieve these goals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546695\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Birth history, including gestational age and complications (prematurity may be a clue to cerebral palsy)",
"     </li>",
"     <li>",
"      Developmental milestones (delayed milestones may be a clue to cerebral palsy)",
"     </li>",
"     <li>",
"      Early hand preference (preference for one side before three years of age may be a sign of hemiplegia) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/19,26\">",
"       19,26",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4104?source=see_link&amp;anchor=H8#H8\">",
"       \"Diagnosis and classification of cerebral palsy\", section on 'Spastic hemiplegia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Family history of in-toeing (internal tibial torsion and femoral anteversion run in families); the clinical course of these problems in a sibling or parent may help to reassure the family about spontaneous resolution and lack of long-term sequelae",
"     </li>",
"     <li>",
"      Onset and clinical course: noticed at birth (metatarsus adductus); when the child began walking (internal tibial torsion or [rarely] hip dislocation); after age three years (increased femoral anteversion); recent change (may indicate pathologic cause).",
"     </li>",
"     <li>",
"      Unilateral or bilateral? Symmetric or asymmetric? Unilateral or asymmetric intoeing is a red flag for cerebral palsy, clubfoot, or skewfoot",
"     </li>",
"     <li>",
"      Associated complaints: pain or limp (red flags for pathologic conditions); tripping or falling (may occur in children with internal tibial torsion or increased femoral anteversion, particularly when they are tired (",
"      <a class=\"graphic graphic_figure graphicRef65723 \" href=\"mobipreview.htm?29/15/29937\">",
"       figure 9",
"      </a>",
"      ), but may be an indication for referral if they persist beyond the normal age of resolution and are severe and disabling); bow-legs (often associated with internal tibial torsion)",
"     </li>",
"     <li>",
"      Perceived difficulties caused by in-toeing (must be addressed during management). (See",
"      <a class=\"local\" href=\"#H21546744\">",
"       'Management'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546702\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination serves to exclude pathologic causes of in-toeing, pinpoint rotational contributions, and identify associated angular problems (eg, bow legs). The examination should include observation of gait, focused examination of the lower extremity, and neurologic examination. In some cases, evaluation of the parental rotational profile also may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25515547\">",
"    <span class=\"h3\">",
"     Observation of gait",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the child is ambulatory, the child's gait should be observed as the child walks toward and away from the examiner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/3\">",
"     3",
"    </a>",
"    ]. The presence or absence of a limp should be noted. Additionally, the foot progression and patellar progression angles should be noted. These angles describe the alignment of the foot and patella, respectively, as they relate to the direction that the patient is moving.",
"    <strong>",
"    </strong>",
"    An internal foot progression angle describes a foot that points toward the midline as the patient walks forward (",
"    <a class=\"graphic graphic_figure graphicRef75796 \" href=\"mobipreview.htm?17/13/17616\">",
"     figure 1",
"    </a>",
"    ). An external patellar progression angle describes a patella that points away from the midline as the patient walks forward. The common causes of in-toeing generally have reproducible gait patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metatarsus adductus &ndash; Internal foot progression angle, neutral or external patella progression angle.",
"     </li>",
"     <li>",
"      Internal tibial torsion &ndash; Internal foot progression angle, neutral or external patella progression angle.",
"     </li>",
"     <li>",
"      Increased femoral anteversion &ndash; Internal foot progression angle, internal patella progression angle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The child should also be observed while running [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A child with increased femoral anteversion may be described to have an egg-beater running pattern with medial rotation of the thighs and outward rotation of the feet during swing phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/8\">",
"     8",
"    </a>",
"    ]. Furthermore, running may accentuate neurologic dysfunction and rotational variations. Unilateral limp while walking or running should raise suspicion of pathologic causes of in-toeing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25515563\">",
"    <span class=\"h3\">",
"     Focused examination of the lower extremities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the rotational alignment of the lower extremities is best done with the patient lying prone on the examination table [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/2\">",
"     2",
"    </a>",
"    ]. The parents should be encouraged to stand with the examiner next to the patient so that they can appreciate the findings as the examination is performed. The examination should progress through the three main sites for rotational variations: foot, tibia, and",
"    <span class=\"nowrap\">",
"     femur/hip.",
"    </span>",
"    This can be accomplished by making the following measurements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heel bisector line &ndash; The heel bisector line is measured with the knee flexed and ankle dorsiflexed so that the plantar surface of the foot is parallel to the ceiling. A visual line is approximated parallel to the heel and extended distally to the toes. A normal heel bisector line goes through the second toe. Metatarsus adductus is diagnosed when this line passes through the more lateral toes (",
"      <a class=\"graphic graphic_figure graphicRef60426 \" href=\"mobipreview.htm?24/19/24882\">",
"       figure 4",
"      </a>",
"      ). The more severe the deformity, the more lateral the line passes. Flexibility of metatarsus adductus also should be assessed by applying lateral force to the great toe and attempting to reduce the heel bisector line back to the second toe. (See",
"      <a class=\"local\" href=\"#H21546653\">",
"       'Metatarsus adductus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thigh-foot angle &ndash; The thigh-foot angle is measured with the knee flexed and the ankle dorsiflexed so that the plantar surface of the foot is parallel to the ceiling. Allow the foot to fall into a neutral position. A visual line is approximated along the long axis of the thigh and a second line along the long axis of the heel. The angle between these two lines is the thigh-foot angle (",
"      <a class=\"graphic graphic_figure graphicRef68556 \" href=\"mobipreview.htm?34/22/35169\">",
"       figure 5",
"      </a>",
"      ). If the line of the heel points toward the midline relative to the thigh, it suggests internal torsion of the tibia. If the line of the heel points away from the midline relative to the thigh, it suggests external torsion of the tibia.",
"      <br/>",
"      <br/>",
"      Normal values for the thigh-foot angle were determined in a study of 1000 limbs of 500 subjects (all white) ranging in age from &lt;1 to 70 years (",
"      <a class=\"graphic graphic_figure graphicRef67096 \" href=\"mobipreview.htm?19/1/19487\">",
"       figure 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/23\">",
"       23",
"      </a>",
"      ]. The average thigh-foot angle at birth is 5 degrees (external) and increases to 15 degrees (external) at maturity.",
"     </li>",
"     <li>",
"      Hip rotation &ndash; Hip rotation is measured with the knees flexed. Internal rotation is measured by rotating the leg away from the axis of the body (rotating the hip internally). External rotation is measured by rotating the leg towards the axis of the body (rotating the hip externally). &nbsp;",
"      <br/>",
"      <br/>",
"      Normal values for hip rotation were determined in a study of 1000 limbs of 500 subjects (all white) ranging in age from &lt;1 to 70 years (",
"      <a class=\"graphic graphic_figure graphicRef71765 \" href=\"mobipreview.htm?26/0/26627\">",
"       figure 10",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/23\">",
"       23",
"      </a>",
"      ]. The average amount of internal hip rotation during childhood is between 40 and 50 degrees. The average amount of external hip rotation during childhood is between 40 and 70 degrees.",
"      <br/>",
"      <br/>",
"      Patients with increased femoral anteversion may have as much as 90 degrees of internal rotation, allowing the legs to rotate flat against the exam table [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/19\">",
"       19",
"      </a>",
"      ]. Similarly, they will have a decreased amount of external rotation, often only to neutral. Conversely, patients with femoral retroversion will have increased external rotation (to almost 90 degrees) and very little internal rotation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other aspects of the lower-extremity examination that may be helpful in identifying associated conditions and excluding pathologic causes of in-toeing include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment for associated angular variations (bow legs are associated with internal tibial torsion; knock-knees are associated with external tibial torsion) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/55/27511?source=see_link&amp;anchor=H4#H4\">",
"       \"Approach to the child with bow-legs\", section on 'Physiologic varus'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6199?source=see_link&amp;anchor=H4#H4\">",
"       \"Approach to the child with knock-knees\", section on 'Physiologic valgus'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Range of motion at the ankle; the ability to dorsiflex the ankle above neutral helps to exclude true clubfoot",
"     </li>",
"     <li>",
"      Observation and palpation of the medial aspect of the foot; a visible or palpable head of the talus may indicate skewfoot although additional evaluation is necessary",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90884693\">",
"    <span class=\"h3\">",
"     Parental rotational profiles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased femoral anteversion and internal tibial torsion tend to run in families. Assessment of the parents&rsquo; rotational profiles may help to predict how the child is likely to be affected as an adult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/8\">",
"     8",
"    </a>",
"    ]. Such information may help to reassure the family about the lack of long-term functional problems. (See",
"    <a class=\"local\" href=\"#H21546744\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264790200\">",
"    <span class=\"h3\">",
"     Focused neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A focused neurologic examination is important to exclude cerebral palsy. The minimal neurologic examination should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper- and lower-extremity reflexes",
"     </li>",
"     <li>",
"      Ankle clonus",
"     </li>",
"     <li>",
"      Measurement of popliteal angles to assess hamstring spasticity. The popliteal angle is measured by flexing the hip and the knee to 90 degrees and then extending the knee up to the point of mild resistance (",
"      <a class=\"graphic graphic_figure graphicRef79116 \" href=\"mobipreview.htm?32/27/33215\">",
"       figure 11",
"      </a>",
"      ). The popliteal angle is the angle between the tibia and the extension of the femur. Values &ge;50 to 55 degrees are considered abnormal in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Asking the child to walk on his or her heels and toes and to hop on each leg. Heel walking demonstrates the ability to dorsiflex the ankle. Toe walking and hopping help to evaluate the child&rsquo;s overall motor coordination level (which varies with age).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546730\">",
"    <span class=\"h2\">",
"     Radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographs generally are not necessary in the assessment of in-toeing. In patients with residual metatarsus adductus, radiographs may be necessary for surgical planning. In the rare patient in whom skewfoot is a consideration, radiographs may exclude the diagnosis. Clubfoot can be excluded clinically. Internal tibial torsion and femoral anteversion, the most common causes of in-toeing in infants and school-age children, are diagnosed clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546737\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with rotational variations of the lower extremity can be followed in the primary care office. In a retrospective review of 202 children (median age four years) with intoeing who were referred for orthopedic surgery consultation by primary care providers, 86 percent were discharged after their first visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/29\">",
"     29",
"    </a>",
"    ]. The distribution of etiologies is displayed in the graph (",
"    <a class=\"graphic graphic_figure graphicRef60011 \" href=\"mobipreview.htm?27/37/28254\">",
"     figure 12",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Indications for referral include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rigid metatarsus adductus, which may require serial casting (refer to pediatric orthopedic surgeon or an orthopedic surgeon with expertise in rotational problems)",
"     </li>",
"     <li>",
"      Unilateral or asymmetric in-toeing associated with clinical findings suggestive of neurologic disorder (refer to a pediatric orthopedic surgeon, pediatric neurologist, or physical medicine and rehabilitation specialist)",
"     </li>",
"     <li>",
"      Children &ge;8 years with activity limiting or cosmetically unacceptable in-toeing due to internal tibial torsion (may be candidates for derotational osteotomy; refer to an orthopedic surgeon with expertise in rotational problems)",
"     </li>",
"     <li>",
"      Children &ge;11 years with activity limiting or cosmetically unacceptable in-toeing due to increased femoral anteversion (may be candidates for derotational osteotomy; refer to an orthopedic surgeon with expertise in rotational problems)",
"     </li>",
"     <li>",
"      In-toeing that does not follow the expected course (eg, increased femoral anteversion that progresses after age five or six years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/16\">",
"       16",
"      </a>",
"      ] (refer to pediatric orthopedic surgeon or an orthopedic surgeon with expertise in rotational problems)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546744\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534273839\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the management of in-toeing is establishing a correct diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/4\">",
"     4",
"    </a>",
"    ]. The natural history of most rotational variations is spontaneous resolution as the child grows and develops. The most important (and usually only) intervention that is necessary for the majority of children with in-toeing is reassurance that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In-toeing is a common developmental variation related to intrauterine positioning",
"     </li>",
"     <li>",
"      In-toeing resolves spontaneously as the child grows. In an observational study of 761 normal subjects (students from kindergarten, elementary, intermediate, nursing, and technical schools), the overall prevalence of in-toeing was 16 percent; the frequency decreased from 30 percent in four-year-old children to 4 percent in adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Even if in-toeing does not completely resolve, long-term functional problems are rare (occurring in approximately 1 in 1000 children) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to address the concerns of the grandparents as well as the parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/8\">",
"     8",
"    </a>",
"    ]. When the grandparents were raising their children, rotational variations were often considered to be a serious problem and were treated with interventions now known to be ineffective (eg, special shoes, orthotics). &nbsp;",
"   </p>",
"   <p>",
"    It may be helpful to ask the family to sit down in a public place and watch people walk by. They will notice considerable variation in the direction that people&rsquo;s feet point when they walk. Some families may be relieved to know that many sprinters and other running athletes in-toe when running [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546751\">",
"    <span class=\"h2\">",
"     Metatarsus adductus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of metatarsus adductus diagnosed in the neonatal period resolve spontaneously. Infants with metatarsus adductus can be managed with observation and parental reassurance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7639?source=see_link&amp;anchor=H6#H6\">",
"     \"Lower extremity positional deformations\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546758\">",
"    <span class=\"h2\">",
"     Internal tibial torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Internal tibial torsion generally corrects spontaneously by five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/23\">",
"     23",
"    </a>",
"    ]. Most patients can be managed with observation and parental reassurance that tibial torsion is physiologic, often resolves spontaneously, and, even if it persists, has few long-term sequelae.",
"   </p>",
"   <p>",
"    The use of special shoes, orthotics, or braces is not recommended. Prospective observational and randomized studies have found them to be ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Adverse effects of orthotics during childhood include unnecessary costs, negative psychosocial sequelae, and interference with sleep or play [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/8,34\">",
"     8,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical treatment for internal tibial torsion rarely is indicated. It should be reserved for patients with severe in-toeing causing functional or cosmetic deformity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. Patients meeting this criterion who are older than eight years with an internal thigh-foot angle greater than 15 degrees may be considered for distal tibial derotational osteotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important aspect of treatment is parental reassurance that internal tibial torsion is physiologic and often resolves spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/35\">",
"     35",
"    </a>",
"    ]. Even cases that do not completely resolve tend to have a benign natural history. In a case-control study, high-school sprinters had a lower mean thigh-foot angle than high-school controls (+3&deg; versus +10&deg;), and in-toed gait during sprinting (but not during walking) was more common among sprinters than controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546765\">",
"    <span class=\"h2\">",
"     Increased femoral anteversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of in-toeing secondary to increased femoral anteversion is that of spontaneous resolution, usually by 11 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/25,30\">",
"     25,30",
"    </a>",
"    ]. The average amount of femoral anteversion at birth is 40 degrees. With normal growth, femoral anteversion decreases about 1.5 degrees per year, resulting in an average of 8 to 14 degrees by maturity. Pathologic sequelae of increased femoral anteversion are rare, even in persistent cases. There is no link between increased femoral anteversion and osteoarthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. However, when combined with external tibial torsion, patients with increased femoral anteversion may be more likely to develop anterior knee pain from so-called &ldquo;miserable malalignment&rdquo; (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30823?source=see_link&amp;anchor=H141829715#H141829715\">",
"     \"Approach to the child with out-toeing\", section on 'External tibial torsion'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most children with increased femoral anteversion can be managed with observation and parental reassurance that increased femoral anteversion is physiologic, often resolves spontaneously and even if it does not, has few long-term sequelae. Prospective observational and randomized studies have found shoe wedges, twister cables, bracing, and splinting to be ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/25,33\">",
"     25,33",
"    </a>",
"    ]. These interventions are not recommended. Likewise, keeping the child from sitting in the &ldquo;W&rdquo; position is not recommended because it is unlikely to change the natural history. &nbsp;",
"   </p>",
"   <p>",
"    Femoral derotational osteotomy is the only treatment that is effective in decreasing femoral anteversion. Given the high likelihood of spontaneous resolution and the historically high complication rate of femoral derotation osteotomy, femoral derotation osteotomy generally is not recommended. It should be reserved for the child &ge;11 years of age who complains of severe functional or cosmetic deformity and has femoral anteversion of greater than 50 degrees (measured radiographically) and internal hip rotation of greater than 80 degrees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42264/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21546772\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a large variation in lower-extremity rotational alignment in children. The most common causes of in-toeing in children are metatarsus adductus (",
"      <a class=\"graphic graphic_picture graphicRef57425 \" href=\"mobipreview.htm?29/44/30414\">",
"       picture 1",
"      </a>",
"      ), internal tibial torsion, and increased femoral anteversion (",
"      <a class=\"graphic graphic_table graphicRef68100 \" href=\"mobipreview.htm?4/27/4541\">",
"       table 2",
"      </a>",
"      ). These rotational variations are related to intrauterine molding and resolve spontaneously through normal growth and development. (See",
"      <a class=\"local\" href=\"#H21546639\">",
"       'Normal physiologic alignment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21546646\">",
"       'Common causes of in-toeing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metatarsus adductus is medial deviation of the forefoot on the hindfoot (",
"      <a class=\"graphic graphic_picture graphicRef57425 \" href=\"mobipreview.htm?29/44/30414\">",
"       picture 1",
"      </a>",
"      ). It is the most common cause of in-toeing in infants younger than one year of age. Metatarsus adductus is characterized by a &ldquo;kidney bean&rdquo; or &ldquo;C&rdquo; shape; heel bisector line that is lateral to the second toe (",
"      <a class=\"graphic graphic_figure graphicRef60426 \" href=\"mobipreview.htm?24/19/24882\">",
"       figure 4",
"      </a>",
"      ); normal range of motion of the ankle and subtalar joint; internal foot progression angle; and a neutral or external patella progression angle. It usually resolves spontaneously by two years of age. (See",
"      <a class=\"local\" href=\"#H21546653\">",
"       'Metatarsus adductus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Internal tibial torsion is internal (medial) rotation of the tibia in relation to the transcondylar axis of the femur. It is the most common cause of in-toeing in children between one and three to four years of age. Internal tibial torsion is characterized by a foot that points inward when the patella faces forward or externally; medial malleolus level with or posterior to the lateral malleolus (with the knee pointed straight); and neutral or internal thigh-foot angle (",
"      <a class=\"graphic graphic_figure graphicRef68556 \" href=\"mobipreview.htm?34/22/35169\">",
"       figure 5",
"      </a>",
"      ). Internal tibial torsion usually resolves spontaneously by five years of age. (See",
"      <a class=\"local\" href=\"#H21546660\">",
"       'Internal tibial torsion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased femoral anteversion is an increased angle of rotation of the femoral neck in relation to transcondylar axis of the femur. It is the most common cause of in-toeing in children older than three years of age. Increased femoral anteversion is characterized by inward facing feet and patella during walking and standing; &ldquo;egg-beater&rdquo; pattern during running; symmetrically increased internal rotation and decreased external rotation of the hips; and preference for sitting in the &ldquo;W&rdquo; position. Increased femoral anteversion tends to improve spontaneously by 11 years of age. (See",
"      <a class=\"local\" href=\"#H21546765\">",
"       'Increased femoral anteversion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pathologic conditions that must be considered in the evaluation of the child with in-toeing include neuromuscular diseases (eg, cerebral palsy), disorders of the hip (eg, developmental dysplasia), and lower leg deformities (eg, skewfoot, clubfoot). These conditions usually can be excluded through history and examination. (See",
"      <a class=\"local\" href=\"#H21546674\">",
"       'Uncommon pathologic causes of in-toeing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21546688\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children with rotational variations of the lower extremity can be followed in the primary care office. The most important aspect of management of rotational causes of in-toeing is parental reassurance that most &ldquo;deformities&rdquo; correct spontaneously and that, even in persistent cases, adverse long-term sequelae are rare. Nonoperative interventions (eg, shoe inserts, braces, twister cables, casting) are ineffective in the treatment of internal tibial torsion and increased femoral anteversion. We recommend against such interventions (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21546744\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for referral include rigid metatarsus adductus; unilateral or asymmetric in-toeing with findings suggestive of cerebral palsy or developmental",
"      <span class=\"nowrap\">",
"       dysplasia/dislocation",
"      </span>",
"      of the hip; cosmetically or functionally unacceptable in-toeing due to internal tibial torsion in a child older than eight years; cosmetically or functionally unacceptable in-toeing due to femoral anteversion in a child older than 11 years; and in-toeing that does not follow the expected clinical course. (See",
"      <a class=\"local\" href=\"#H21546737\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/1\">",
"      Staheli LT. Lower positional deformity in infants and children: a review. J Pediatr Orthop 1990; 10:559.",
"     </a>",
"    </li>",
"    <li>",
"     Schoenecker PL, Rich MM. The lower extremity. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1158.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/3\">",
"      LeDamany P. La torsion du tibia, normal, pathologique, experimentale. J Anat Physiol 1909; 45:598.",
"     </a>",
"    </li>",
"    <li>",
"     Staheli LT. Lower limb. In: Fundamentals of Pediatric Orthopedics, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/5\">",
"      Pitkow RB. External rotation contracture of the extended hip. A common phenomenon of infancy obscuring femoral neck anteversion and the most frequent cause of out-toeing gait in children. Clin Orthop Relat Res 1975; :139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/6\">",
"      Li YH, Leong JC. Intoeing gait in children. Hong Kong Med J 1999; 5:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/7\">",
"      Bruce RW Jr. Torsional and angular deformities. Pediatr Clin North Am 1996; 43:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/8\">",
"      Staheli LT. Rotational problems in children. Instr Course Lect 1994; 43:199.",
"     </a>",
"    </li>",
"    <li>",
"     Herring JA, Karol LA, Richards BS, Johnston CE. Disorders of the foot. In: Tachdjian's Pediatric Orthopaedics, 4th, Herring JA (Ed), Saunders, Philadelphia 2008. p.1035.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/10\">",
"      JACOBS JE. Metatarsus varus and hip dysplasia. Clin Orthop 1960; 16:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/11\">",
"      Kumar SJ, MacEwen GD. The incidence of hip dysplasia with metatarsus adductus. Clin Orthop Relat Res 1982; :234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/12\">",
"      Gruber MA, Lozano JA. Metatarsus varus and developmental dysplasia of the hip: is there a relationship? Orthop Trans 1991; 15:336.",
"     </a>",
"    </li>",
"    <li>",
"     Kasser JR. The foot. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1257.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/14\">",
"      WYNNE-DAVIES R. FAMILY STUDIES AND THE CAUSE OF CONGENITAL CLUB FOOT. TALIPES EQUINOVARUS, TALIPES CALCANEO-VALGUS AND METATARSUS VARUS. J Bone Joint Surg Br 1964; 46:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/15\">",
"      Widhe T, Aaro S, Elmstedt E. Foot deformities in the newborn--incidence and prognosis. Acta Orthop Scand 1988; 59:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/16\">",
"      Lincoln TL, Suen PW. Common rotational variations in children. J Am Acad Orthop Surg 2003; 11:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/17\">",
"      Rushforth GF. The natural history of hooked forefoot. J Bone Joint Surg Br 1978; 60-B:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/18\">",
"      Scherl SA. Common lower extremity problems in children. Pediatr Rev 2004; 25:52.",
"     </a>",
"    </li>",
"    <li>",
"     Tachdjian MO. The knee and leg. In: Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management, Appleton and Lange, Stamford 1997. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/20\">",
"      Katz K, Naor N, Merlob P, Wielunsky E. Rotational deformities of the tibia and foot in preterm infants. J Pediatr Orthop 1990; 10:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/21\">",
"      Katz JF. Behavior of internal tibial torsion in infancy. Mt Sinai J Med 1982; 49:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/22\">",
"      Staheli LT, Engel GM. Tibial torsion: a method of assessment and a survey of normal children. Clin Orthop Relat Res 1972; 86:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/23\">",
"      Staheli LT, Corbett M, Wyss C, King H. Lower-extremity rotational problems in children. Normal values to guide management. J Bone Joint Surg Am 1985; 67:39.",
"     </a>",
"    </li>",
"    <li>",
"     Muscular Affectations of the Muscular System. In: Clinical Pediatric Orthopaedics: The Art of Diagnosis and Principles of Management, Tachdjians, MO (Eds), Appleton and Lange, Stamford 1997. p.381.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/25\">",
"      Fabry G, MacEwen GD, Shands AR Jr. Torsion of the femur. A follow-up study in normal and abnormal conditions. J Bone Joint Surg Am 1973; 55:1726.",
"     </a>",
"    </li>",
"    <li>",
"     Tachdjian MO. Generalized affectations of the muscular skeletal system. In: Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management, Appleton and Lange, Stamford 1997. p.369.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/27\">",
"      Katz K, Rosenthal A, Yosipovitch Z. Normal ranges of popliteal angle in children. J Pediatr Orthop 1992; 12:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/28\">",
"      Kuo L, Chung W, Bates E, Stephen J. The hamstring index. J Pediatr Orthop 1997; 17:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/29\">",
"      Blackmur JP, Murray AW. Do children who in-toe need to be referred to an orthopaedic clinic? J Pediatr Orthop B 2010; 19:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/30\">",
"      Svenningsen S, Apalset K, Terjesen T, Anda S. Regression of femoral anteversion. A prospective study of intoeing children. Acta Orthop Scand 1989; 60:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/31\">",
"      Fuchs R, Staheli LT. Sprinting and intoeing. J Pediatr Orthop 1996; 16:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/32\">",
"      Heinrich SD, Sharps CH. Lower extremity torsional deformities in children: a prospective comparison of two treatment modalities. Orthopedics 1991; 14:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/33\">",
"      Knittel G, Staheli LT. The effectiveness of shoe modifications for intoeing. Orthop Clin North Am 1976; 7:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/34\">",
"      Driano AN, Staheli L, Staheli LT. Psychosocial development and corrective shoewear use in childhood. J Pediatr Orthop 1998; 18:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/35\">",
"      Weseley MS, Barenfeld PA, Eisenstein AL. Thoughts on in-toeing and out-toeing: twenty years' experience with over 5000 cases and a review of the literature. Foot Ankle 1981; 2:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/36\">",
"      Wedge JH, Munkacsi I, Loback D. Anteversion of the femur and idiopathic osteoarthrosis of the hip. J Bone Joint Surg Am 1989; 71:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/37\">",
"      Hubbard DD, Staheli LT, Chew DE, Mosca VS. Medial femoral torsion and osteoarthritis. J Pediatr Orthop 1988; 8:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/38\">",
"      Kitaoka HB, Weiner DS, Cook AJ, et al. Relationship between femoral anteversion and osteoarthritis of the hip. J Pediatr Orthop 1989; 9:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42264/abstract/39\">",
"      Delgado ED, Schoenecker PL, Rich MM, Capelli AM. Treatment of severe torsional malalignment syndrome. J Pediatr Orthop 1996; 16:484.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14481 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42264=[""].join("\n");
var outline_f41_17_42264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21546772\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21546632\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21546639\">",
"      NORMAL PHYSIOLOGIC ALIGNMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21546646\">",
"      COMMON CAUSES OF IN-TOEING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21546653\">",
"      Metatarsus adductus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21546660\">",
"      Internal tibial torsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21546667\">",
"      Increased femoral anteversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21546674\">",
"      UNCOMMON PATHOLOGIC CAUSES OF IN-TOEING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21546681\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21546688\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21546695\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21546702\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25515547\">",
"      - Observation of gait",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25515563\">",
"      - Focused examination of the lower extremities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90884693\">",
"      - Parental rotational profiles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H264790200\">",
"      - Focused neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21546730\">",
"      Radiographs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21546737\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21546744\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H534273839\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21546751\">",
"      Metatarsus adductus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21546758\">",
"      Internal tibial torsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21546765\">",
"      Increased femoral anteversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21546772\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14481\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14481|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/13/17616\" title=\"figure 1\">",
"      In-toeing and out-toeing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/33/26129\" title=\"figure 2\">",
"      Lower extremity rotational alignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/62/37858\" title=\"figure 3\">",
"      Intrauterine position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/19/24882\" title=\"figure 4\">",
"      Eval metatarsus adductus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/22/35169\" title=\"figure 5\">",
"      Thigh foot angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/1/19487\" title=\"figure 6\">",
"      Physiologic progression of the thigh-foot angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/56/37760\" title=\"figure 7\">",
"      Femoral anteversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/4/28736\" title=\"figure 8\">",
"      W sitting position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/15/29937\" title=\"figure 9\">",
"      Femoral anteversion and in-toeing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/0/26627\" title=\"figure 10\">",
"      Normal hip rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/27/33215\" title=\"figure 11\">",
"      Measurement of popliteal angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/37/28254\" title=\"figure 12\">",
"      Etiology of in-toeing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14481|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/44/30414\" title=\"picture 1\">",
"      Metatarsus adductus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/34/33314\" title=\"picture 2\">",
"      Excessive femoral anteversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14481|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/4/13387\" title=\"table 1\">",
"      Physiologic progression of lower-extremity rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/27/4541\" title=\"table 2\">",
"      Common causes of in-toeing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/55/27511?source=related_link\">",
"      Approach to the child with bow-legs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6199?source=related_link\">",
"      Approach to the child with knock-knees",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30823?source=related_link\">",
"      Approach to the child with out-toeing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27113?source=related_link\">",
"      Clinical features and diagnosis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43798?source=related_link\">",
"      Congenital muscular torticollis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4104?source=related_link\">",
"      Diagnosis and classification of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/199?source=related_link\">",
"      Epidemiology and pathogenesis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7639?source=related_link\">",
"      Lower extremity positional deformations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_17_42265="Brief intervention for unhealthy alcohol and other drug use";
var content_f41_17_42265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Brief intervention for unhealthy alcohol and other drug use",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/17/42265/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/17/42265/contributors\">",
"     Richard Saitz, MD, MPH, FACP, FASAM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/17/42265/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/17/42265/contributors\">",
"     Andrew J Saxon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/17/42265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/17/42265/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/17/42265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H521138\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unhealthy alcohol and other drug use are among the most common causes of preventable death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/1\">",
"     1",
"    </a>",
"    ]. &ldquo;Unhealthy use&rdquo; describes use of amounts that risk consequences or have resulted in consequences, as well as the DSM-IV-TR disorders substance abuse and dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite their frequent presentation in primary care, unhealthy alcohol and other drug use often go unrecognized. The combination of screening all adult primary care patients to identify individuals with unhealthy use and a brief counseling intervention has been proposed as population-wide, preventive interventions in primary care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/3\">",
"     3",
"    </a>",
"    ]. Clinical trials support the use of screening and brief intervention for unhealthy alcohol use for adults.",
"   </p>",
"   <p>",
"    This topic reviews treatment with brief intervention of adult primary care patients identified by screening to have unhealthy alcohol or other drug use. Screening for unhealthy alcohol and other drug use is described separately. The epidemiology, clinical manifestations, and diagnosis of substance abuse and dependence are described separately as are pharmacotherapy and psychosocial interventions for the disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=see_link\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3784?source=see_link\">",
"     \"Opioid abuse and dependence: Overview and patient evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21783?source=see_link\">",
"     \"Cannabis use disorders: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8728671\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2654772\">",
"    <span class=\"h2\">",
"     Unhealthy alcohol and other drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Unhealthy use&rdquo; refers to the spectrum of use that can result in health consequences, from use that risks consequences, to use with consequences that do not meet DSM-IV-TR criteria, to the DSM-IV-TR diagnoses, abuse and dependence. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link&amp;anchor=H2788940#H2788940\">",
"     \"Screening for unhealthy use of alcohol and other drugs\", section on 'Unhealthy alcohol or drug use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2654753\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Preventive Services Task Force (USPSTF) has recommended that all adults in primary care be screened to identify unhealthy alcohol use, and that those with unhealthy use receive a brief counseling intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15097354\">",
"     'Efficacy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening and brief intervention can also be done for drugs other than alcohol, and in high prevalence settings other than primary care (eg, emergency departments or hospitals), though the evidence on health outcomes is either limited or mixed. (See",
"    <a class=\"local\" href=\"#H15097354\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15097291\">",
"    <span class=\"h1\">",
"     INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief intervention involves counseling the patient at least once; some definitions include up to four 30-minute visits. Most brief interventions with proven efficacy include more than one 10 to 15 minute contact, although duration of the intervention has not been an important determinant of brief intervention effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The active elements of brief intervention are believed to be a repeated, consistent message from a clinician with whom the patient has a relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H229650\">",
"    <span class=\"h2\">",
"     Goals of brief intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of a brief intervention for non-dependent individuals include either reduction of use or abstinence, as well as change in related behaviors (eg, avoiding bars). The actual goals will depend on patient readiness and negotiation. Ideal goals are described below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H229657\">",
"    <span class=\"h3\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abstinence is generally the best option for patients with unhealthy alcohol use who meet one of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Under age 21, for legal reasons related to alcohol use and because of possible detrimental effects on the developing brain",
"     </li>",
"     <li>",
"      A diagnosis of dependence",
"     </li>",
"     <li>",
"      Failed prior attempts to cut down",
"     </li>",
"     <li>",
"      Pregnant or planning to conceive",
"     </li>",
"     <li>",
"      A physical or mental health condition secondary to use",
"     </li>",
"     <li>",
"      Take a medication that contraindicates any alcohol use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior consequences (eg, substance-related injury) or family history of an alcohol use disorder suggest abstinence may be the best option. Cutting down is a reasonable option for others using risky amounts, or who have had some consequences but not dependence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H229664\">",
"    <span class=\"h3\">",
"     Other drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the risks of other drug use vary by drug, amount, and frequency of use, many consider any other drug use, either illegal drugs or misuse of prescription drugs, as risky, thus suggesting a goal of abstinence. Some consider the risk of legal consequences alone to warrant an abstinence goal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H229671\">",
"    <span class=\"h3\">",
"     Dependence",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with dependence, the optimal clinical goal of brief intervention is abstinence and reduction in consequences. Because these goals may be unrealistic to expect after a brief intervention, an intermediate goal would be engagement in treatment for dependence. This may include receipt of specialized treatments, some of which can be provided in primary care settings and others through referral to specialty care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4361?source=see_link\">",
"     \"Ambulatory alcohol detoxification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1191?source=see_link\">",
"     \"Opioid detoxification during treatment for addiction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, many dependent patients in primary care are not ready for a referral, and do not follow through when one is provided. Nonetheless, such referrals should be part of the menu of options discussed (presented as the clinician&rsquo;s &ldquo;best medical advice&rdquo;). A referral would be prescribed in a brief intervention as part of a negotiated plan.",
"   </p>",
"   <p>",
"    When patients with dependence remain in primary care, the best approach to maintaining treatment engagement is repeated brief intervention, for example, at routine follow-up visits at one to three month intervals, the clinician can inquire about use, attempts to cut down or quit, pros and cons of use, readiness to change, and interest in treatment options. The goals remain the same as above.",
"   </p>",
"   <p>",
"    If the clinician has the ability, and the patient is willing, medications for substance dependence can be prescribed and the patient can be monitored for side effects, adherence, and treatment response in primary care. Other specialized methods can be used, including motivational interviewing or referral for cognitive behavioral therapies,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a mutual help group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15097298\">",
"    <span class=\"h2\">",
"     Components",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different models for brief interventions have been tested, mostly for unhealthy alcohol use. Some are adaptations of motivational interviewing, which is relatively unstructured. Others are highly structured, with the clinician undertaking successive actions.",
"   </p>",
"   <p>",
"    A structured brief intervention generally begins with personalized feedback regarding the patient&rsquo;s substance use, followed by a discussion of possible goals, along with provision of information. The clinician should provide an explicit recommendation for behavior change. The session ends with negotiation and confirmation of goals and arrangement of follow-up. Key components of successful brief interventions are described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Feedback on the patient&rsquo;s personal risk or impairment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Results of screening or assessment, including physical or laboratory findings of adverse consequences, and potential consequences of the patient&rsquo;s continued use",
"     </li>",
"     <li>",
"      Feedback should usually be accompanied by an expression of concern",
"     </li>",
"     <li>",
"      Feedback is best followed by an open-ended question asking what the patient thinks of the feedback and of his or her substance use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emphasis that the patient has the responsibility for changing their use; he or she has to decide how.",
"     </li>",
"     <li>",
"      Providing clear advice to change:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Identifying the problem, explaining why change is important, advocating specific changes",
"     </li>",
"     <li>",
"      Advice is best provided after asking the patient for permission",
"     </li>",
"     <li>",
"      Advise abstinence or cutting down or drinking in less risky situations (eg, not before driving) (See",
"      <a class=\"local\" href=\"#H229650\">",
"       'Goals of brief intervention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presenting and discussing a menu of options and goals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Elicit what the patient thinks of the clinician&rsquo;s advice and recommendations regarding goals",
"     </li>",
"     <li>",
"      Goals should optimally be generated at least in part by the patient (these goals may be more specific than drinking changes and may include strategies to achieve goals, eg avoiding friends who drink too much, not having alcohol in the home, or spacing out drinks)",
"     </li>",
"     <li>",
"      Discussion can be directed toward options in which the patient shows interest",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the ideal goal is identified, and the patient responds to it, discussion should lead to next steps that balance what might be ideal for health with what the patient is willing to try.",
"     </li>",
"     <li>",
"      Use of an empathic counseling style, which involves listening, understanding, and reflecting that understanding (See",
"      <a class=\"local\" href=\"#H603432\">",
"       'Reflective listening'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Reinforcing the patient&rsquo;s self-efficacy or belief in his or her competence to change behavior. The clinician should state her or his belief that the patient can make a change.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603432\">",
"    <span class=\"h3\">",
"     Reflective listening",
"    </span>",
"    &nbsp;&mdash;&nbsp;One clinical skill that is useful in addressing behavior change is reflective listening. Reflective listening allows the patient to feel understood. A simple reflection involves repeating or rephrasing what the patient said. Paraphrasing and inferring some meaning, or reflecting feelings, are more complex forms of reflective listening.",
"   </p>",
"   <p>",
"    As an example, if a patient says &ldquo;I really should cut down on my drinking because I am always late to work,&rdquo; the clinician might say one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;It sounds like you really want to cut down on your drinking&rdquo; (a simple reflection)",
"     </li>",
"     <li>",
"      &ldquo;You want to cut down and doing so might help you at work&rdquo; (paraphrase)",
"     </li>",
"     <li>",
"      &ldquo;Your drinking causes you stress&rdquo; (reflects feeling)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A reflection is always a statement and not a question. Patients feel more understood when the clinician makes an attempt to check if they have understood what the patient has said by making a statement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603354\">",
"    <span class=\"h3\">",
"     Readiness to change",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although readiness to change is on a continuum, it can be useful to consider stages of readiness when thinking about how best to customize a brief intervention to an individual patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/9\">",
"     9",
"    </a>",
"    ]. The content and goal of brief intervention can be tailored to these stages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precontemplation &mdash; Patient is not concerned about substance use and is not considering change",
"     </li>",
"     <li>",
"      Contemplation &mdash; Patient has considered change or the possibility that their use may not be best for them",
"     </li>",
"     <li>",
"      Determination &mdash; Patient has decided to reduce or stop their use",
"     </li>",
"     <li>",
"      Action &mdash; Patient is reducing or stopping use",
"     </li>",
"     <li>",
"      Maintenance &mdash; Patient has reduced or stopped use and is continuing on that course",
"     </li>",
"     <li>",
"      Relapse &mdash; Patient has returned to previous, unhealthy levels of use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who screen positive for unhealthy alcohol or other drug use vary widely in their readiness for change. Some patients may have no idea that his or her substance use is unhealthy and no intent to seek advice or counsel about it, while others may recognize harmful consequences and seek help. Awareness of readiness can be used to provide an appropriate brief intervention.",
"   </p>",
"   <p>",
"    Clinicians can often recognize the patient&rsquo;s stage of readiness to change. Simple questions can be used to elicit information about readiness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How important is it for you right now to cut down on your drinking?",
"     </li>",
"     <li>",
"      If you did decide to stop using drugs, how confident are you that you would succeed?",
"     </li>",
"     <li>",
"      You&rsquo;ve decided to quit, you think it is important, and you believe you can do it; how ready are you to do it now?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Obtaining responses in the form of a score, eg, 1 through 10, can provide language with which to discuss change with the patient and assess changes in readiness over time.",
"   </p>",
"   <p>",
"    Another way to determine and discuss readiness is to find out the patient&rsquo;s perception of his or her use, and their need and perceived ability to change behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/10\">",
"     10",
"    </a>",
"    ]. One example is to ask &ldquo;Do you think your drug use is a problem?&rdquo;",
"   </p>",
"   <p>",
"    Once the patient&rsquo;s stage of readiness is established, the information can inform the clinician&rsquo;s approach to the problem.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precontemplation &mdash; For those who do not recognize a problem, the goal of the brief intervention is to increase the patient&rsquo;s perception that there is a concern. The clinician should express concern about the patient&rsquo;s use, state the problem non-judgmentally, agree to disagree about the importance of the concern, and emphasize the importance of follow-up even if the patient does not change behavior.",
"      <br/>",
"      <br/>",
"      Advice can still be given (eg, &ldquo;My best medical advice is to stop drinking, but I understand that may not work for you now&rdquo;.). A trial of abstinence or cutting down may be a useful learning experience for patients who express the belief that they can do it. A follow-up visit can be scheduled to discuss the experience.",
"     </li>",
"     <li>",
"      Contemplation &mdash; For those who have considered change or the possibility that their use may not be best for them, the goal is to tip the balance between pros and cons of the behavior towards greater concern and behavior change. It is useful at this stage for the clinician to ask the patient to discuss pros and cons of alcohol or other drug use. Examples include: &ldquo;What do you like about drinking?&rdquo; and &ldquo;Does drinking ever cause you any trouble?&rdquo;",
"      <br/>",
"      <br/>",
"      Elicit positive and negative aspects of not drinking (eg, &ldquo;What would happen if you didn&rsquo;t drink for a week?&rdquo;). Summarize these for the patient; the information can demonstrate a discrepancy between their behavior and their values and goals. As an example, when asked, the patient may report missing a child&rsquo;s weekend soccer game because of a hangover. He or she may immediately recognize the discrepancy between highly valuing attendance and drinking too much leading to missing the event. For the contemplation stage, advising a trial of cutting down or abstinence is reasonable.",
"     </li>",
"     <li>",
"      Determination &mdash; When the patient has decided to make a change, it is not useful, and possibly counterproductive, to work on motivation to change. Even at this stage, however, patients will likely be ambivalent about change, so reminding them of their reasons to change can still have a role in the brief intervention.",
"      <br/>",
"      <br/>",
"      The goal at this stage is to determine the best course of action. The clinician should help the patient decide on achievable goals. This conversation should be a negotiation, with the clinician providing a menu of options, and eliciting what the patient feels ready to do. The approach most likely to be successful is one the patient comes up with or chooses. The conversation should:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Remind patients of their strengths (eg, a prior change they made successfully, or the fact they are present discussing the issue)",
"     </li>",
"     <li>",
"      Caution patients that change may not be easy",
"     </li>",
"     <li>",
"      Reassure that relapse or not achieving the agreed upon goals will not disrupt the patients&rsquo; relationship with the clinician.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Action &mdash; Once the patient is making a change, the goal is to help him or her take steps that continue that change. Brief counseling should provide support and encouragement, reinforce the importance of change (summarize the patient&rsquo;s own reasons), and acknowledge discomfort or difficulty that can arise (eg, withdrawal symptoms, losses).",
"     </li>",
"     <li>",
"      Maintenance &mdash; When patients have made a change and are maintaining it, the goal is to help prevent relapse or return to alcohol or other drug use. Brief counseling should:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Provide recognition when this stage represents an ongoing challenge for the patient",
"     </li>",
"     <li>",
"      Support the patient&rsquo;s decision and ongoing efforts",
"     </li>",
"     <li>",
"      Reiterate that relapse with not disrupt the relationship with the clinician",
"     </li>",
"     <li>",
"      Anticipate difficult situations or triggers to return to use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapse &mdash; In the event of a return to use (relapse), the goal is to renew the process of contemplation. Brief intervention should:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Begin with expression of concern (though it is likely that the patient will already be aware of it)",
"     </li>",
"     <li>",
"      Emphasize the positive aspects of prior change and of current efforts to seek help",
"     </li>",
"     <li>",
"      Explore what can be learned from the relapse",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H229551\">",
"    <span class=\"h3\">",
"     Change talk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discussion should aim to elicit &ldquo;change talk&rdquo; or statements from the patient that are in the direction of change. Means for eliciting such statements include discussion of the patient&rsquo;s readiness and how the patient&rsquo;s current behavior relates to his or her personal goals. Elements of change talk can be abbreviated with the acronym DARN-C, ie, when the patient expresses:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Desire",
"      </strong>",
"      to change",
"     </li>",
"     <li>",
"      <strong>",
"       Ability",
"      </strong>",
"      to change",
"     </li>",
"     <li>",
"      <strong>",
"       Reasons",
"      </strong>",
"      for change",
"     </li>",
"     <li>",
"      <strong>",
"       Need",
"      </strong>",
"      to change",
"     </li>",
"     <li>",
"      Ultimately,",
"      <strong>",
"       Commitment",
"      </strong>",
"      to change.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient&rsquo;s ratings of readiness to change can be used to elicit change talk. As an example, if a patient rates the importance of change as a 3 on a scale of 1 to 10, the clinician can recognize that the score was not zero and ask why. This may lead the patient to identify his or her concerns about substance use. The clinician can ask the patient what it would take for the score (importance) to increase. The patient&rsquo;s response will likely be about change.",
"   </p>",
"   <p>",
"    When the patient expresses such talk, the clinician should use reflective listening. With that approach, the patient then hears their own words from the clinician, a very effective approach that facilitates actual behavior change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1008367\">",
"    <span class=\"h3\">",
"     Motivational interviewing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motivational interviewing is a directive, client-centered counseling style for eliciting behavior change in which patients explore and resolve ambivalence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Motivational interviewing is less structured than the brief intervention described here, but effective brief interventions have been developed that are adaptations of motivational interviewing or involve similar skills. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2313?source=see_link\">",
"     \"Motivational interviewing for substance use disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In motivational interviewing, patients are helped to recognize a discrepancy between their values and goals and their current actions which can lead them to consider change. Motivational interviewing involves collaboration with the patient, eliciting the patient&rsquo;s thoughts and listening to them, and making it clear that the patient has choices and the autonomy and ability to make them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15097319\">",
"    <span class=\"h3\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials most strongly support brief intervention delivered over a series of contacts rather than in a single encounter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/6\">",
"     6",
"    </a>",
"    ]. The clinician should make clear that follow up is desired and important, and that the patient is welcome regardless of whether or not they change their alcohol or other drug use. Follow up can be in person or by telephone. Steps at follow up include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reassessment of use and consequences",
"     </li>",
"     <li>",
"      Review of the patient&rsquo;s goals, experiences, and progress",
"     </li>",
"     <li>",
"      Reassessment of readiness to change",
"     </li>",
"     <li>",
"      Feedback and reinforcement of any positive changes",
"     </li>",
"     <li>",
"      Advice and discussion of options",
"     </li>",
"     <li>",
"      Repeated laboratory tests (if part of the patient&rsquo;s plan)",
"     </li>",
"     <li>",
"      Plan for further follow-up",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15097354\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of brief intervention is well established for patients in primary care identified by screening as having non-dependent unhealthy alcohol use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Insufficient trials have been conducted to determine whether screening combined with brief intervention has efficacy for other drugs or for individuals with alcohol dependence. Results of clinical trials of screening and brief intervention in settings other than primary care are mixed.",
"   </p>",
"   <p>",
"    The brief intervention reviewed here is for patients identified by screening, excluding patients identified through their request for help from the primary care clinician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/15\">",
"     15",
"    </a>",
"    ]. People seeking help have a higher level of readiness and severity when compared with populations identified by screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197037\">",
"    <span class=\"h2\">",
"     Alcohol use in primary care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several systematic reviews and meta-analyses confirm the efficacy of brief intervention for unhealthy alcohol use in primary care patients identified by screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/5,6,16-18\">",
"     5,6,16-18",
"    </a>",
"    ]. As an example, a meta-analysis of eight trials of 2,784 patients found that brief intervention decreased the proportion of patients drinking risky amounts one year later. Fewer patients who received brief intervention consumed risky amounts at one year compared to patients who did not receive brief intervention (57 versus 69 percent; absolute risk reduction of 12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/18\">",
"     18",
"    </a>",
"    ]. A meta-analysis of 9 trials reported consumption outcomes for intention-to-treat participants at 6 or 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/17\">",
"     17",
"    </a>",
"    ]. Receiving brief intervention decreased patients&rsquo; drinking by an additional three standard drinks per week compared to patients not receiving brief intervention.",
"   </p>",
"   <p>",
"    Studies have found brief intervention in this population to reduce health care utilization, and result in cost savings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In one trial, 774 patients with unhealthy alcohol use identified by screening for risky drinking amounts were randomized to brief intervention or usual care in 17 primary care practices with a total of 64 physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/19\">",
"     19",
"    </a>",
"    ]. The intervention, consisting of two 10 to 15-minute physician discussions and a nurse follow-up phone call, decreased consumption more than usual care, an effect that persisted at 36 months. Hospital use was lower over the three year period in patients assigned to the intervention compared to patients receiving usual care (420 versus 663 days). The intervention was estimated to have saved $546 per patient in medical costs and $7780 per patient in total costs (primarily due to a reduction in motor vehicle crashes).",
"   </p>",
"   <p>",
"    Three randomized trials have found brief intervention for alcohol use to be efficacious in pregnant women or peri-conception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. As an example, brief intervention increased abstinence and birth weight, and reduced fetal death, among 345 pregnant women who were drinking alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link&amp;anchor=H1272541#H1272541\">",
"     \"Screening for unhealthy use of alcohol and other drugs\", section on 'Special populations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197044\">",
"    <span class=\"h2\">",
"     Alcohol use in other settings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114013502\">",
"    <span class=\"h3\">",
"     Hospital inpatients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials of brief intervention for alcohol use in hospital inpatients identified by screening have not found the intervention to reduce consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. Mixed findings have been found for alcohol-related consequences, with a decrease in alcohol-related problems in three of five studies, and decreased serum GGT in two of three studies. &nbsp;",
"   </p>",
"   <p>",
"    One trial examined the use of brief intervention to facilitate referral of hospital inpatients to subsequent alcohol treatment. In a randomized trial, 263 general hospital inpatients who screened positive for unhealthy alcohol use were randomized to either a brief intervention focused on referral for subsequent alcohol treatment or to a control. The brief intervention increased initiation of alcohol treatment after discharge over 18 months from 4 to 14 percent. Most patients with dependence were excluded from the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One reason that brief intervention may have less efficacy in hospitalized patients than in outpatient primary care may be that inpatients identified by screening have more severe unhealthy alcohol use; about two-thirds have been found to meet criteria for dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/24,26,30-32\">",
"     24,26,30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114013509\">",
"    <span class=\"h3\">",
"     Emergency departments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 10 randomized trials examined the effectiveness of brief intervention for alcohol use in patients receiving treatment in an emergency department [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/33\">",
"     33",
"    </a>",
"    ]. No difference was seen overall in the quantity or frequency of alcohol consumption between patients who received brief intervention compared to those assigned to a control condition. In the three trials that reported the outcome, brief intervention led to decreased alcohol related injury. Other trials, limited to patients with unhealthy use treated for traumatic injury, had mixed findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of trials conducted in emergency care settings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial screened 16,182 patients and randomly assigned 500 people with nondependent unhealthy alcohol use or an alcohol-related injury to either brief intervention or a control intervention (scripted discharge instructions) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/35\">",
"       35",
"      </a>",
"      ]. No difference in alcohol consumption was seen between the two groups.",
"     </li>",
"     <li>",
"      A trial randomly assigned 762 patients, who screened positive for alcohol use while receiving treatment for injury at a trauma center, to a brief intervention or a control condition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/36\">",
"       36",
"      </a>",
"      ]. After 12 months, the intervention group showed a greater reduction in alcohol use compared to the control group (21.8 versus 6.7 drinks per week). However, 46 percent of patients were lost to follow-up at 12 months, making bias a possible explanation for the reduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More research is needed into whether brief intervention is effective for specific subpopulations in hospital and emergency settings. Reasons why widespread efficacy may be lacking in these settings for the broader population identified through screening include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Not only are patients in such settings often not seeking help for their drinking, patients may not be expecting attention to preventive care.",
"     </li>",
"     <li>",
"      Patients do not typically have longitudinal relationships with the clinicians.",
"     </li>",
"     <li>",
"      Patients under treatment for a traumatic injury or other consequence of alcohol use may have already made the connection between their drinking and a health consequence, and thus may change their drinking behavior without the need for a brief intervention",
"     </li>",
"     <li>",
"      Severity of unhealthy alcohol use is often greater in these settings, and may not be responsive to brief intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114013528\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A city-wide, population-based, public health intervention trial in Sweden enrolled a population-based cohort of 585 middle-aged men with a screening serum gamma-glutamyl transferase (GGT) value in the top decile as an isolated abnormality, and self-report of at least 20 grams of alcohol consumption daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/15,37\">",
"     15,37",
"    </a>",
"    ]. Participants were randomized to frequent checks of GGT, and repeated nurse and physician brief interventions, or to a one-time letter informing them of the results. After 16 years, no difference was seen in total mortality, but alcohol-related mortality was lower in the intervention group compared to the control group (4 versus 7 percent). Of all deaths in the cohort, 48 percent were alcohol-related",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15097375\">",
"    <span class=\"h2\">",
"     Alcohol dependence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few randomized trials have been conducted of brief intervention for alcohol dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/38\">",
"     38",
"    </a>",
"    ]. As illustrated below, findings have been mostly negative. (See",
"    <a class=\"local\" href=\"#H229671\">",
"     'Dependence'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link&amp;anchor=H2788982#H2788982\">",
"     \"Screening for unhealthy use of alcohol and other drugs\", section on 'Substance abuse and dependence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In trial of hospital inpatients identified by screening, with 77 percent meeting criteria for dependence, brief intervention did not reduce drinking or alcohol consequences compared to usual care. In secondary analyses, use of services to address alcohol use increased for women and young men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in a randomized trial of 1336 patients who screened positive for unhealthy alcohol use while receiving treatment for injury at a trauma center, brief intervention decreased use and consequences among patients with dependence, but not among those without dependence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two trials of brief intervention for primary care patients with very heavy drinking or dependence did not find differences in outcome between patients receiving brief intervention and the control group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197278\">",
"    <span class=\"h2\">",
"     Other drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the more extensive literature on alcohol use, screening and brief intervention has received limited study for drug use in adults. &nbsp;A large observational trial reported positive results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/40\">",
"     40",
"    </a>",
"    ]; however, results from randomized trials, below, have been mixed, and only one included some adult primary care settings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a clinical trial, 126 hospitalized inpatients (of 10,900 screened) reported abusing or using addictive prescription drugs on at least 60 of last 90 days and were randomly assigned to two sessions of motivational interviewing or to usual care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. There were no significant differences in drug amounts used, discontinuation rate, or other outcomes between the two groups at 12 months. At 3 months, a greater proportion of patients in the brief intervention group decreased use compared to the usual care group (52 versus 30 percent). Limiting the usefulness of these data, the trial included both individuals who misused prescription drugs and individuals who used them appropriately.",
"     </li>",
"     <li>",
"      In a large trial, 1175 outpatients (of 23,660 screened) reporting problem use of heroin or cocaine on the Drug Abuse Screening Test (DAST) were randomized to a brief negotiated interview or were given written advice and a list of referral options [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/43\">",
"       43",
"      </a>",
"      ]. At 6 months, the brief intervention group was more likely to be abstinent from opiates compared to the control intervention group (40 versus 31 percent) and cocaine (22 versus 17 percent). There were no differences in contact with drug treatment between groups.",
"     </li>",
"     <li>",
"      In a multinational randomized trial, 731 outpatients in Brazil, the United States, India, or Australia who screened positive for frequent drug use and &ldquo;moderate risk&rdquo; using the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) were randomly assigned to receive brief motivational counseling or to usual care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/44\">",
"       44",
"      </a>",
"      ]. After three months, patients assigned to receive brief intervention experienced a reduction in substance use compared to the usual care group; however, the difference was small and may not have been clinically significant. Reductions in cannabis and stimulant use were greater for brief intervention patients compared to controls; opioid scores did not differ by intervention group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197255\">",
"    <span class=\"h2\">",
"     Related modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bibliotherapy and online interventions have convincing effects in clinical trials of their use in patients with nondependent unhealthy alcohol use, though they have not been studied as widely as in-person approaches in primary care settings, and have not been adequately compared to in-person approaches. &nbsp;As such, they are currently best suited as an adjunct to in person brief intervention (eg, they could be offered to patients as part of a menu of options) or for people who seek these resources or for those who do not receive in-person brief intervention in primary care. They could also be incorporated into primary care brief intervention by recommending them to patients who screen positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1562536244\">",
"    <span class=\"h3\">",
"     Bibliotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Bibliotherapy&rdquo; or an individual&rsquo;s use of a book as self-help has been found to be as effective as clinician counseling for non-dependent unhealthy alcohol use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. A revised version of the book used in the trial, with materials to support self-change, is available for use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197189\">",
"    <span class=\"h3\">",
"     Online interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening, assessment, and counseling interventions are available online for patients to use and for clinicians to recommend [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/48\">",
"     48",
"    </a>",
"    ]. A review of eight online-intervention trials found some evidence for reduced alcohol use; intervention components and study rigor varied across trials. A high proportion of individuals initiating participation dropped out. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A trial compared an online screening, assessment, and motivational intervention to screening only in a university health service primary care clinic among students age 17 to 29 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/49\">",
"       49",
"      </a>",
"      ]. Drinking in the past two weeks was lower in the brief intervention group at six months compared to the screening-only group (relative risk 0.77, median 21 versus 29 drinks).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A trial evaluated the efficacy of an online program that conducts a free evaluation of the user&rsquo;s alcohol consumption at",
"      <a class=\"external\" href=\"file://www.drinkerscheckup.com/\">",
"       www.drinkerscheckup.com",
"      </a>",
"      <a class=\"external\" href=\"www.drinkerscheckup.com\">",
"      </a>",
"      , and provides the user with feedback as to whether his or her drinking is unhealthy. If it is, and the user seeks support for making a change, he or she is directed to a fee-based, online training in lower risk drinking at",
"      <a class=\"external\" href=\"file://www.moderatedrinking.com/\">",
"       www.moderatedrinking.com",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      The online training intervention plus access to online informational resources (",
"      <a class=\"external\" href=\"file://www.moderation.org/\">",
"       www.moderation.org",
"      </a>",
"      ) were compared to access to the informational resources alone in a single randomized trial of 80 adults reporting heavy drinking [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. The authors did not specify a primary outcome and results across outcomes were mixed. Both groups decreased their drinking over 12 months, with the group assigned to the intervention reporting a greater percentage of days abstinent (43 percent versus 29 percent). &nbsp;There were no significant differences between groups in drinks per day, or in alcohol problems or consequences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15097389\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of screening and brief intervention are not well studied, are likely few, and do not likely outweigh benefits where established.",
"   </p>",
"   <p>",
"    Although evidence for efficacy from individual randomized trials suggests either benefit or no benefit, but not harm, the confidence intervals from at least five alcohol screening and brief intervention trials include the possibility of harm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/18\">",
"     18",
"    </a>",
"    ]. At least one study of children found increases in drinking after intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/52\">",
"     52",
"    </a>",
"    ]. A brief intervention, particularly if done poorly, could lead to increased substance use. Training necessary for clinicians to do brief intervention properly is often more extensive than can be disseminated easily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that stigma related to substance use documented in the medical record could lead to lower quality care. Breech of the confidentiality of that information could have social consequences. Depending on local law, for example, a pregnant woman identified as using drugs could be jailed for harming the child when born, or a patient injured while drinking may be denied health insurance benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/55-60\">",
"     55-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening and brief intervention could theoretically harm the clinician-patient relationship. In several alcohol brief intervention randomized trials, attrition has been higher in intervention groups than in control groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/6\">",
"     6",
"    </a>",
"    ]. However, patients counseled for unhealthy alcohol use in an observational study perceived their quality of care to be better than those not counseled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/61-64\">",
"     61-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114012816\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although brief intervention can be delivered by different types of clinicians and non-clinicians who have been trained to do them, the best evidence for efficacy among patients identified by screening is for brief intervention done by the patient&rsquo;s primary care clinician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/5,6,16-18\">",
"     5,6,16-18",
"    </a>",
"    ]. However, there are other options for implementing screening and brief intervention with specialized staff",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electronic support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114012823\">",
"    <span class=\"h2\">",
"     Clinician type",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time required to complete screening and brief intervention has limited their use by primary care physicians and led to considerations of alternative delivery models. Responsibilities can be split where a medical assistant screens patients prior to their visit with the physician, who interprets the results and does the brief intervention.",
"   </p>",
"   <p>",
"    Evidence is accumulating that brief intervention done at least in part by non-physicians in primary care has similar efficacy to those done by physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/65\">",
"     65",
"    </a>",
"    ]. Nurses, nurse practitioners, physician assistants and other health professionals can be trained to incorporate screening and brief intervention into their roles in primary care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/66\">",
"     66",
"    </a>",
"    ]. This model has been used by large screening, brief intervention referral and treatment programs funded by Federal grants to many states in the US. &nbsp;",
"   </p>",
"   <p>",
"    Employment of behavioral health specialists (eg, psychologists, social workers) in primary care settings has been advocated as a means of improving access to mental health and substance-related care. Screening and brief intervention could be part of this role, though research is needed on the efficacy of such an approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=see_link&amp;anchor=H71601971#H71601971\">",
"     \"Overview of psychotherapies\", section on 'Psychotherapy in primary care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Traditional substance abuse counselors may not be well-suited to screening and brief intervention, at least not without additional training. In general, substance abuse counselors have little familiarity with patients who use alcohol and other drugs but do not have substance dependence. Since the majority of patients identified by screening in primary care settings will not have dependence, and since 12-step and other abstinence based approaches are inappropriate and even counter-productive for such patients, counselors need training to reorient their approaches and become familiar with a new condition. Some may find the reorientation difficult or impossible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114012830\">",
"    <span class=\"h2\">",
"     Online resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tools for patients can be helpful to support brief intervention. Materials addressing alcohol use, below, are available at:",
"    <a class=\"external\" href=\"file://rethinkingdrinking.niaaa.nih.gov/\">",
"     file://rethinkingdrinking.niaaa.nih.gov",
"    </a>",
"    ; they can be easily adapted for drug use. (See",
"    <a class=\"local\" href=\"#H197189\">",
"     'Online interventions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A drinking diary can help patients see how much they are drinking",
"     </li>",
"     <li>",
"      A worksheet structures an accounting of pros and cons of drinking",
"     </li>",
"     <li>",
"      A worksheet facilitates development of a plan for change",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The National Institute of Drug Abuse (NIDA) makes available an online assessment tool based on the ASSIST for clinicians to identify unhealthy drug use and determine level of risk (",
"    <a class=\"external\" href=\"file://nida.nih.gov/nidamed/\">",
"     file://nida.nih.gov/nidamed/",
"    </a>",
"    ). The levels suggest whether brief intervention alone is likely sufficient, or whether referral or specialized treatment might be indicated.",
"   </p>",
"   <p>",
"    Watching examples of brief intervention can help clinicians learn how to do the intervention. Video of brief intervention for alcohol use is available at",
"    <a class=\"external\" href=\"file://www.mdalcoholtraining.org/\">",
"     www.mdalcoholtraining.org",
"    </a>",
"    and at",
"    <a class=\"external\" href=\"file://www.niaaa.nih.gov/publications/clinical-guides-and-manuals/niaaa-clinicians-guide-online-training\">",
"     file://www.niaaa.nih.gov/publications/clinical-guides-and-manuals/niaaa-clinicians-guide-online-training",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114012837\">",
"    <span class=\"h2\">",
"     Electronic health record support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening tests can be embedded into electronic health records (EHRs) that record and score responses, and display results. EHRs are capable of providing decision support that recommends, for example, further assessment and advice specific to patients based on their results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. At Veterans Affairs Medical Centers in the US, where clinicians are required to screen all patients annually, the AUDIT-C is available and scored in the EHR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42265/abstract/67,71\">",
"     67,71",
"    </a>",
"    ]. A clinical reminder prompts the clinician to administer the screening at a patient visit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15097403\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that all adult patients in primary care who are identified through screening to have non-dependent, unhealthy alcohol use be treated (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"       \"Screening for unhealthy use of alcohol and other drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For such patients, we suggest brief intervention rather than other treatment options (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2654753\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15097354\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening and brief intervention can also be done for drugs other than alcohol and in high prevalence settings other than primary care (eg, emergency departments or hospitals) though the evidence on health outcomes is either insufficient to determine efficacy or mixed. (See",
"      <a class=\"local\" href=\"#H15097354\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of brief intervention in primary care will differ according to severity and type of substance use. (See",
"      <a class=\"local\" href=\"#H229650\">",
"       'Goals of brief intervention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cutting down is appropriate for those using amounts of alcohol that risk health consequences but who have experienced few or no problems.",
"     </li>",
"     <li>",
"      Abstinence is the best goal for patients who have failed attempts to reduce alcohol use, have contraindications to alcohol use, have alcohol dependence, and generally for any illegal drug use.",
"     </li>",
"     <li>",
"      For those with substance dependence (who do not abstain after brief intervention) other treatments for addiction in primary care, or by referral, are the optimal goals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brief intervention involves provision of personalized feedback regarding the patient&rsquo;s substance use and risks, emphasis on patient autonomy, a menu of options, clear advice, support of self-efficacy, and a nonjudgmental empathic approach. (See",
"      <a class=\"local\" href=\"#H15097298\">",
"       'Components'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An understanding of the patient&rsquo;s readiness to change can be used to customize the content of brief intervention to the patient. (See",
"      <a class=\"local\" href=\"#H603354\">",
"       'Readiness to change'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/1\">",
"      Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004; 291:1238.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/3\">",
"      U.S. Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med 2004; 140:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/4\">",
"      Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med 2005; 352:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/5\">",
"      Kaner EF, Dickinson HO, Beyer F, et al. The effectiveness of brief alcohol interventions in primary care settings: a systematic review. Drug Alcohol Rev 2009; 28:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/6\">",
"      Whitlock EP, Polen MR, Green CA, et al. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/7\">",
"      Friedmann PD, Saitz R, Samet JH. Management of adults recovering from alcohol or other drug problems: relapse prevention in primary care. JAMA 1998; 279:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/8\">",
"      Bien TH, Miller WR, Tonigan JS. Brief interventions for alcohol problems: a review. Addiction 1993; 88:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/9\">",
"      Prochaska JO, DiClemente CC, Norcross JC. In search of how people change. Applications to addictive behaviors. Am Psychol 1992; 47:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/10\">",
"      Samet JH, Rollnick S, Barnes H. Beyond CAGE. A brief clinical approach after detection of substance abuse. Arch Intern Med 1996; 156:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/11\">",
"      Rollnick S, Butler CC, Stott N. Helping smokers make decisions: the enhancement of brief intervention for general medical practice. Patient Educ Couns 1997; 31:191.",
"     </a>",
"    </li>",
"    <li>",
"     Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change, Guilford Press, New York 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/13\">",
"      Rollnick S, Heather N, Bell A. Negotiating behavior change in medical settings: The development of brief motivational interviewing. Journal of Mental Health 1992; 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     Rollnick S, Mason P, Butler C. Health Behavior Change, Churchill Livingstone, Edinburgh 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/15\">",
"      Kristenson H, Ohlin H, Hult&eacute;n-Nosslin MB, et al. Identification and intervention of heavy drinking in middle-aged men: results and follow-up of 24-60 months of long-term study with randomized controls. Alcohol Clin Exp Res 1983; 7:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/16\">",
"      Ballesteros J, Duffy JC, Querejeta I, et al. Efficacy of brief interventions for hazardous drinkers in primary care: systematic review and meta-analyses. Alcohol Clin Exp Res 2004; 28:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/17\">",
"      Bertholet N, Daeppen JB, Wietlisbach V, et al. Reduction of alcohol consumption by brief alcohol intervention in primary care: systematic review and meta-analysis. Arch Intern Med 2005; 165:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/18\">",
"      Beich A, Thorsen T, Rollnick S. Screening in brief intervention trials targeting excessive drinkers in general practice: systematic review and meta-analysis. BMJ 2003; 327:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/19\">",
"      Fleming MF, Mundt MP, French MT, et al. Brief physician advice for problem drinkers: long-term efficacy and benefit-cost analysis. Alcohol Clin Exp Res 2002; 26:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/20\">",
"      Solberg LI, Maciosek MV, Edwards NM. Primary care intervention to reduce alcohol misuse ranking its health impact and cost effectiveness. Am J Prev Med 2008; 34:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/21\">",
"      O'Connor MJ, Whaley SE. Brief intervention for alcohol use by pregnant women. Am J Public Health 2007; 97:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/22\">",
"      Hankin JR. Fetal alcohol syndrome prevention research. Alcohol Res Health 2002; 26:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/23\">",
"      Project CHOICES Intervention Research Group. Reducing the risk of alcohol-exposed pregnancies: a study of a motivational intervention in community settings. Pediatrics 2003; 111:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/24\">",
"      Emmen MJ, Schippers GM, Bleijenberg G, Wollersheim H. Effectiveness of opportunistic brief interventions for problem drinking in a general hospital setting: systematic review. BMJ 2004; 328:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/25\">",
"      Saitz R, Palfai TP, Cheng DM, et al. Brief intervention for medical inpatients with unhealthy alcohol use: a randomized, controlled trial. Ann Intern Med 2007; 146:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/26\">",
"      Freyer-Adam J, Coder B, Baumeister SE, et al. Brief alcohol intervention for general hospital inpatients: a randomized controlled trial. Drug Alcohol Depend 2008; 93:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/27\">",
"      McQueen J, Howe TE, Allan L, Mains D. Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev 2009; :CD005191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/28\">",
"      Liu SI, Wu SI, Chen SC, et al. Randomized controlled trial of a brief intervention for unhealthy alcohol use in hospitalized Taiwanese men. Addiction 2011; 106:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/29\">",
"      Elvy GA, Wells JE, Baird KA. Attempted referral as intervention for problem drinking in the general hospital. Br J Addict 1988; 83:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/30\">",
"      Bischof G, Reinhardt S, Freyer-Adam J, et al. Severity of unhealthy alcohol consumption in medical inpatients and the general population: is the general hospital a suitable place for brief interventions? Int J Public Health 2010; 55:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/31\">",
"      Saitz R. Most inpatients with unhealthy alcohol use have an alcohol use disorder. Int J Public Health 2010; 55:527.",
"     </a>",
"    </li>",
"    <li>",
"     Belen-Martinez A, Roson B, Hernandez R, Lazaro M, Bolao F, Vallejo J, et al. Usefulness of AUDIT-C as screening tool in an opportunistic brief intervention program for alcohol problems in hospitalized patients. Presentation November 19, 2007 at the meeting of the International Network on Brief Interventions for Alcohol Problems. Brussels, Belgium.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/33\">",
"      Havard A, Shakeshaft A, Sanson-Fisher R. Systematic review and meta-analyses of strategies targeting alcohol problems in emergency departments: interventions reduce alcohol-related injuries. Addiction 2008; 103:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/34\">",
"      Nilsen P, Baird J, Mello MJ, et al. A systematic review of emergency care brief alcohol interventions for injury patients. J Subst Abuse Treat 2008; 35:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/35\">",
"      D'Onofrio G, Pantalon MV, Degutis LC, et al. Brief intervention for hazardous and harmful drinkers in the emergency department. Ann Emerg Med 2008; 51:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/36\">",
"      Gentilello LM, Rivara FP, Donovan DM, et al. Alcohol interventions in a trauma center as a means of reducing the risk of injury recurrence. Ann Surg 1999; 230:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/37\">",
"      Kristenson H, Osterling A, Nilsson JA, Lindg&auml;rde F. Prevention of alcohol-related deaths in middle-aged heavy drinkers. Alcohol Clin Exp Res 2002; 26:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/38\">",
"      Saitz R. Alcohol screening and brief intervention in primary care: Absence of evidence for efficacy in people with dependence or very heavy drinking. Drug Alcohol Rev 2010; 29:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/39\">",
"      Field CA, Caetano R. The effectiveness of brief intervention among injured patients with alcohol dependence: who benefits from brief interventions? Drug Alcohol Depend 2010; 111:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/40\">",
"      Madras BK, Compton WM, Avula D, et al. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend 2009; 99:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/41\">",
"      Otto C, Crackau B, L&ouml;hrmann I, et al. Brief intervention in general hospital for problematic prescription drug use: 12-month outcome. Drug Alcohol Depend 2009; 105:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/42\">",
"      Zahradnik A, Otto C, Crackau B, et al. Randomized controlled trial of a brief intervention for problematic prescription drug use in non-treatment-seeking patients. Addiction 2009; 104:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/43\">",
"      Bernstein J, Bernstein E, Tassiopoulos K, et al. Brief motivational intervention at a clinic visit reduces cocaine and heroin use. Drug Alcohol Depend 2005; 77:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/44\">",
"      Humeniuk R, Ali R, Babor T, et al. A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health-care settings in four countries. Addiction 2012; 107:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/45\">",
"      Miller WR, Taylor CA. Relative effectiveness of bibliotherapy, individual and group self-control training in the treatment of problem drinkers. Addict Behav 1980; 5:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/46\">",
"      Miller WR, Baca LM. Two-year follow-up of bibliotherapy and therapist-directed controlled drinking training for problem drinkers. Behav Ther 1983; 6:441.",
"     </a>",
"    </li>",
"    <li>",
"     Miller WR, Mu&ntilde;oz RF. Controlling your drinking : tools to make moderation work for you, Guilford Press, New York 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/48\">",
"      Vernon ML. A review of computer-based alcohol problem services designed for the general public. J Subst Abuse Treat 2010; 38:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/49\">",
"      Kypri K, Langley JD, Saunders JB, et al. Randomized controlled trial of web-based alcohol screening and brief intervention in primary care. Arch Intern Med 2008; 168:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/50\">",
"      Hester RK, Delaney HD, Campbell W, Handmaker N. A web application for moderation training: initial results of a randomized clinical trial. J Subst Abuse Treat 2009; 37:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/51\">",
"      Hester RK, Delaney HD, Campbell W. ModerateDrinking.Com and moderation management: outcomes of a randomized clinical trial with non-dependent problem drinkers. J Consult Clin Psychol 2011; 79:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/52\">",
"      Stevens MM, Olson AL, Gaffney CA, et al. A pediatric, practice-based, randomized trial of drinking and smoking prevention and bicycle helmet, gun, and seatbelt safety promotion. Pediatrics 2002; 109:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/53\">",
"      Miller WR, Moyers TB, Arciniega L, et al. Training, supervision and quality monitoring of the COMBINE Study behavioral interventions. J Stud Alcohol Suppl 2005; :188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/54\">",
"      Miller WR, Yahne CE, Moyers TB, et al. A randomized trial of methods to help clinicians learn motivational interviewing. J Consult Clin Psychol 2004; 72:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/55\">",
"      Gentilello LM, Samuels PN, Henningfield JE, Santora PB. Alcohol screening and intervention in trauma centers: confidentiality concerns and legal considerations. J Trauma 2005; 59:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/56\">",
"      Rivara FP, Tollefson S, Tesh E, Gentilello LM. Screening trauma patients for alcohol problems: are insurance companies barriers? J Trauma 2000; 48:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/57\">",
"      Burns DL. Positive toxicology screening in newborns: ethical issues in the decision to legally intervene. Pediatr Nurs 1997; 23:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/58\">",
"      Pelham TL, DeJong AR. Nationwide practices for screening and reporting prenatal cocaine abuse: a survey of teaching programs. Child Abuse Negl 1992; 16:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/59\">",
"      Adirim TA, Sen Gupta N. A national survey of state maternal and newborn drug testing and reporting policies. Public Health Rep 1991; 106:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/60\">",
"      Connolly WB Jr, Marshall AB. Drug addiction, pregnancy, and childbirth: legal issues for the medical and social services communities. Clin Perinatol 1991; 18:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/61\">",
"      Saitz R, Horton NJ, Cheng DM, Samet JH. Alcohol counseling reflects higher quality of primary care. J Gen Intern Med 2008; 23:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/62\">",
"      Lock CA, Kaner EF. Implementation of brief alcohol interventions by nurses in primary care: do non-clinical factors influence practice? Fam Pract 2004; 21:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/63\">",
"      Kaner EF, Heather N, Brodie J, et al. Patient and practitioner characteristics predict brief alcohol intervention in primary care. Br J Gen Pract 2001; 51:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/64\">",
"      Beich A, Gannik D, Malterud K. Screening and brief intervention for excessive alcohol use: qualitative interview study of the experiences of general practitioners. BMJ 2002; 325:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/65\">",
"      Sullivan LE, Tetrault JM, Braithwaite RS, et al. A meta-analysis of the efficacy of nonphysician brief interventions for unhealthy alcohol use: implications for the patient-centered medical home. Am J Addict 2011; 20:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/66\">",
"      Lock CA, Kaner E, Heather N, et al. Effectiveness of nurse-led brief alcohol intervention: a cluster randomized controlled trial. J Adv Nurs 2006; 54:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/67\">",
"      Bradley KA, Williams EC, Achtmeyer CE, et al. Implementation of evidence-based alcohol screening in the Veterans Health Administration. Am J Manag Care 2006; 12:597.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Veterans Affairs Quality Enhancement Research Initiative. Clinical reminder for follow-up of positive alcohol use screen (AUDIT-C). file://www.queri.research.va.gov/tools/alcohol-misuse/alcohol-clinical-reminder-followup.cfm (Accessed on March 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/69\">",
"      Williams EC, Achtmeyer CE, Kivlahan DR, et al. Evaluation of an electronic clinical reminder to facilitate brief alcohol-counseling interventions in primary care. J Stud Alcohol Drugs 2010; 71:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42265/abstract/70\">",
"      Lapham GT, Achtmeyer CE, Williams EC, et al. Increased documented brief alcohol interventions with a performance measure and electronic decision support. Med Care 2012; 50:179.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Veterans Affairs Quality Enhancement Research Initiative. Alcohol Use Screening Clinical Reminder. file://www.queri.research.va.gov/tools/alcohol-misuse/alcohol-clinical-reminder-screening.cfm (Accessed on March 06, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14832 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42265=[""].join("\n");
var outline_f41_17_42265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15097403\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H521138\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8728671\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2654772\">",
"      Unhealthy alcohol and other drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2654753\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15097291\">",
"      INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H229650\">",
"      Goals of brief intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H229657\">",
"      - Alcohol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H229664\">",
"      - Other drug use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H229671\">",
"      - Dependence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15097298\">",
"      Components",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H603432\">",
"      - Reflective listening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H603354\">",
"      - Readiness to change",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H229551\">",
"      - Change talk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1008367\">",
"      - Motivational interviewing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15097319\">",
"      - Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15097354\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H197037\">",
"      Alcohol use in primary care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H197044\">",
"      Alcohol use in other settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114013502\">",
"      - Hospital inpatients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114013509\">",
"      - Emergency departments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114013528\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15097375\">",
"      Alcohol dependence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H197278\">",
"      Other drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H197255\">",
"      Related modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1562536244\">",
"      - Bibliotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H197189\">",
"      - Online interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15097389\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114012816\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114012823\">",
"      Clinician type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114012830\">",
"      Online resources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114012837\">",
"      Electronic health record support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15097403\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=related_link\">",
"      Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4361?source=related_link\">",
"      Ambulatory alcohol detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21783?source=related_link\">",
"      Cannabis use disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2313?source=related_link\">",
"      Motivational interviewing for substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3784?source=related_link\">",
"      Opioid abuse and dependence: Overview and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1191?source=related_link\">",
"      Opioid detoxification during treatment for addiction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_17_42266="Therapeutic use of warfarin";
var content_f41_17_42266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapeutic use of warfarin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/17/42266/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/17/42266/contributors\">",
"     Karen A Valentine, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/17/42266/contributors\">",
"     Russell D Hull, MBBS, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/17/42266/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/17/42266/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/17/42266/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/17/42266/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/17/42266/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    and other",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    antagonists (VKAs; eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    , phenprocoumon, fluindione) are the standard oral anticoagulants used in a variety of clinical settings. The general principles underlying the clinical use of VKAs, including their complications and laboratory monitoring, will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/1\">",
"     1",
"    </a>",
"    ]. Other aspects of VKA therapy are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The outpatient management of the patient taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , including the importance of strict INR control (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35880?source=see_link&amp;anchor=H7#H7\">",
"       \"Outpatient management of oral anticoagulation\", section on 'Importance of strict INR control'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Correction of excess anticoagulation on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link\">",
"       \"Correcting excess anticoagulation after warfarin\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Management of anticoagulation in patients who have had, or are at risk for, intracranial bleeding (see",
"      <a class=\"local\" href=\"#H34\">",
"       'Intracranial bleeding'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      A patient information document on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOLOGICAL PROPERTIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercially-available",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is a racemic mixture of S and R enantiomers. The more potent S form of the drug is metabolized primarily by the CYP2C9 hepatic microsomal enzyme system. This enzyme system is inducible by many drugs and has a number of genetic variants, both of which may profoundly alter warfarin's in vivo activity (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Genetic interactions'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    is strongly protein-bound, primarily to albumin; only the non-protein-bound fraction is biologically active. Accordingly, any agent that is also bound to albumin may displace warfarin from its albumin binding sites and increase its biological activity.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    is water soluble and completely absorbed after oral administration. The majority of the drug is absorbed in the proximal small bowel, although successful use of the sublingual route has been described in two patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Excretion is via the urine, primarily as drug metabolites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other vitamin K antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    has a biological half-life of 36 to 42 hours, considerably longer than that of the closely related anticoagulant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    (8 to 11 hours) and shorter than that of phenprocoumon (3 to 5 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/4\">",
"     4",
"    </a>",
"    ] and fluindione (69 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moderate overdosage of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"       acenocoumarol",
"      </a>",
"      may be more easily treated by omitting a single dose of this agent, in comparison to a similar overdosage of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link&amp;anchor=H8#H8\">",
"       \"Correcting excess anticoagulation after warfarin\", section on 'INR 5 to 9 without bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because of its longer-half life, phenprocoumon produces more stable anticoagulation than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"       acenocoumarol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/4\">",
"       4",
"      </a>",
"      ] and may be less susceptible to the effects of CYP2C9 polymorphisms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Tecarfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tecarfarin (ATI-5923) is a novel",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    antagonist currently in clinical trials; it is metabolized by esterases rather than the cytochrome P450 system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/8\">",
"     8",
"    </a>",
"    ]. Accordingly, it is not susceptible to the drug-drug, drug-food, and genetic alterations common to the other vitamin K antagonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticoagulant effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is mediated through inhibition of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    -dependent gamma-carboxylation of coagulation factors II, VII, IX, and X [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/32/20999?source=see_link\">",
"     \"Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    results in the synthesis of immunologically detectable but biologically inactive forms of these coagulation proteins. Warfarin also inhibits the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    -dependent gamma-carboxylation of proteins C and S, which have anticoagulant properties through their inhibition of activated factors VIII and V [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of these competing effects,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    antagonists, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , create a biochemical paradox by producing an anticoagulant effect due to the inhibition of procoagulants (factors II, VII, IX, and X) and a potentially thrombogenic effect by impairing the synthesis of naturally occurring inhibitors of coagulation (proteins C and S) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ultimate anticoagulant effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is delayed until the normal clotting factors, especially prothrombin, are cleared from the circulation. The peak effect does not occur until 36 to 72 hours after drug administration (",
"    <a class=\"graphic graphic_figure graphicRef50940 \" href=\"mobipreview.htm?26/56/27534\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/11\">",
"     11",
"    </a>",
"    ], especially because the plasma half-life of factor II (prothrombin) is approximately three days (",
"    <a class=\"graphic graphic_table graphicRef51595 \" href=\"mobipreview.htm?9/38/9836\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    During the first few days of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, prolongation of the prothrombin time mainly reflects its action on the extrinsic coagulation pathway, through the depression of factor VII, which has a half-life of four to six hours (",
"    <a class=\"graphic graphic_table graphicRef51595 \" href=\"mobipreview.htm?9/38/9836\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"mobipreview.htm?23/62/24558\">",
"     figure 2",
"    </a>",
"    ). The other",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    -dependent factors within the common and intrinsic coagulation pathways (ie, factors II, IX, and X) remain relatively unchanged during the first few days. Accordingly, the patient is not fully anticoagulated with warfarin until these other components are also reduced.",
"   </p>",
"   <p>",
"    Equilibrium levels of factors II (prothrombin), IX, and X, approximately 10 to 35 percent of normal at therapeutic INR levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/12\">",
"     12",
"    </a>",
"    ], are reached about one week after the initiation of therapy. For this reason, parenteral anticoagulants and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should",
"    <strong>",
"     overlap",
"    </strong>",
"    by four to five days when warfarin is initiated in patients with acute thrombotic disease (eg, venous thromboembolism,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H43#H43\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Initial anticoagulation regimen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H2392980#H2392980\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Transition to warfarin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     WARFARIN INTERACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphisms in the genes for the following two enzymes have been associated with altered sensitivity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/13-19\">",
"     13-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic cytochrome P-450 2C9 (CYP2C9), involved in the metabolic clearance of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of pharmacogenomics\", section on 'CYP isoenzymes and drug metabolism'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       Vitamin K",
"      </a>",
"      epoxide reductase complex 1 (VKORC1), which recycles vitamin K and is required for gamma carboxylation of vitamin K-dependent coagulation factors (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23432?source=see_link&amp;anchor=H4#H4\">",
"       \"Vitamin K and the synthesis of gamma carboxyglutamic acid\", section on 'Recycling of vitamin K'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cytochrome P-450 2C9",
"    </span>",
"    &nbsp;&mdash;&nbsp;A well-studied cause for individuality in patient responses to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is the presence of genetic variation (polymorphisms) in the hepatic cytochrome P-450 2C9 (CYP2C9) isoenzyme, which inactivates both warfarin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/20,21\">",
"     20,21",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These polymorphisms (wild-type CYP2C9*1 and variants CYP2C9*2 and CYP2C9*3) were studied in 561",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -treated patients; mean maintenance doses required to reach a target INR of 2.5 were, according to genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      *1*1 wild type (70 percent of group) &mdash; 5.0 mg",
"     </li>",
"     <li>",
"      *1*2 heterozygote (19 percent) &mdash; 4.3 mg",
"     </li>",
"     <li>",
"      *1*3 heterozygote (9 percent) &mdash; 4.0 mg",
"     </li>",
"     <li>",
"      *2*3 compound heterozygote (1 percent) &mdash; 4.1 mg",
"     </li>",
"     <li>",
"      *2*2 homozygote (0.5 percent) &mdash; 3.0 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this and an additional study, patients whose daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    requirement was &le;1.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    were five to six times more likely to have a variant allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/20,24,25\">",
"     20,24,25",
"    </a>",
"    ]. During induction of therapy, they were six times more likely to have an INR &gt;4.0 and four times more likely to have major bleeding. In addition, those with at least one variant allele required a significantly longer time (median difference 95 days) to reach a stable dose, effects seen in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of CYP2C9 polymorphisms on the time to the first INR within the therapeutic range, to the first INR &gt;4, and the average dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    after 29 days was studied in 297 patients undergoing warfarin anticoagulation with an average starting dose of 4.8 &plusmn; 0.8",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CYP2C9 genotype was not a significant predictor of the time to first INR within the therapeutic range, but was a significant predictor of the time to the first INR &gt;4.",
"     </li>",
"     <li>",
"      The CYP2C9 genotype was a significant predictor of the average dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      required after day 29 to achieve the desired INR. The dose was highest in those with the",
"      <span class=\"nowrap\">",
"       *1/*1",
"      </span>",
"      genotype (5.2",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      intermediate in those with the",
"      <span class=\"nowrap\">",
"       *1/*2",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       *1/*3",
"      </span>",
"      genotype (4.2",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and lowest in those with the",
"      <span class=\"nowrap\">",
"       *2/*2,",
"      </span>",
"      <span class=\"nowrap\">",
"       *3/*3,",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       *2/*3",
"      </span>",
"      genotypes (3.4",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a separate study, a significant interaction between the presence of local bleeding sources and the CYP2C9*2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    *3 alleles was seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Vitamin K epoxide reductase complex 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphisms in the gene encoding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    epoxide reductase complex 1 (VKORC1) affect the patient's response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/14,23,30-34\">",
"     14,23,30-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23432?source=see_link&amp;anchor=H5#H5\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\", section on 'Mutations and polymorphisms of the VKOR complex'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, a low-dose haplotype group (group A) and a high-dose haplotype group (non-A or group B) were identified, with the following mean",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    maintenance doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Group",
"      <span class=\"nowrap\">",
"       A/A",
"      </span>",
"      &mdash; 2.7 &plusmn; 0.2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      Group",
"      <span class=\"nowrap\">",
"       A/B",
"      </span>",
"      &mdash; 4.9 &plusmn; 0.2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      Group",
"      <span class=\"nowrap\">",
"       B/B",
"      </span>",
"      &mdash; 6.2 &plusmn; 0.3",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Asian-Americans had a higher proportion of group A haplotypes, while African-Americans had a higher proportion of group B haplotypes. It was estimated from this study that genetic alterations in CYP2C9 and VKORC1 accounted for 6 to 10 percent and 21 to 25 percent of the variance in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    dose, respectively. Similar studies in patients from France, Slovenia, and Sweden have estimated that polymorphisms in these two enzymes can account for up to 60 percent of interindividual variability in response to treatment with warfarin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/19,35\">",
"     19,35",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of VKORC1 polymorphisms on the time to the first INR within the therapeutic range, to the first INR &gt;4, and the average dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    after 29 days to achieve the desired INR was studied in 297 patients undergoing warfarin anticoagulation with an average starting dose of 4.8 &plusmn; 0.8",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The VKORC1 genotype was a significant predictor of both the time to first INR within the therapeutic range as well as the time to the first INR &gt;4. Presence of the A allele was associated with an accelerated and greater sensitivity to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Initial variability in the INR response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      was more strongly associated with genetic variability in VKORC1 than with CYP2C9.",
"     </li>",
"     <li>",
"      The VKORC1 genotype was a significant predictor of the average dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      required after day 29 to achieve the desired therapeutic INR. The dose was highest in those with the",
"      <span class=\"nowrap\">",
"       non-A/non-A",
"      </span>",
"      genotype (5.7",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      intermediate in those with the",
"      <span class=\"nowrap\">",
"       non-A/A",
"      </span>",
"      genotype (4.4",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and lowest in those with the",
"      <span class=\"nowrap\">",
"       A/A",
"      </span>",
"      genotype (3.7",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A reduced starting dose may be considered in patients with A haplotypes, in Asian-Americans, and in selected patients known to require lower doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (eg, age &gt;65, presence of liver disease, malnourished patient, or taking a medication that potentiates warfarin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Initial dose'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Genotype testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cytochrome P-450 4F2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the exact mechanism by which this enzyme affects",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    metabolism is not known, a DNA variant in cytochrome P-450 4F2 (CYP4F2 V433M) was associated with warfarin dose in three independent cohorts of patients taking stable doses of warfarin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/36\">",
"     36",
"    </a>",
"    ]. The difference amounted to a 4 to 12 percent increase in the required warfarin dose per T allele, as compared with that needed in those having the more common CC variant.",
"   </p>",
"   <p>",
"    Similarly, CYP4F2 V433M polymorphism has been shown to play a relevant role in the earliest response to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    and the required maintenance dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pharmacokinetic and pharmacogenetic dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the many variables affecting the maintenance dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    antagonists, as well as their narrow therapeutic range, efforts are underway to develop computer-assisted dosing programs for selecting appropriate initial dosing for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/15,38-44\">",
"     15,38-44",
"    </a>",
"    ], and for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    and phenprocoumon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/45\">",
"     45",
"    </a>",
"    ]. While some of these programs have aided selection of initial dosing of warfarin, especially for those requiring the lowest (&le;21",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    or highest (&ge;49",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    stable doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/41,46\">",
"     41,46",
"    </a>",
"    ], randomized, controlled studies using these programs have not yet resulted in a significant improvement in clinical outcomes (eg, longer time in therapeutic range, lesser incidence of adverse events); initial studies also differ as to whether or not these programs are cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/42,47,48\">",
"     42,47,48",
"    </a>",
"    ]. Some of these studies are reviewed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 369 patients taking a stable dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , an algorithm that included multiple factors (eg, age, race, sex, body surface area, CYP2C9 polymorphisms, target INR, use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      ) explained 39 percent of the variance in the maintenance warfarin dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/49\">",
"       49",
"      </a>",
"      ]. It was estimated that significantly fewer (6.5 percent) patients in this study would have been overdosed via the use of pharmacogenetic dosing compared with the 16 percent of patients who would have been overdosed if they had been prescribed an empirical dose of 5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      This algorithm is available online at",
"      <a class=\"external\" href=\"file://www.WarfarinDosing.org/Source/Home.aspx\">",
"       www.WarfarinDosing.org/Source/Home.aspx",
"      </a>",
"      , and needs to be validated for other clinical settings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study, 206 patients were randomly assigned to start",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy using either a standard dosing regimen or pharmacogenetic-guided therapy (PGT) using a regression equation including CYP2C9 and VKORC1 genotypes, age, sex, and weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/39\">",
"       39",
"      </a>",
"      ]. While PGT predicted stable warfarin doses more accurately than the standard regimen, the percent out-of-range INRs (31 versus 33 percent), the primary end point of the study, did not differ significantly between treatment arms.",
"     </li>",
"     <li>",
"      An international randomized study of oral anticoagulant dosing using two commercial computer-assisted dosage programs (PARMA 5 and DAWN AC) versus manual medical staff dosage was performed in 13,052 patients from 32 centers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/40\">",
"       40",
"      </a>",
"      ]. The time in target INR range was significantly improved by computer assistance as compared with medical staff dosage, with the greatest advantage being seen at those medical centers with fewer patient-years of experience. However, the overall number of adverse clinical events (ie, bleeding, thrombosis, death) was not significantly reduced (5.5 versus 6.0",
"      <span class=\"nowrap\">",
"       events/100",
"      </span>",
"      patient-years for the computer-assisted and manual dosage groups, respectively; adjusted incidence rate ratio 0.90; 95% CI 0.80-1.02).",
"     </li>",
"     <li>",
"      In a study of 266",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"       acenocoumarol",
"      </a>",
"      -treated patients, 89 of whom had gastrointestinal bleeding, the presence of a VKORC1 or cytochrome P450 polymorphism did not constitute a significant bleeding risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/51\">",
"       51",
"      </a>",
"      ]. The risk of bleeding in such carriers was significantly increased only if the weekly acenocoumarol dose exceeded 15 mg, or if the patient was also taking either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In a study of 1496 Swedish patients starting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy and genotyped for 183 polymorphisms in 29 candidate genes, homozygosity for CYP2CP or VKORC1 variant alleles significantly increased the risk of over-anticoagulation (ie, INR &gt;4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/19\">",
"       19",
"      </a>",
"      ]. However, no significant association was found between CYP2CP or VKORC1 genotypes and clinical bleeding during the study.",
"     </li>",
"     <li>",
"      In a non-randomized study, the 896 subjects who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      genotyping for CYP2C9 and VKORC1 had a significantly lower six-month risk for hospitalization for bleeding or thromboembolism than a matched historical group of 2688 controls (HR 0.72; 95% CI 0.53-0.97) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The accuracy of several",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    dose prediction tables and algorithms was compared in a cohort of 1378 patients taking a stable dose of warfarin, who also had complete data for dose prediction by all dosing methods. Methods included a clinical algorithm, dosing according to a newly revised warfarin label, dosing according to a genotype mean table, empiric dosing of 35",
"    <span class=\"nowrap\">",
"     mg/week,",
"    </span>",
"    and a pharmacogenetic algorithm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/53\">",
"     53",
"    </a>",
"    ]. While the pharmacogenetic algorithm was significantly more accurate in predicting (within &plusmn; 20 percent) the actual therapeutic warfarin dose than all of the other methods, 48 percent of the patients were ultimately not dosed accurately even by this method.",
"   </p>",
"   <p>",
"    The National Heart, Lung, and Blood Institute will be sponsoring a randomized trial comparing trial and error dosing, clinical algorithm dosing, and clinical plus genetic algorithm dosing. However, pharmacogenetic-based dosing was not recommended for routine use in the 2008 or the 2012 ACCP Guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/2,54\">",
"     2,54",
"    </a>",
"    ], and a cost-effectiveness study of using pharmacogenetic information for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    dosing concluded that, at its current cost (see below), routine genotyping before warfarin dosing is unlikely to be cost-effective for typical patients with nonvalvular atrial fibrillation (ie, an estimated marginal cost-effectiveness of testing exceeding $170,000 per quality-adjusted life-year gained) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In May 2009 the Centers for Medicare and Medicaid Services (CMS) announced a decision to decline payment for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    genetic testing unless administered as part of a clinical trial comparing outcomes in tested and untested patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Genotype testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Food and Drug Administration has approved a genetic test for detecting variants of the CYP2C9 and VKORC1 genes, which will help clinicians assess whether a patient may be especially sensitive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Information on this test (the Nanosphere Verigene Warfarin Metabolism Nucleic Acid Test), which has been estimated to cost approximately 300 to 400 US Dollars per patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/47\">",
"     47",
"    </a>",
"    ], is available on the United States FDA website at:",
"    <a class=\"external\" href=\"file://www.accessdata.fda.gov/cdrh_docs/pdf7/K070804.pdf\">",
"     www.accessdata.fda.gov/cdrh_docs/pdf7/K070804.pdf",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=see_link\">",
"     \"Overview of pharmacogenomics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large and increasing number of drugs interact with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Critical appraisal of the literature reporting such interactions indicates that the evidence substantiating some of the claims is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/56\">",
"     56",
"    </a>",
"    ]. Nonetheless, interactions leading to over-anticoagulation, under-anticoagulation, or increased bleeding independent of changes in the INR are well described for a large number of drugs. Mechanisms that can be associated with such interactions include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered platelet function (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/58\">",
"       58",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Gastrointestinal injury (eg, NSAIDs)",
"     </li>",
"     <li>",
"      Altered",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      synthesis in the GI tract (eg, antibiotics)",
"     </li>",
"     <li>",
"      Alterations in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      metabolism (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Interference with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      metabolism (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/60,61\">",
"       60,61",
"      </a>",
"      ], although the effect is variable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/62,63\">",
"       62,63",
"      </a>",
"      ])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example of how often these medication interactions occur, in one study performed in a primary care setting, nearly one-third of patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    had also been prescribed a medication known to interact with warfarin (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , non-steroidal anti-inflammatory drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , sulfamethoxazole) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accordingly, patients must be warned against taking",
"    <strong>",
"     any new drugs",
"    </strong>",
"    , including herbal products, over-the-counter medications, and even cutaneous application of large amounts of potentially interfering drugs (eg, topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/56/4995?source=see_link\">",
"     econazole",
"    </a>",
"    or bifonazole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/65\">",
"     65",
"    </a>",
"    ]) without the knowledge of the responsible clinician (",
"    <a class=\"graphic graphic_table graphicRef62697 \" href=\"mobipreview.htm?41/7/42108\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76808 \" href=\"mobipreview.htm?1/7/1149\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of herbal medicine and dietary supplements\", section on 'Herb-drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A population-based cohort study evaluated the risk of over-anticoagulation, as defined by an INR &gt;6.0, caused by concomitant antibiotic use in outpatients taking the coumarin anticoagulants",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    or phenprocoumon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/66\">",
"     66",
"    </a>",
"    ]. Overall, 351 of the 1124 subjects (31 percent) developed an INR &gt;6.0, with an incidence of 6.9 per 10,000 treatment days. The risk of over-anticoagulation was most strongly increased by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , often within the first three days of antibiotic usage.",
"   </p>",
"   <p>",
"    The relationship between hospitalization for upper gastrointestinal hemorrhage and the use of antibiotics was studied in a population-based nested case-control study of Ontario residents &ge;66 years of age who had been taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for at least 180 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/67\">",
"     67",
"    </a>",
"    ]. Concomitant use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (OR 3.84; 95% CI 2.33-6.33) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (OR 1.94; 95% CI 1.28-2.95) was associated with a significant increase in hospital admission for UGI hemorrhage. Admission for UGI hemorrhage was not associated with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    in the 14 days prior to admission. Approximately 10 percent of those hospitalized for this complication died before hospital discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17812656\">",
"    <span class=\"h3\">",
"     Proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A population-based cohort study evaluated the risk of over-anticoagulation, as defined by an INR &gt;6.0, caused by concomitant use of proton pump inhibitors in outpatients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/68\">",
"     68",
"    </a>",
"    ]. Overall, 887 of the 2755 subjects (32 percent) developed an INR &gt;6.0. The risk of over-anticoagulation was most strongly increased by use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    (HR 1.99; 95% CI 1.55-2.55) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    (HR 1.49; 95% CI 1.05-2.10). The authors did not detect a modification of these results according to the subjects&rsquo; CYP2C19*2 genotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Use of NSAIDs and antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , nonsteroidal anti-inflammatory drugs (NSAIDs), and antiplatelet agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    ) increases the risk of bleeding in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    antagonist-treated patients via multiple mechanisms, including gastrointestinal toxicity, enhancing the effect of the antagonist by increasing the INR, as well as interference with platelet function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1336?source=see_link&amp;anchor=H5#H5\">",
"     \"NSAIDs: Mechanism of action\", section on 'Cyclooxygenase inhibition'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H28\">",
"     'Bleeding'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of COX-2-selective NSAIDs may lead to fewer bleeding complications, as these agents do not interfere with platelet function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of selective COX-2 inhibitors\", section on 'Lack of effect upon platelets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lower bleeding risk with COX-2 selective NSAIDs was demonstrated in a nested case-control study from the Netherlands in patients taking phenprocoumon or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    along with NSAIDs. Over a two-year period there were 1491 bleeding episodes, 15 percent of which involved the use of NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/70\">",
"     70",
"    </a>",
"    ]. On multiple regression analysis, there was a significantly increased risk for bleeding in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of a nonselective versus a COX-2 selective NSAID &mdash; odds ratio (OR) 3.1",
"     </li>",
"     <li>",
"      NSAID use for &gt;1 month (versus &le;1 month) &mdash; OR 3.0",
"     </li>",
"     <li>",
"      Last INR &gt;4.0 (versus &le;4.0) &mdash; OR 1.9",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Low-dose aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    along with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (ie, 81 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is quite common. In one study of Kaiser Permanente Colorado members &ge;18 years of age, the prevalence of this treatment combination was 328 per 1000 patients anticoagulated with warfarin, and was most commonly employed in patients with heart failure, coronary heart disease, stroke, or transient ischemic attack [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/71\">",
"     71",
"    </a>",
"    ]. The overall benefits and risks of this combination of low-dose aspirin and warfarin are discussed in depth elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link&amp;anchor=H5#H5\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\", section on 'Warfarin plus aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H5#H5\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one large study using records from the United Kingdom,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    plus low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , as well as its combination with an NSAID or Cox-2 inhibitor, was associated with a risk for gastrointestinal bleeding greater than that for either agent alone, as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No drugs &mdash; adjusted risk (AR) 1.00 (comparator)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      alone &mdash; AR 1.4",
"     </li>",
"     <li>",
"      Cox-2 inhibitors alone &mdash; AR 1.6",
"     </li>",
"     <li>",
"      NSAID alone &mdash; AR 1.8",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      alone &mdash; AR 1.9",
"     </li>",
"     <li>",
"      Cox-2 inhibitor plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      &mdash; AR 4.6",
"     </li>",
"     <li>",
"      NSAID plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      &mdash; AR 4.8",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      &mdash; AR 6.5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were obtained from a large primary care database, in which the adjusted relative risks for development of upper gastrointestinal bleeding were 1.00, 1.77, 1.82, and 3.62 for those taking no drugs (comparator), oral anticoagulants alone, low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone, or both agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Influence of diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influence of dietary intake of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    on the stability of control of anticoagulation with vitamin K antagonists is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35880?source=see_link&amp;anchor=H10#H10\">",
"     \"Outpatient management of oral anticoagulation\", section on 'Influence of diet'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11843799\">",
"    <span class=\"h2\">",
"     Influence of smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review and meta-analysis has concluded that smoking may potentially cause significant interaction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    by increasing warfarin clearance, requiring a 12 percent (95% CI 7-17) increase in warfarin dosage compared with nonsmokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     WARFARIN ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6922379\">",
"    <span class=\"h2\">",
"     Baseline testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that the patient have a baseline PT and aPTT measured with an INR determination before initiation of treatment. This is important for comparison once the patient is on therapy as well as for diagnosing any preexisting abnormalities. If the baseline INR or aPTT is unexpectedly abnormal, this can be addressed.",
"   </p>",
"   <p>",
"    At this point, a plan can also be made regarding whether thrombophilia testing is indicated and the ideal time to perform it, taking into account effects of acute thrombosis and anticoagulant therapy on the results of such testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link&amp;anchor=H23#H23\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Technical screening issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14825?source=see_link\">",
"     \"Screening for inherited thrombophilia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Loading doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    with initial (\"loading\") doses in excess of 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    has several potential complications, including a transient hypercoagulable state due to a precipitous decline in protein C levels in first 36 hours (",
"    <a class=\"graphic graphic_figure graphicRef50940 \" href=\"mobipreview.htm?26/56/27534\">",
"     figure 1",
"    </a>",
"    ). These higher doses of warfarin also produce a precipitous decline in factor VII, resulting in an initial prolongation of the INR before onset of the full antithrombotic effect, which does not occur until there has been significant reduction in factor II. This also illustrates the necessity for overlap of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and warfarin therapy for four to five days, in order to have the benefit of anticoagulation from heparin until the full effect of warfarin has been achieved.",
"   </p>",
"   <p>",
"    The safety and efficacy of two different loading doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    were evaluated in a trial of 49 patients who were randomly assigned to receive initial warfarin doses of either 5 or 10 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/75\">",
"     75",
"    </a>",
"    ]. This trial used surrogate laboratory markers for safety (prothrombin time elevation and protein C levels) and efficacy (time course of factor II reduction). The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference between the two regimens with respect to the reduction in factor II levels as a marker of efficacy.",
"     </li>",
"     <li>",
"      The 5 mg loading dose was less likely to produce excess anticoagulation (ie, INR greater than 3.0) than the 10 mg dose; it also produced a less marked fall in protein C and factor VII levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar conclusion was reached in a second study involving 53 patients, which investigated the ability of initial loading doses of 5 or 10 mg to reach both of the following goals: attainment of a therapeutic INR (2.0 to 3.0) on two consecutive daily determinations on days 3, 4, or 5 of the study; and avoidance of an INR &gt;3.0 at any point [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/76\">",
"     76",
"    </a>",
"    ]. These goals were reached in 66 percent of patients randomly assigned to receive the 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    initial doses and in only 24 percent of patients receiving the 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    doses.",
"   </p>",
"   <p>",
"    In an analogous study, the 66 subjects randomly assigned to receive the 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    initial dose achieved a therapeutic INR significantly earlier than the 66 receiving the 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    initial dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/77\">",
"     77",
"    </a>",
"    ]. Mean INRs on the fifth to seventh day of treatment were in the excessive range (ie, 3.0 to 5.0) for 58 to 61 percent of those in the 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    group as compared with 8 to 12 percent for those in the 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    group. Bleeding and thrombotic events were similar in the two treatment groups.",
"   </p>",
"   <p>",
"    In a study in 201 patients randomly assigned to receive initial doses of either 5 or 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    those in the 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    arm achieved therapeutic INR levels at a mean of 1.4 days earlier than those in the 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    arm; significantly more patients in the 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    arm were in the therapeutic range at five days (83 versus 46 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/78\">",
"     78",
"    </a>",
"    ]. There were no differences between the two arms in terms of recurrent thrombotic events, major bleeding, survival, or number of INR measurements exceeding 5.0.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Initial dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of available studies, we suggest that initial doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in excess of 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    not be employed (",
"    <a class=\"graphic graphic_table graphicRef71791 \" href=\"mobipreview.htm?18/28/18892\">",
"     table 4",
"    </a>",
"    ). This suggestion is more conservative than the 2012 ACCP Guidelines, which suggest an initial dose of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for the first two days in patients sufficiently healthy to be treated as outpatients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/54\">",
"     54",
"    </a>",
"    ], but is consistent with their 2008 suggestion of reduced initial doses (ie, &le;5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in elderly patients, those that are debilitated or malnourished, have congestive failure, liver disease, recent major surgery, or are taking medication known to increase sensitivity to warfarin (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=see_link\">",
"     \"Anticoagulation in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of variability in the rate of drug metabolism and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    dietary status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/79-82\">",
"     79-82",
"    </a>",
"    ], the selection of the initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    must be individualized, especially in older patients and others at increased risk for bleeding. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Genetic interactions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Drug interactions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H28\">",
"     'Bleeding'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=see_link&amp;anchor=H20187280#H20187280\">",
"     \"Anticoagulation in older adults\", section on 'Initiation and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suggested initial oral doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for the first two days have ranged from a low of 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to as high as 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    with the daily dose subsequently adjusted up or down according to the INR. Higher initial (\"loading\") doses of warfarin are not recommended for reasons presented elsewhere. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Loading doses'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link&amp;anchor=H6#H6\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following issues are of importance in the selection of the initial dose within this suggested range:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial doses at the lower end of this range (ie, 2 to 5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      are suggested for patients with hepatic impairment, poor nutrition, debilitation, congestive failure, the elderly, those with severe chronic kidney disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/83\">",
"       83",
"      </a>",
"      ], and those at high risk of bleeding. Patients with certain genetic polymorphisms or those taking a medication that decreases the metabolic degradation rate of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      may also require lower starting doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/2,84\">",
"       2,84",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Genetic interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial doses at the high end of this range (ie, &le;10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      may be reasonable in highly selected patients, such as stable, reliable patients with a low bleeding risk in whom prior treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      required higher maintenance doses, or, as suggested in the 2012 ACCP Guidelines, in patients sufficiently healthy to be treated as outpatients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/54\">",
"       54",
"      </a>",
"      ]. However, as noted above, such higher doses have resulted in over-anticoagulation in three randomized trials. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Loading doses'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of testing for genetic polymorphisms for determination of the starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is not clear, although the 2012 ACCP Guidelines have recommended against their routine use for guiding doses of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    antagonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/54\">",
"     54",
"    </a>",
"    ]. The United States Food and Drug Administration (FDA) is involved in a Critical Path project related to the pharmacogenetics of warfarin therapy in an effort to resolve this issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31520063\">",
"    <span class=\"h2\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The test most commonly used to measure the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is the one-stage prothrombin time (PT). The PT is sensitive to reduced activity of factors II, VII, and X, but is insensitive to reduced activity of factor IX. Confusion about the appropriate therapeutic range has occurred because the different tissue thromboplastins used for measuring the PT vary considerably in their sensitivity to the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    -dependent clotting factors and in response to warfarin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical use of coagulation tests\", section on 'Prothrombin time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In order to promote standardization of the PT for monitoring oral anticoagulant therapy, the World Health Organization (WHO) developed an international reference thromboplastin from human brain tissue and recommended that the PT ratio be expressed as the International Normalized Ratio or INR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31520084\">",
"    <span class=\"h3\">",
"     Use of the INR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The INR is the PT ratio obtained by testing a given sample using the WHO reference thromboplastin. For practical clinical purposes, the INR for a given plasma sample is equivalent to the PT ratio obtained using a standardized human brain thromboplastin known as the Manchester Comparative Reagent, which has been widely used in the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical use of coagulation tests\", section on 'Measurement of INR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serial monitoring of the INR will detect many patients who are over-anticoagulated before they have had a bleeding episode. However, monitoring is not completely protective because, among patients who have a bleeding episode associated with a high INR, there may be only a brief warning period during which a slightly elevated INR predicts for an imminent bleeding event. This was illustrated in a review of 32 patients with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -related hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/89\">",
"     89",
"    </a>",
"    ]. The mean INR at the time of the bleeding event was 5.9; in contrast, the mean INR at the last prior measurement, which was obtained an average of 12 days before the bleeding event, was 3.0.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    vary significantly from patient to patient, ranging from &lt;2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to &ge;10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    depending upon a number of factors, such as the patient's nutritional status, hepatic and renal function, rate of intestinal absorption, genetic factors altering warfarin pharmacokinetics, degree of compliance, and the presence of drug interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/90-93\">",
"     90-93",
"    </a>",
"    ]. The goal INR varies with the clinical state, ranging from 2.0 to 3.0 in venous thromboembolism to somewhat higher ranges in patients with mechanical heart valves. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Warfarin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H673114\">",
"    <span class=\"h3\">",
"     Adjusting warfarin dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;No protocols for adjusting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    dosing have been uniformly accepted, and practice varies widely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/2,54,76,78,84,94-97\">",
"     2,54,76,78,84,94-97",
"    </a>",
"    ]. However, initial studies suggest that the use of algorithms improve time in therapeutic range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/98\">",
"     98",
"    </a>",
"    ], an endpoint that is associated with a lower risk of thromboembolic events and bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. We agree with the American College of Chest Physicians guidelines that recommend the use of protocols (eg, anticoagulation clinics, computerized warfarin management systems) for the adjustment of warfarin dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/2,54\">",
"     2,54",
"    </a>",
"    ]. A reasonable approach to adjusting warfarin dosing is outlined in the warfarin dosing protocol used by the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial investigators in several thousand patients with atrial fibrillation (",
"    <a class=\"graphic graphic_table graphicRef87435 \" href=\"mobipreview.htm?19/31/19964\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/98\">",
"     98",
"    </a>",
"    ]. This algorithm is based upon INR measurements obtained at least every four weeks for patients with an INR of 2 to 3 and at least weekly for patients with INR values outside of this therapeutic range. In addition, we offer the following caveats:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This protocol only applies to patients already taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , and it should not be used for warfarin initiation or during the first week of warfarin therapy.",
"     </li>",
"     <li>",
"      Frequent INR determinations are required initially to establish that therapeutic anticoagulation levels have been achieved. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35880?source=see_link&amp;anchor=H7#H7\">",
"       \"Outpatient management of oral anticoagulation\", section on 'Importance of strict INR control'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once the anticoagulant effect and patient's",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      dose requirements have been stabilized for at least one to two weeks, the INR can be monitored less frequently, at intervals in the range of every two to four weeks, throughout the course of warfarin therapy for venous thromboembolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/2,101\">",
"       2,101",
"      </a>",
"      ]. Routine dosing assessment at intervals longer than four weeks has been evaluated in a number of studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/102-104\">",
"       102-104",
"      </a>",
"      ], and the 2012 ACCP Guidelines have suggested an INR testing frequency of up to 12 weeks, rather than every four weeks, for those patients with consistently stable INRs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The INR should be monitored more frequently if there are factors that may produce an unpredictable response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (eg, concomitant drug therapy, other medical conditions, variable intake of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/2,56,105\">",
"       2,56,105",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Excessive anticoagulation'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35880?source=see_link&amp;anchor=H10#H10\">",
"       \"Outpatient management of oral anticoagulation\", section on 'Influence of diet'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The INR should also be monitored more frequently when substitution of one",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      preparation for another has occurred, in order to screen for differences in drug availability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/106-108\">",
"       106-108",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of a dosing algorithm was shown to improve clinical outcomes in a subset of 6022 patients on the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    arm of the RE-LY trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/98\">",
"     98",
"    </a>",
"    ]. In this trial, investigators were instructed to adjust warfarin to maintain a target INR of 2 to 3 in most patients. While its use was not mandated, investigators were provided with and encouraged to use a warfarin dosing algorithm (",
"    <a class=\"graphic graphic_table graphicRef71791 \" href=\"mobipreview.htm?18/28/18892\">",
"     table 4",
"    </a>",
"    ). A post-hoc analysis evaluated patient outcomes according to whether warfarin dose adjustments were consistent with the proposed algorithm. As compared to patients taking warfarin who did not have algorithm-consistent dosing, patients who did have algorithm-consistent dosing spent more days with their INR in the therapeutic range (13 versus 22 percent of days). The patients with algorithm-consistent dosing also experienced a lower incidence of stroke, embolism, or bleeding. While the use of the algorithm likely varied by center, the improvements in clinical outcomes did not appear to be due to other center variations in patient care, since these outcomes did not differ among centers in patients in the original RE-LY trial who were assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7574832\">",
"    <span class=\"h2\">",
"     Transitioning to or from dabigatran",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    has been approved for use in patients with non-valvular atrial fibrillation in a number of countries, there may be a desire to change treatment from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (or another",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    antagonist, VKA) to dabigatran, or vice versa. Recommendations on how to accomplish this are as follows (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H14#H14\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Dabigatran'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       From",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      <strong>",
"       or other VKAs to",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      ��� Discontinue VKA and initiate dabigatran when the INR is &lt;2.0.",
"     </li>",
"     <li>",
"      <strong>",
"       From",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      <strong>",
"       to",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ��� Initiate warfarin three, two, or one day before discontinuation of dabigatran in patients with a creatinine clearance of &gt;50, 31 to 50, or 15 to 30",
"      <span class=\"nowrap\">",
"       mL/minute,",
"      </span>",
"      respectively. This recommendation does not cover transition from dabigatran to the other VKAs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Warfarin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    resistance&rdquo; has been used by some clinicians for cases requiring high doses of warfarin to attain a therapeutic INR. We prefer to avoid this term. It implies a specific clinical entity, when in fact a variety of factors may impact warfarin dose requirements. These include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/90-92,110\">",
"     90-92,110",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nutritional status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       Vitamin K",
"      </a>",
"      intake",
"     </li>",
"     <li>",
"      Hepatic function",
"     </li>",
"     <li>",
"      Rate of intestinal absorption",
"     </li>",
"     <li>",
"      Medication compliance",
"     </li>",
"     <li>",
"      Drug interactions",
"     </li>",
"     <li>",
"      Genetic factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of hereditary factors may be associated with a need for increased doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , including an inability to absorb this agent from the gastrointestinal tract; altered affinity of the warfarin receptor; unusually high CYP2C9 activity; and certain missense mutations or single nucleotide polymorphisms within the gene for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    epoxide reductase complex subunit 1 (VKORC1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/111-114\">",
"     111-114",
"    </a>",
"    ]. Patients with genetic factors that alter warfarin pharmacokinetics require doses that are fivefold to 20-fold higher than average to achieve an anticoagulant effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23432?source=see_link&amp;anchor=H6#H6\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\", section on 'Hereditary warfarin resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Outpatient management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of options are available for the outpatient management of anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . These include supervision by hospital-based or community-based clinicians, anticoagulation clinics, and self-monitoring and self-management programs. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35880?source=see_link\">",
"     \"Outpatient management of oral anticoagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the safe use and quality control of oral anticoagulation have been published and updated regularly by the British Committee for Standards in Hematology (available at:",
"    <a class=\"external\" href=\"file://www.bcshguidelines.com/\">",
"     www.bcshguidelines.com",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/1,115\">",
"     1,115",
"    </a>",
"    ] and have been updated periodically by the American College of Chest Physicians, with the latest version appearing in February 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1230806\">",
"    <span class=\"h2\">",
"     Resumption of warfarin after bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies are available to guide decision making regarding whether and when to resume",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    following an episode of warfarin-associated bleeding. We suggest that the decision of whether to resume warfarin take into account the risk of thrombosis without warfarin and the cause of bleeding. In our experience, a significant subset of patients is able to resume warfarin safely.",
"   </p>",
"   <p>",
"    As an example, in a retrospective analysis of 442 patients who experienced a gastrointestinal (GI) bleed while on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , 59 percent resumed warfarin at a median of four days after the bleeding episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/116\">",
"     116",
"    </a>",
"    ]. When compared with those who remained off warfarin, patients who resumed warfarin had a trend towards an increased incidence of recurrent bleeding (10 versus 5.5 percent), which did not reach statistical significance. There were no fatal bleeds. Patients who resumed warfarin were less likely to experience a thrombotic event (0.4 versus 6 percent) or to die (6 versus 20 percent). Compared with patients who did not resume warfarin, patients who resumed warfarin were more likely to be treated and released from the emergency room (31.9 versus 13.2 percent) and less likely to be treated in the intensive care unit (21.2 versus 44.0 percent), suggesting that patients who resumed warfarin were more stable than those who did not resume warfarin.",
"   </p>",
"   <p>",
"    Prospective studies are needed to better evaluate the safety of anticoagulation following bleeding in this and other settings. Resumption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    following intracranial bleeding, endoscopy, and elective surgery is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Resumption of anticoagulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\", section on 'Resumption of anticoagulants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link&amp;anchor=H2441410#H2441410\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Resumption of warfarin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    is among the top 10 drugs with the largest number of serious adverse event reports submitted to the United States FDA during the 1990 and 2000 decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/117\">",
"     117",
"    </a>",
"    ]. Anticoagulants also ranked first in 2003 and 2004 in the number of total mentions of death for drugs \"causing adverse effects in therapeutic use\" and are a common cause of emergency department visits. Accordingly, the FDA has required that a \"black box\" warning about warfarin's bleeding risk be added to US product labeling, that a Medication Guide be provided to the patient with each prescription [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/118\">",
"     118",
"    </a>",
"    ], and that clinicians should counsel patients about preventive measures to minimize bleeding and to report immediately signs and symptoms of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of major bleeding episodes in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is related to the degree of anticoagulation as well as the presence in the patient of pre-existing risk factors for bleeding. Typical bleeding rates reported in randomized trials are in the range of 1 to 3 percent per person year. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H8#H8\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Bleeding risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=see_link&amp;anchor=H10#H10\">",
"     \"Anticoagulation in older adults\", section on 'Risk of bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An exception to this general rule may be retroperitoneal hemorrhage. This complication is common in patients taking anticoagulants, even when INR levels are within the therapeutic range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link&amp;anchor=H19#H19\">",
"     \"Approach to the adult patient with anemia\", section on 'Blood loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Major risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many patient characteristics that have been associated with an increased risk of bleeding following the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    antagonists (VKAs). The ones listed below have been associated with a significantly increased risk of bleeding on one or more multivariate analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/58,59,83,120-135\">",
"     58,59,83,120-135",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased age (variously given as &gt;60, &gt;65, &gt;75, or &gt;80 years)",
"     </li>",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Presence of malignancy",
"     </li>",
"     <li>",
"      Hypertension (ie, systolic &gt;180 or diastolic &gt;100 mmHg)",
"     </li>",
"     <li>",
"      Acute or chronic alcoholism, liver disease",
"     </li>",
"     <li>",
"      Severe chronic kidney disease; elevated creatinine",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      Poor drug compliance or clinic attendance",
"     </li>",
"     <li>",
"      Prior stroke or intracerebral hemorrhage",
"     </li>",
"     <li>",
"      Presence of bleeding lesions (eg, gastrointestinal blood loss, peptic ulcer disease)",
"     </li>",
"     <li>",
"      Bleeding disorder (coagulation defects, thrombocytopenia)",
"     </li>",
"     <li>",
"      Concomitant use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , nonsteroidal antiinflammatory drugs (NSAIDs), antiplatelet agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ), antibiotics,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , statins, fibrates",
"     </li>",
"     <li>",
"      Instability of INR control and INR &gt;3.0",
"     </li>",
"     <li>",
"      Pre-treatment INR &gt;1.2",
"     </li>",
"     <li>",
"      Previous severe hemorrhage during treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      with an INR in the therapeutic range",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with one or more of these risk factors for bleeding have generally been excluded from the very same pivotal trials that established the effectiveness of VKAs for their clinical condition (eg, atrial fibrillation, VTE, coronary heart disease). Despite this, many patients with an increased bleeding risk still receive treatment with VKAs. This was shown in a case-control study of 1986",
"    <strong>",
"     hospitalized",
"    </strong>",
"    patients receiving VKAs, one-half of whom were admitted for bleeding and the other half for infection (control group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/136\">",
"     136",
"    </a>",
"    ]. Findings of this study included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subjects admitted with bleeding, when compared with the control group, had a significantly higher incidence of an INR &ge;5.0 (30 versus 4.5 percent), creatinine &gt;1.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;150 microM, 5.9 versus 2.7 percent), and liver failure (2.4 versus 1.0 percent).",
"     </li>",
"     <li>",
"      Twenty-three percent of the controls and 40 percent of the patients presenting with bleeding had one or more risk factors that would have excluded them from participation in these pivotal trials.",
"     </li>",
"     <li>",
"      The relative risks for bleeding when one, two, or three or more of these exclusion criteria were present were 2.9, 3.8, and 14.9, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further support for a higher real world risk of bleeding in",
"    <strong>",
"     outpatients",
"    </strong>",
"    receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    was provided by an observational study of 125,195 adults aged &ge;66 years (median 77 years) who were given warfarin for atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/137\">",
"     137",
"    </a>",
"    ]. Bleeding was defined as that resulting in a visit to the hospital. Findings included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall rate of bleeding was 3.8 percent, with the highest risk during the first month of therapy (11.8 percent).",
"     </li>",
"     <li>",
"      Risk was increased in those with a higher CHADS",
"      <sub>",
"       2",
"      </sub>",
"      score (congestive heart failure, hypertension, age &ge;75, diabetes mellitus, and prior stroke, transient ischemic attack, or thromboembolism) (",
"      <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"       table 6",
"      </a>",
"      ). Those with a CHADS",
"      <sub>",
"       2",
"      </sub>",
"      score &ge;4 had risks of 16.7 and 6 percent per person-year in the first month and first year, respectively. Those with a CHADS",
"      <sub>",
"       2",
"      </sub>",
"      score of &lt;2 had a bleeding risk of 1.8 percent per person year.",
"     </li>",
"     <li>",
"      Risk increased in with age. For those &gt;75 years, risk was 4.6 percent per person-year; for those &le;75 risk was 2.9 percent per person-year.",
"     </li>",
"     <li>",
"      The five-year all-cause mortality for this cohort was 35.7 percent. Comparison numbers for age-matched controls without atrial fibrillation or with atrial fibrillation not receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      were not provided. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link&amp;anchor=H29#H29\">",
"       \"Overview of atrial fibrillation\", section on 'Long-term outcome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, these bleeding rates are higher than those reported in randomized trials testing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    efficacy, but lower than those evaluating shorter treatment intervals, highlighting the decline in risk after the first month of warfarin therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24437056\">",
"    <span class=\"h2\">",
"     Use of bleeding risk scoring systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of studies have provided retrospectively",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prospectively derived indices for estimating the risk of bleeding following the use of oral anticoagulants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/123,125,128,131,133,138-140\">",
"     123,125,128,131,133,138-140",
"    </a>",
"    ]; however,",
"    <strong>",
"     no one index can reliably predict bleeding risk in a particular patient",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best way to measure risk of bleeding in an individual patient is unclear, but physician assessment likely provides a valid measure. As an example, a prospective study of the performance of seven bleeding risk scores in 515 patients taking VKAs found that only one of these scoring systems (ATRIA) performed better than chance, and only slightly so, in predicting a major bleeding event during the year after enrollment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important caveat is that bleeding risk in a younger patient anticoagulated for an episode of deep vein thrombosis might result in a relatively benign episode of gastrointestinal bleeding following the concomitant use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or a nonsteroidal anti-inflammatory agent, whereas anticoagulant-associated bleeding in an elderly patient with hypertension and atrial fibrillation might result in a fatal episode of cerebral hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Outpatient bleeding risk index (OBRI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to estimate the probability of major bleeding in outpatients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , an outpatient bleeding risk index (OBRI) was derived in a retrospective cohort of 556 patients, and then prospectively validated in a separate cohort of 264 outpatients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/123\">",
"     123",
"    </a>",
"    ]. The index included the following four adverse risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;65 years",
"     </li>",
"     <li>",
"      History of stroke",
"     </li>",
"     <li>",
"      History of gastrointestinal bleeding",
"     </li>",
"     <li>",
"      One or more of the following: recent myocardial infarction, hematocrit &lt;30 percent, serum creatinine &gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;133",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      diabetes mellitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cumulative incidence of major bleeding at 48 months in the low (no risk factors), intermediate (one to two), and high (three or more) risk groups was 3, 12, and 53 percent, respectively (",
"    <a class=\"graphic graphic_table graphicRef59051 \" href=\"mobipreview.htm?32/58/33707\">",
"     table 7",
"    </a>",
"    ). Of the 18 episodes of major bleeding occurring in high-risk patients, 17 were potentially preventable (eg, avoidance of over-anticoagulation and avoidance of NSAID use) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     HEMORR2HAGES risk index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three earlier risk models, including the outpatient bleeding risk index noted above, were compared with a newer risk index in a validation cohort of 3932 elderly patients with atrial fibrillation (AF) receiving treatment with oral anticoagulants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/131\">",
"     131",
"    </a>",
"    ]. This study population was larger than any of the derivation or validation cohorts from the earlier risk models and offered the potential for more generalizable results. This index, called, HEMORR2HAGES, included a large number of risk factors drawn from the earlier models, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatic or renal disease",
"     </li>",
"     <li>",
"      Ethanol abuse",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"     <li>",
"      Older age (&gt;75 years)",
"     </li>",
"     <li>",
"      Reduced platelet count or function, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy",
"     </li>",
"     <li>",
"      Rebleeding risk (history of prior bleed)",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      Genetic factors",
"     </li>",
"     <li>",
"      Excessive fall risk",
"     </li>",
"     <li>",
"      Stroke",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to similar average relative risks of bleeding in prior studies, all risk factors were assigned one point, except for history of a prior bleed (rebleeding risk), which was assigned two points, for a total score ranging from zero to 12. The validation cohort was drawn from a multistate registry of AF patients. Among 1604 patients prescribed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , the risks of a major bleed per 100 patient-years of warfarin therapy were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 points &mdash; 1.9",
"     </li>",
"     <li>",
"      1 point &mdash; 2.5",
"     </li>",
"     <li>",
"      2 points &mdash; 5.3",
"     </li>",
"     <li>",
"      3 points &mdash; 8.4",
"     </li>",
"     <li>",
"      4 points &mdash; 10.4",
"     </li>",
"     <li>",
"      &ge;5 points &mdash; 12.3",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two-thirds of the major bleeding events were gastrointestinal and 15 percent were intracranial. Although the HEMORR2HAGES model identified subgroups at elevated bleeding risk, the predictive value for individual patients was limited and similar to other models.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24437063\">",
"    <span class=\"h3\">",
"     HAS-BLED bleeding risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HAS-BLED bleeding risk score was designed to include risk factors either readily available from the clinical history or routinely tested in patients with atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/139,143,144\">",
"     139,143,144",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef75259 \" href=\"mobipreview.htm?38/14/39148\">",
"     table 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an unselected nationwide cohort of hospitalized patients with atrial fibrillation, the HAS-BLED score performed similarly to the HEMORR2HAGES risk score in predicting for bleeding risk, but appeared to be simpler and easier to use in everyday clinical practice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/145\">",
"       145",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective analysis of the dataset from the AMADEUS trial, which evaluated the use of three different anticoagulants in patients with atrial fibrillation, the HAS-BLED score performed somewhat better than the HEMORR2HAGES and ATRIA risk scores for predicting clinically relevant bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/146\">",
"       146",
"      </a>",
"      ]. However, only the HAS-BLED score demonstrated a significant predictive performance for intracranial hemorrhage, perhaps the most feared complication of anticoagulation in this group of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The HAS-BLED risk score has been proposed for use in making clinical decisions about whether or not to use anticoagulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiplatelet therapy in various cardiac disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/143\">",
"     143",
"    </a>",
"    ] and to assess the risk of bleeding during perioperative bridging therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/147\">",
"     147",
"    </a>",
"    ], and has been recommended within the European Society of Cardiology and Canadian guidelines for assessing the risk of bleeding in atrial fibrillation management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/148,149\">",
"     148,149",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=see_link&amp;anchor=H10666069#H10666069\">",
"     \"Anticoagulation in older adults\", section on 'HAS-BLED risk score'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Bleeding risk if anticoagulation is continued'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156062\">",
"    <span class=\"h3\">",
"     ATRIA risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;A risk score for predicting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated bleeding in patients with atrial fibrillation was developed from the results of the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Five independent variables were included in the final model, with weighting as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/150\">",
"     150",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anemia ��� 3 points",
"     </li>",
"     <li>",
"      Severe renal disease (estimated glomerular filtration rate &lt;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      or dialysis-dependent) ��� 3 points",
"     </li>",
"     <li>",
"      Age &ge;75 years ��� 2 points",
"     </li>",
"     <li>",
"      Any prior hemorrhage ��� 1 point",
"     </li>",
"     <li>",
"      Diagnosed hypertension ��� 1 point",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subjects were considered low risk (score zero to 3 points), intermediate risk (4 points), or high risk (5 to 10 points), with major bleeding rates of 0.76, 2.62, and 5.76",
"    <span class=\"nowrap\">",
"     events/100",
"    </span>",
"    patient-years, respectively.",
"   </p>",
"   <p>",
"    A prospective cohort study of 515 adult outpatients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for a variety of indications (61 percent for atrial fibrillation) compared the ability of quantitative risk scores with physician subjective estimation to predict major bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/142\">",
"     142",
"    </a>",
"    ]. The OBRI, HEMORR2HAGES, HAS-BLED, and ATRIA risk scores all showed a trend toward predicting bleeding, but only the ATRIA score could predict bleeding risk with statistical significance; ATRIA was the largest of the studies. As compared to the bleeding risk scores, subjective estimates of bleeding risk made by the treating physicians, who had a mean clinical experience of three years, had similar accuracy in predicting bleeding in this cohort. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Thrombomodulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-risk patients may have bleeding episodes at INR values in the therapeutic or subtherapeutic range. In order to improve the ability to predict major bleeding, measurements in addition to the INR have been evaluated. As an example, in three reports, the risk of hemorrhage was associated with increased levels of thrombomodulin, an endothelium-derived antithrombotic cell-surface glycoprotein that is mainly present on the luminal surface of endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/151-153\">",
"     151-153",
"    </a>",
"    ]. The anticoagulant properties of thrombomodulin result from its binding to thrombin and subsequent activation of the natural anticoagulant protein C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Other causes for bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all bleeding episodes in anticoagulated patients are due to the anticoagulation. In one report of 243 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    who were prospectively followed for two years, the incidence of hematuria was similar to that of a control group not receiving warfarin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/154\">",
"     154",
"    </a>",
"    ]. Furthermore, evaluation of patients who developed hematuria revealed a genitourinary cause in 81 percent of cases. Infection was most common, but papillary necrosis, renal cysts, and several malignancies of the bladder were also found. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, hematuria in a patient taking chronic stable",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy requires evaluation rather than assuming it is related to the anticoagulation. A probable exception is that specific evaluation of the urinary tract may not be necessary in patients with hematuria and an excessively elevated INR who are also bleeding from other sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Intracranial bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discussions of the risk of intracranial bleeding following the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in patients with advanced age, hypertension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prior or potential intracranial bleeding lesions (eg, aneurysm, brain tumor, prior intracranial bleeding, infective endocarditis) are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=see_link\">",
"     \"Anticoagulation in older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33348?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/39/30327?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8089?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33415?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Excessive anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    frequently become excessively anticoagulated, even those who have been stable for many months. The most common causes are interactions between warfarin and other drugs and superimposed diseases (eg, liver disease, malabsorption) that may interfere with warfarin ingestion, absorption, or metabolism (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Drug interactions'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Studies in patients with atrial fibrillation indicate that the risk of bleeding increases substantially at INR values &ge;5.0 (",
"    <a class=\"graphic graphic_figure graphicRef65373 \" href=\"mobipreview.htm?42/18/43296\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef61232 \" href=\"mobipreview.htm?41/58/42924\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/155-157\">",
"     155-157",
"    </a>",
"    ], although other studies have shown that this risk increases for patients given oral anticoagulation for a number of indications when the INR is &gt;3.0 or &gt;3.5 (",
"    <a class=\"graphic graphic_figure graphicRef78252 \" href=\"mobipreview.htm?41/27/42430\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H8#H8\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Bleeding risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35880?source=see_link&amp;anchor=H7#H7\">",
"     \"Outpatient management of oral anticoagulation\", section on 'Importance of strict INR control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A more complete discussion of other causes underlying excessive anticoagulation as well as its treatment and prevention are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Activity limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    are at increased risk of spontaneous as well as trauma-induced bleeding. Reasonable precautions that can be taken concerning avoidance of falls, cuts, and other trauma are detailed elsewhere. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link&amp;anchor=H11#H11\">",
"     \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\", section on 'Other recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Participation in sports",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines are not available to assist patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in determining which sports activities are to be avoided and which are acceptable. Common sense must prevail, however, and individuals taking anticoagulants should not participate in contact or collision sports, or in activities in which there is an increased risk of serious trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/158,159\">",
"     158,159",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     OTHER COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to excess bleeding following the use of oral anticoagulants, there are a number of other concerns, including that of skin necrosis as well as special patient situations (factor IX mutation, pregnancy). These are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Skin necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin necrosis has been reported in some patients within the first few days of receiving large (loading) doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/160\">",
"     160",
"    </a>",
"    ]. The skin lesions may occur on the extremities, breasts, trunk, and penis and marginate over a period of hours from an initial central erythematous macule (",
"    <a class=\"graphic graphic_picture graphicRef80462 \" href=\"mobipreview.htm?42/34/43553\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62792 \" href=\"mobipreview.htm?32/11/32946\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef51999 \" href=\"mobipreview.htm?9/7/9330\">",
"     picture 3",
"    </a>",
"    ). Biopsies demonstrate fibrin thrombi within cutaneous vessels with interstitial hemorrhage.",
"   </p>",
"   <p>",
"    Skin necrosis appears to be mediated by the rapid reduction of protein C levels on the first day of therapy, which induces a transient hypercoagulable state. Approximately one-third of patients have underlying protein C deficiency; however, among patients with protein C deficiency, skin necrosis is an infrequent complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/161\">",
"     161",
"    </a>",
"    ]. Case reports have also described skin necrosis or thrombosis at other sites in association with an acquired functional deficiency of protein C or S [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/162\">",
"     162",
"    </a>",
"    ], heterozygous protein S deficiency, and factor V Leiden. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=see_link&amp;anchor=H13#H13\">",
"     \"Protein C deficiency\", section on 'Warfarin-induced skin necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Factor IX mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare mutation in factor IX, found in less than 1.5 percent of the population, causes bleeding following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    treatment without excessive prolongation of the prothrombin time. In these patients, factor IX levels, which are not reflected in the prothrombin time (",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"mobipreview.htm?23/62/24558\">",
"     figure 2",
"    </a>",
"    ), are markedly reduced following warfarin therapy, while levels of the other",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    -dependent coagulation factors are reduced to about 30 to 40 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23432?source=see_link&amp;anchor=H8#H8\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\", section on 'Recognition site mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    derivatives are generally contraindicated during at least the first trimester of pregnancy because of their teratogenic effects. This subject is discussed in detail separately, along with guidelines for anticoagulation during pregnancy using alternative agents (eg, low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link&amp;anchor=H3#H3\">",
"     \"Anticoagulation during pregnancy\", section on 'Warfarin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link&amp;anchor=H10#H10\">",
"     \"Anticoagulation during pregnancy\", section on 'General recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Cholesterol embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolization of cholesterol crystals (cholesterol microembolism) is a rare complication of anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Typically, this occurs after several weeks of therapy, and may present as a dark, purplish, mottled discoloration of the plantar and lateral surfaces of the lower extremities. This condition has been variously called \"blue toe syndrome\" or \"purple toe syndrome\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/163-165\">",
"     163-165",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31994?source=see_link&amp;anchor=H8#H8\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\", section on 'Skin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13368?source=see_link&amp;anchor=H11#H11\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\", section on 'Blue toe syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1217599869\">",
"    <span class=\"h2\">",
"     Vascular calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have suggested that the chronic use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    may lead to arterial calcification (eg, aortic valve, coronary arteries, femoral artery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/166-168\">",
"     166-168",
"    </a>",
"    ]. This effect was evaluated in a study in which coronary artery calcium scans were performed in 157 patients with low-risk atrial fibrillation but without significant cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/169\">",
"     169",
"    </a>",
"    ]. Mean coronary calcium scores increased significantly with the duration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    antagonist (VKA) use, and were 53, 90, and 236 in those not treated with VKA, treated with a VKA for 6 to 60 months, and treated with a VKA for &gt;60 months, respectively.",
"   </p>",
"   <p>",
"    This effect may be the result of inhibition of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    -dependent matrix Gla protein, important in inhibiting calcification. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/32/20999?source=see_link&amp;anchor=H8#H8\">",
"     \"Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins\", section on 'Gla-containing proteins of mineralized tissue'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Interference with thrombophilia testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;One cannot reliably test for congenital deficiencies of proteins S or C when patients are taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef76966 \" href=\"mobipreview.htm?43/22/44396\">",
"     table 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link&amp;anchor=H23#H23\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Technical screening issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12437430\">",
"    <span class=\"h2\">",
"     Allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-allergy between coumarin derivatives has been described, but details are sketchy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Known hypersensitivity to coumarin derivatives, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , is listed as a contraindication on the UK-EU labeling of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"       acenocoumarol",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In a case report, a single patient developed a maculopapular rash following treatment with three different coumarin derivatives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/17/42266/abstract/170\">",
"       170",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The paucity of information concerning the safety of switching from one coumarin derivative to another because of an allergic reaction is such that the clinician will need to make clinical decisions on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the type of surgery planned, anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    may or may not have to be temporarily interrupted. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2755?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/43/28337?source=see_link\">",
"       \"Patient information: Prothrombin time (PT) test and International Normalized Ratio (INR) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       Vitamin K",
"      </a>",
"      antagonists (VKAs; eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"       acenocoumarol",
"      </a>",
"      , phenprocoumon, fluindione) have a high incidence of adverse effects (mainly bleeding), a narrow therapeutic window, and a high propensity to be adversely affected by changes in diet and medications. Accordingly, all patients should be fully informed of the risks and benefits of VKA therapy before such treatment is initiated.",
"      <br/>",
"      <br/>",
"      The major factors increasing the risk of bleeding following the use of VKAs include increased age, presence of bleeding lesions, coagulation disorders, and the concomitant use of antiplatelet agents. Several bleeding risk indices are available for determination of such risks. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For initial therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , we suggest using a starting oral dose of approximately 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for most patients (",
"      <a class=\"graphic graphic_table graphicRef71791 \" href=\"mobipreview.htm?18/28/18892\">",
"       table 4",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Doses of &le;5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      may be more appropriate in the elderly, debilitated, or malnourished patient, or those with congestive failure, liver disease, severe chronic kidney disease, recent major surgery, or are taking medication known to increase sensitivity to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Initial dose'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=see_link\">",
"       \"Anticoagulation in older adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Initial doses &gt;5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      can be employed in selected patients deemed to be at low risk for bleeding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in those previously treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      at maintenance doses &gt;5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Loading doses &gt;10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      should be avoided. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Loading doses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       against",
"      </strong>",
"      the routine use of pharmacogenetic testing for guiding dosing of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      antagonists (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Genetic interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient is to be transitioned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      from unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , low molecular weight heparin, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      , the two agents should be given simultaneously for a minimum of five days. The heparin or fondaparinux can be discontinued on day 5 or 6 if the INR has been in the therapeutic range for at least 24 hours or two consecutive days. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H43#H43\">",
"       \"Treatment of lower extremity deep vein thrombosis\", section on 'Initial anticoagulation regimen'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that the patient have a baseline INR determination before initiation of treatment, receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      once a day for two days, and have the INR checked again on the following day. Subsequent doses are modified, up or down (",
"      <a class=\"graphic graphic_table graphicRef71791 \" href=\"mobipreview.htm?18/28/18892\">",
"       table 4",
"      </a>",
"      ), in order to achieve a target INR of 2.5 (target range: 2.0 to 3.0) for most conditions requiring anticoagulation (",
"      <a class=\"graphic graphic_figure graphicRef78252 \" href=\"mobipreview.htm?41/27/42430\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Once the anticoagulant effect and patient's",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      dose requirements have been stabilized for at least one to two weeks, the INR can be monitored less frequently, at intervals in the range of every two to four weeks, with appropriate warfarin dose adjustments (",
"      <a class=\"graphic graphic_table graphicRef87435 \" href=\"mobipreview.htm?19/31/19964\">",
"       table 5",
"      </a>",
"      ). For highly selected patients with consistently stable INRs, there is some support for an INR testing frequency of up to 12 weeks. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ideally, the patient's anticoagulation status should be followed in a systematic and coordinated outpatient setting which covers such items as patient education, self-testing, diet, and the importance of strict INR control. This subject is covered separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35880?source=see_link\">",
"       \"Outpatient management of oral anticoagulation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      may be safely restarted in selected patients following a gastrointestinal bleeding event. (See",
"      <a class=\"local\" href=\"#H1230806\">",
"       'Resumption of warfarin after bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The correction of excess anticoagulation from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is covered separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link\">",
"       \"Correcting excess anticoagulation after warfarin\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/1\">",
"      Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011; 154:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/2\">",
"      Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/3\">",
"      Batke-Hastings S, Carman TL. Sublingual administration of warfarin: a novel form of delivery. Vasc Med 2008; 13:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/4\">",
"      Fihn SD, Gadisseur AA, Pasterkamp E, et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003; 90:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/5\">",
"      Mentr&eacute; F, Pousset F, Comets E, et al. Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin Pharmacol Ther 1998; 63:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/6\">",
"      Ageno W, Crowther M, Steidl L, et al. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial. Thromb Haemost 2002; 88:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/7\">",
"      Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008; 100:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/8\">",
"      Ellis DJ, Usman MH, Milner PG, et al. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation 2009; 120:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/9\">",
"      Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992; 32:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/10\">",
"      Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med 1986; 314:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/11\">",
"      O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose. Circulation 1968; 38:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/12\">",
"      Lind SE, Callas PW, Golden EA, et al. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 1997; 8:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/13\">",
"      Shikata E, Ieiri I, Ishiguro S, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/14\">",
"      D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/15\">",
"      Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/16\">",
"      Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/17\">",
"      Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/18\">",
"      Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/19\">",
"      Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/20\">",
"      Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/21\">",
"      Leung AY, Chow HC, Kwong YL, et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001; 98:2584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/22\">",
"      Hermida J, Zarza J, Alberca I, et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 2002; 99:4237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/23\">",
"      Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/24\">",
"      Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/25\">",
"      Joffe HV, Xu R, Johnson FB, et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004; 91:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/26\">",
"      Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/27\">",
"      Schalekamp T, van Geest-Daalderop JH, de Vries-Goldschmeding H, et al. Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin Pharmacol Ther 2004; 75:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/28\">",
"      Meckley LM, Wittkowsky AK, Rieder MJ, et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008; 100:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/29\">",
"      Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/30\">",
"      Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/31\">",
"      Montes R, Ruiz de Gaona E, Mart&iacute;nez-Gonz&aacute;lez MA, et al. The c.-1639G &gt; A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 2006; 133:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/32\">",
"      Loebstein R, Dvoskin I, Halkin H, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 109:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/33\">",
"      Wang D, Chen H, Momary KM, et al. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/34\">",
"      Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115:3827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/35\">",
"      Herman D, Peternel P, Stegnar M, et al. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 2006; 95:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/36\">",
"      Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111:4106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/37\">",
"      P&eacute;rez-Andreu V, Rold&aacute;n V, Ant&oacute;n AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009; 113:4977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/38\">",
"      Tham LS, Goh BC, Nafziger A, et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 2006; 80:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/39\">",
"      Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116:2563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/40\">",
"      Poller L, Keown M, Ibrahim S, et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost 2008; 6:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/41\">",
"      International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/42\">",
"      Jowett S, Bryan S, Poller L, et al. The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study. J Thromb Haemost 2009; 7:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/43\">",
"      Gong IY, Tirona RG, Schwarz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011; 118:3163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/44\">",
"      Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 2012; 125:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/45\">",
"      van Schie RM, Wessels JA, le Cessie S, et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011; 32:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/46\">",
"      Moyer TP, O'Kane DJ, Baudhuin LM, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 2009; 84:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/47\">",
"      Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009; 150:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/48\">",
"      Rosove MH, Grody WW. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann Intern Med 2009; 151:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/49\">",
"      Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/50\">",
"      Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/51\">",
"      Montes R, Nantes O, Alonso A, et al. The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients. Br J Haematol 2008; 143:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/52\">",
"      Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55:2804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/53\">",
"      Finkelman BS, Gage BF, Johnson JA, et al. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 2011; 57:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/54\">",
"      Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e152S.",
"     </a>",
"    </li>",
"    <li>",
"     www.accessdata.fda.gov/cdrh_docs/pdf7/K070804.pdf (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/56\">",
"      Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/57\">",
"      Juurlink DN. Drug interactions with warfarin: what clinicians need to know. CMAJ 2007; 177:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/58\">",
"      Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/59\">",
"      Schelleman H, Bilker WB, Brensinger CM, et al. Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 2010; 123:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/60\">",
"      Thijssen HH, Soute BA, Vervoort LM, Claessens JG. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/61\">",
"      Lopes RD, Horowitz JD, Garcia DA, et al. Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. Blood 2011; 118:6269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/62\">",
"      Kwan D, Bartle WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/63\">",
"      Mah&eacute; I, Bertrand N, Drouet L, et al. Paracetamol: a haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol 2005; 59:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/64\">",
"      Feldstein AC, Smith DH, Perrin N, et al. Reducing warfarin medication interactions: an interrupted time series evaluation. Arch Intern Med 2006; 166:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/65\">",
"      Alexandra JF, Pautas E, Gouin-Thibault I, et al. Overanticoagulation with coumarin and cutaneous azole therapy. Ann Intern Med 2008; 148:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/66\">",
"      Visser LE, Penning-van Bees FJ, Kasbergen AA, et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002; 88:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/67\">",
"      Fischer HD, Juurlink DN, Mamdani MM, et al. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 2010; 170:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/68\">",
"      Teichert M, van Noord C, Uitterlinden AG, et al. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol 2011; 153:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/69\">",
"      van Dijk KN, Plat AW, van Dijk AA, et al. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype. Thromb Haemost 2004; 91:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/70\">",
"      Knijff-Dutmer EA, Van der Palen J, Schut G, Van de Laar MA. The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users. QJM 2003; 96:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/71\">",
"      Johnson SG, Witt DM, Eddy TR, Delate T. Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management service. Chest 2007; 131:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/72\">",
"      Johnson SG, Rogers K, Delate T, Witt DM. Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest 2008; 133:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/73\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Lin KJ, Hern&aacute;ndez-D&iacute;az S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011; 123:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/74\">",
"      Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, et al. Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. Chest 2011; 139:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/75\">",
"      Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/76\">",
"      Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999; 159:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/77\">",
"      Farahmand S, Saeedi M, Seyed Javadi HH, Khashayar P. High doses of warfarin are more beneficial than its low doses in patients with deep vein thrombosis. Am J Emerg Med 2011; 29:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/78\">",
"      Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 2003; 138:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/79\">",
"      Cushman M, Booth SL, Possidente CJ, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/80\">",
"      Lubetsky A, Dekel-Stern E, Chetrit A, et al. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 1999; 81:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/81\">",
"      Khan T, Wynne H, Wood P, et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 2004; 124:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/82\">",
"      Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 2004; 116:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/83\">",
"      Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/84\">",
"      Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000; 109:481.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/oc/initiatives/criticalpath/warfarin.html (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     Warfarin label change falls short of recommending genetic testing. \"The Pink Sheet\", F-D-C Reports 2007; 69:8. August 20, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/87\">",
"      Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/88\">",
"      Hirsh J, Poller L. The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med 1994; 154:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/89\">",
"      Kucher N, Connolly S, Beckman JA, et al. International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle. Arch Intern Med 2004; 164:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/90\">",
"      Lefr&egrave;re JJ, Guyon F, Horellou MH, et al. [Resistance to vitamin K antagonists. 6 cases]. Ann Med Interne (Paris) 1986; 137:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/91\">",
"      Hallak HO, Wedlund PJ, Modi MW, et al. High clearance of (S)-warfarin in a warfarin-resistant subject. Br J Clin Pharmacol 1993; 35:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/92\">",
"      Hulse ML. Warfarin resistance: diagnosis and therapeutic alternatives. Pharmacotherapy 1996; 16:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/93\">",
"      Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010; 56:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/94\">",
"      Barnes GD, Froehlich JB. Anticoagulation: a pathway to clinical effectiveness. Am J Med 2009; 122:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/95\">",
"      Kim YK, Nieuwlaat R, Connolly SJ, et al. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost 2010; 8:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/96\">",
"      Le Gal G, Carrier M, Tierney S, et al. Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping? J Thromb Haemost 2010; 8:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/97\">",
"      Borgman MP, Pendleton RC, McMillin GA, et al. Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. Thromb Haemost 2012; 108:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/98\">",
"      Van Spall HG, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2012; 126:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/99\">",
"      Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/100\">",
"      Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/101\">",
"      Rose AJ, Ozonoff A, Berlowitz DR, et al. Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: results from the Veterans Affairs study to improve anticoagulation. Chest 2011; 140:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/102\">",
"      Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 2011; 155:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/103\">",
"      Fihn SD, McDonell MB, Vermes D, et al. A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. National Consortium of Anticoagulation Clinics. J Gen Intern Med 1994; 9:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/104\">",
"      Pengo V, Barbero F, Biasiolo A, et al. A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. Am J Clin Pathol 2003; 120:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/105\">",
"      Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007; 109:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/106\">",
"      Halkin H, Shapiro J, Kurnik D, et al. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin Pharmacol Ther 2003; 74:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/107\">",
"      Milligan PE, Banet GA, Waterman AD, et al. Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother 2002; 36:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/108\">",
"      Witt DM, Tillman DJ, Evans CM, et al. Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program. Pharmacotherapy 2003; 23:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/109\">",
"      Rose AJ. Improving the management of warfarin may be easier than we think. Circulation 2012; 126:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/110\">",
"      P&eacute;rez-Andreu V, Rold&aacute;n V, L&oacute;pez-Fern&aacute;ndez MF, et al. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. J Thromb Haemost 2010; 8:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/111\">",
"      O'Reilly RA, Pool JG, Aggeler PM. Hereditary resistance to coumarin anticoagulant drugs in man and rat. Ann N Y Acad Sci 1968; 151:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/112\">",
"      Alving BM, Strickler MP, Knight RD, et al. Hereditary warfarin resistance. Investigation of a rare phenomenon. Arch Intern Med 1985; 145:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/113\">",
"      Bodin L, Perdu J, Diry M, et al. Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. J Thromb Haemost 2008; 6:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/114\">",
"      Schmeits PC, Hermans MH, van Geest-Daalderop JH, et al. VKORC1 mutations in patients with partial resistance to phenprocoumon. Br J Haematol 2010; 148:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/115\">",
"      Baglin TP, Cousins D, Keeling DM, et al. Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol 2007; 136:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/116\">",
"      Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 172:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/117\">",
"      Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/118\">",
"      Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. Cleve Clin J Med 2003; 70:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/119\">",
"      Gonz&aacute;lez C, Penado S, Llata L, et al. The clinical spectrum of retroperitoneal hematoma in anticoagulated patients. Medicine (Baltimore) 2003; 82:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/120\">",
"      Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ 2002; 325:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/121\">",
"      Veeger NJ, Piersma-Wichers M, Tijssen JG, et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005; 128:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/122\">",
"      Od&eacute;n A, Fahl&eacute;n M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002; 325:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/123\">",
"      Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/124\">",
"      Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/125\">",
"      Kuijer PM, Hutten BA, Prins MH, B&uuml;ller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/126\">",
"      Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/127\">",
"      van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/128\">",
"      Wells PS, Forgie MA, Simms M, et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 2003; 163:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/129\">",
"      Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35:2362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/130\">",
"      Douketis JD, Arneklev K, Goldhaber SZ, et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med 2006; 166:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/131\">",
"      Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/132\">",
"      Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/133\">",
"      Ru&iacute;z-Gim&eacute;nez N, Su&aacute;rez C, Gonz&aacute;lez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/134\">",
"      Nieto JA, Solano R, Ruiz-Rib&oacute; MD, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2010; 8:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/135\">",
"      Zhao HJ, Zheng ZT, Wang ZH, et al. \"Triple therapy\" rather than \"triple threat\": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 2011; 139:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/136\">",
"      Levi M, Hovingh GK, Cannegieter SC, et al. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111:4471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/137\">",
"      Gomes T, Mamdani MM, Holbrook AM, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ 2013; 185:E121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/138\">",
"      Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006; 130:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/139\">",
"      Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/140\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/141\">",
"      Dahri K, Loewen P. The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost 2007; 98:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/142\">",
"      Donz&eacute; J, Rodondi N, Waeber G, et al. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med 2012; 125:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/143\">",
"      Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/144\">",
"      Lip GY. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med 2011; 124:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/145\">",
"      Olesen JB, Lip GY, Hansen PR, et al. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 2011; 9:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/146\">",
"      Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012; 60:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/147\">",
"      Limantoro I, Pisters R. Peri-procedural antithrombotic bridging and the assessment of the associated risk of major bleeding. Thromb Haemost 2012; 108:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/148\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/149\">",
"      Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011; 27:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/150\">",
"      Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/151\">",
"      Jansson JH, Boman K, Br&auml;nnstr&ouml;m M, Nilsson TK. High concentration of thrombomodulin in plasma is associated with hemorrhage: a prospective study in patients receiving long-term anticoagulant treatment. Circulation 1997; 96:2938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/152\">",
"      van der Heijden JF, Rekk&eacute; B, Hutten BA, et al. Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX. J Thromb Haemost 2004; 2:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/153\">",
"      Lind M, Boman K, Johansson L, et al. Thrombomodulin as a marker for bleeding complications during warfarin treatment. Arch Intern Med 2009; 169:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/154\">",
"      Culclasure TF, Bray VJ, Hasbargen JA. The significance of hematuria in the anticoagulated patient. Arch Intern Med 1994; 154:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/155\">",
"      Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med 1995; 333:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/156\">",
"      Torn M, van der Meer FJ, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med 2004; 164:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/157\">",
"      Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/158\">",
"      Meyering C, Howard T. Hypercoagulability in athletes. Curr Sports Med Rep 2004; 3:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/159\">",
"      Mellwig KP, van Buuren F, Gohlke-Baerwolf C, Bj&oslash;rnstad HH. Recommendations for the management of individuals with acquired valvular heart diseases who are involved in leisure-time physical activities or competitive sports. Eur J Cardiovasc Prev Rehabil 2008; 15:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/160\">",
"      Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol 1993; 129:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/161\">",
"      Teepe RG, Broekmans AW, Vermeer BJ, et al. Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency. Arch Dermatol 1986; 122:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/162\">",
"      Haran MZ, Lichman I, Berebbi A, et al. Unbalanced protein S deficiency due to warfarin treatment as a possible cause for thrombosis. Br J Haematol 2007; 139:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/163\">",
"      Bols A, Nevelsteen A, Verhaeghe R. Atheromatous embolization precipitated by oral anticoagulants. Int Angiol 1994; 13:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/164\">",
"      Rauh G, Spengel FA. Blue toe syndrome after initiation of low-dose oral anticoagulation. Eur J Med Res 1998; 3:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/165\">",
"      Hyman BT, Landas SK, Ashman RF, et al. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987; 82:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/166\">",
"      Koos R, Mahnken AH, M&uuml;hlenbruch G, et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 2005; 96:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/167\">",
"      Koos R, Krueger T, Westenfeld R, et al. Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost 2009; 101:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/168\">",
"      Rennenberg RJ, van Varik BJ, Schurgers LJ, et al. Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood 2010; 115:5121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/169\">",
"      Weijs B, Blaauw Y, Rennenberg RJ, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011; 32:2555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/17/42266/abstract/170\">",
"      Kruis-de Vries MH, Stricker BH, Coenraads PJ, Nater JP. Maculopapular rash due to coumarin derivatives. Dermatologica 1989; 178:109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1334 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42266=[""].join("\n");
var outline_f41_17_42266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H46\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOLOGICAL PROPERTIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other vitamin K antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Tecarfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      WARFARIN INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cytochrome P-450 2C9",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Vitamin K epoxide reductase complex 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cytochrome P-450 4F2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pharmacokinetic and pharmacogenetic dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Genotype testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17812656\">",
"      - Proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Use of NSAIDs and antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Low-dose aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Influence of diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11843799\">",
"      Influence of smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      WARFARIN ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6922379\">",
"      Baseline testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Loading doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Initial dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31520063\">",
"      Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31520084\">",
"      - Use of the INR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H673114\">",
"      - Adjusting warfarin dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7574832\">",
"      Transitioning to or from dabigatran",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Warfarin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1230806\">",
"      Resumption of warfarin after bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Major risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24437056\">",
"      Use of bleeding risk scoring systems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Outpatient bleeding risk index (OBRI)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - HEMORR2HAGES risk index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24437063\">",
"      - HAS-BLED bleeding risk score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6156062\">",
"      - ATRIA risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Thrombomodulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Other causes for bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Intracranial bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Excessive anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Activity limitations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Participation in sports",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      OTHER COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Skin necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Factor IX mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Cholesterol embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1217599869\">",
"      Vascular calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Interference with thrombophilia testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12437430\">",
"      Allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1334\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1334|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/56/27534\" title=\"figure 1\">",
"      Warfarin and clotting proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/62/24558\" title=\"figure 2\">",
"      Coagulation pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/18/43296\" title=\"figure 3\">",
"      Events in AF according to INR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/27/42430\" title=\"figure 4\">",
"      Optimal INR oral anticoag",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1334|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/34/43553\" title=\"picture 1\">",
"      Cutaneous necrosis warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/11/32946\" title=\"picture 2\">",
"      Warfarin-induced skin necrosis on extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/7/9330\" title=\"picture 3\">",
"      Warfarin-induced skin necrosis on thighs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1334|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/38/9836\" title=\"table 1\">",
"      Properties of coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/7/42108\" title=\"table 2\">",
"      Warfarin drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/7/1149\" title=\"table 3\">",
"      Anticoagulant herbs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/28/18892\" title=\"table 4\">",
"      Warfarin dosing protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/31/19964\" title=\"table 5\">",
"      Warfarin maintenance dose adjustment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/45/40668\" title=\"table 6\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/58/33707\" title=\"table 7\">",
"      Bleeding risk index warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/14/39148\" title=\"table 8\">",
"      HAS-BLED risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/58/42924\" title=\"table 9\">",
"      Anticoagulation bleeding AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/22/44396\" title=\"table 10\">",
"      Thrombophilia test interference",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8089?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33348?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/39/30327?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33415?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=related_link\">",
"      Anticoagulation in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35880?source=related_link\">",
"      Outpatient management of oral anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/43/28337?source=related_link\">",
"      Patient information: Prothrombin time (PT) test and International Normalized Ratio (INR) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2755?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14825?source=related_link\">",
"      Screening for inherited thrombophilia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23432?source=related_link\">",
"      Vitamin K and the synthesis of gamma carboxyglutamic acid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/32/20999?source=related_link\">",
"      Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_17_42267="Emergency Rx fVIII inhibitor";
var content_f41_17_42267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of life-threatening hemorrhage or emergency surgery in hemophilic patients with factor VIII inhibitors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Begin therapy with a bolus infusion of porcine factor VIII concentrate at a dose of 100 units/kg. At the same time, blood should be drawn to determine the pre-infusion antibody titer to both porcine and human factor VIII.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood is drawn 10 minutes after the infusion for factor VIII assay to evaluate the adequacy of the infusion. The goal is to raise the factor VIII level to 30 to 50 units/mL, which is in the hemostatic range. If this is not achieved, the porcine factor VIII dose should be increased by 50 units/kg. Blood should be drawn again and the sequence repeated until the goal factor VIII level is attained.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If there is an inhibitor to porcine factor VIII with a titer above 10 Bethesda units and the desired factor VIII level has not been attained, plasmapheresis can be performed to acutely lower the inhibitor titer following by a massive dose of porcine factor VIII. If the patient still does not respond, either prothrombin complex concentrates or recombinant human factor VIIa can be given.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Once the goal factor VIII level has been attained, porcine factor VIII should be administered at frequent intervals or by continuous infusion at a dose of 1000 units or 10 units/kg per hour and factor VIII levels measured frequently.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Porcine factor VIII infusions should be continued for several days as long as hemostatic levels of factor VIII are maintained. If hemostatic levels of factor VIII cannot be maintained because of a rise in inhibitor titers, the patient can be treated with prothrombin complex concentrates or recombinant human factor VIIa.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: Porcine factor VIII products are NOT COMMERCIALLY AVAILABLE at this time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Feinstein DI. Inhibitors in hemophilia: In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al, Churchill Livingstone, New York 2000. p.1504.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42267=[""].join("\n");
var outline_f41_17_42267=null;
var title_f41_17_42268="Imaging ACS";
var content_f41_17_42268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Strengths and weaknesses of available noninvasive imaging modalities for patients presenting with suspected ACS in an ED setting",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Modality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Strengths",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weaknesses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial perfusion scintigraphy",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Widely available",
"        </p>",
"        <p>",
"         &bull; Standard interpretive approaches, can be quantitated",
"        </p>",
"        <p>",
"         &bull; Images the process responsible for symptoms",
"        </p>",
"        <p>",
"         &bull; Multiple RCTs and observational data support use",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Usually not available 24/7",
"        </p>",
"        <p>",
"         &bull; Rest imaging not as useful &gt;&sim;2 to 3 hours after symptoms but stress imaging is useful",
"        </p>",
"        <p>",
"         &bull; Entails radiation exposure",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echocardiography",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Widely available",
"        </p>",
"        <p>",
"         &bull; Standard interpretive approaches",
"        </p>",
"        <p>",
"         &bull; Images a process associated with symptoms",
"        </p>",
"        <p>",
"         &bull; RCT and observational data support use",
"        </p>",
"        <p>",
"         &bull; Relatively low cost",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; May not be available 24/7",
"        </p>",
"        <p>",
"         &bull; Rest imaging not as useful after symptom cessation but stress imaging is useful",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary CTA",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Widely available",
"        </p>",
"        <p>",
"         &bull; Standard qualitative interpretive approaches",
"        </p>",
"        <p>",
"         &bull; Images anatomy indirectly associated with symptoms",
"        </p>",
"        <p>",
"         &bull; Multiple RCTs and observational data support use",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; May not be available 24/7",
"        </p>",
"        <p>",
"         &bull; Coronary calcium may interfere with interpretation",
"        </p>",
"        <p>",
"         &bull; Implications of \"moderate\" stenoses or non-obstructive plaque not clear, patients would need further testing",
"        </p>",
"        <p>",
"         &bull; Substantial minority of patients not eligible due to renal dysfunction or atrial fibrillation",
"        </p>",
"        <p>",
"         &bull; Entails radiation exposure",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echocardiography with contrast for perfusion imaging",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Images the process responsible for symptoms",
"        </p>",
"        <p>",
"         &bull; Large observational data suggests incremental diagnostic information",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Not available for general use - contrast agents for perfusion not FDA approved",
"        </p>",
"        <p>",
"         &bull; Interpretive approaches not standardized",
"        </p>",
"        <p>",
"         &bull; Most data come from specialized centers",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular MR",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Comprehensively images anatomy and physiology associated with symptoms (including coronary arteries, myocardial perfusion, infarction, ventricular function)",
"        </p>",
"        <p>",
"         &bull; Small amount of observational data support use",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Expertise for comprehensive imaging not widely available",
"        </p>",
"        <p>",
"         &bull; Interpretive approaches not standardized",
"        </p>",
"        <p>",
"         &bull; Data come from specialized centers",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CTA: computed tomographic angiography; MR: magnetic resonance; RCT: randomized controlled trial.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Prem Soman and James Udelson.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42268=[""].join("\n");
var outline_f41_17_42268=null;
var title_f41_17_42269="Antidotes pediatric poisoning A";
var content_f41_17_42269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70409%7EPEDS%2F81720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70409%7EPEDS%2F81720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended antidotes in pediatric poisonings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antidote",
"       </td>",
"       <td class=\"subtitle1\">",
"        Poisoning indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pediatric dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N-acetylcysteine",
"       </td>",
"       <td>",
"        Acetaminophen",
"       </td>",
"       <td>",
"        <p>",
"         Oral Loading dose: 140 mg/kg orally; oral maintenance doses: 70 mg/kg every four hours for 17 doses",
"        </p>",
"        <p>",
"         Intravenous (IV)&nbsp;administration: 150mg/kg over 1 hour (loading dose); 50 mg/kg IV over 4 hours; 100 mg/kg IV over 16 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Atropine",
"       </td>",
"       <td>",
"        Carbamate insecticide",
"       </td>",
"       <td rowspan=\"2\">",
"        0.02 mg/kg IV bolus (0.1 mg minimum dose; maximum single dose 0.5 mg for children and 1.0 mg for adolescents) repeat doses titrated to effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organophosphate insecticide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crotalid antivenin",
"       </td>",
"       <td>",
"        Crotalid snakes",
"       </td>",
"       <td>",
"        4 to 6 vials (more if severe)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Calcium gluconate and calcium chloride (10 percent)",
"       </td>",
"       <td>",
"        Calcium channel blocker",
"       </td>",
"       <td rowspan=\"2\">",
"        Gluconate: 100 to 200 mg/kg IV Chloride: 20 to 30 mg/kg IV repeat doses and IV infusions are common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrogen fluoride (HF)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanide antidote kit (may contain sodium nitrite 3 percent ,sodium thiosulfate, and/or hydroxocobalamin)",
"       </td>",
"       <td>",
"        Cyanide",
"       </td>",
"       <td>",
"        <p>",
"         Sodium thiosulfate: 400 mg/kg IV (maximum 12.5 grams)",
"        </p>",
"        <p>",
"         Hydroxocobalamin: 70 mg/kg IV (maximum 5 grams)",
"        </p>",
"        <p>",
"         Sodium nitrite: 6 mg/kg by slow IV infusion (maximum 300 mg, only give if",
"         <strong>",
"          not",
"         </strong>",
"         contraindicated and hydroxocobolamin is",
"         <strong>",
"          not",
"         </strong>",
"         available), refer to UpToDate topics on cyanide poisoning",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deferoxamine",
"       </td>",
"       <td>",
"        Iron",
"       </td>",
"       <td>",
"        5 to 15 mg/kg per hour IV infusion, titrated to effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Digoxin immune Fab",
"       </td>",
"       <td>",
"        Digoxin",
"       </td>",
"       <td rowspan=\"3\">",
"        Empiric dosing: 10 to 20 vials IV bolus fo life-threatening toxicity; see package insert for other dosing regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digitoxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natural product (eg, plants, toads)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Dimercaprol (BAL, British antilewisite)",
"       </td>",
"       <td>",
"        Acute arsenic",
"       </td>",
"       <td rowspan=\"3\">",
"        2.5 to 4 mg/kg IM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inorganic mercury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead (with encephalopathy)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Dart, RC, Goldfrank, LR, Chyka, PA, Lotzer, D. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med 2000; 36:126 and Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. Ann Emerg Med 1999; 33:735.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended antidotes in pediatric poisonings (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antidote",
"       </td>",
"       <td class=\"subtitle1\">",
"        Poisoning indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pediatric dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Ethanol (10 percent)",
"       </td>",
"       <td>",
"        Methanol",
"       </td>",
"       <td rowspan=\"2\">",
"        Loading dose 10 mg/kg IV or PO, followed by maintenance dose 1 to 2 mL/kg per hour IV or PO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethylene glycol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Fomepizole (4-methylpyrazole)",
"       </td>",
"       <td>",
"        Methanol",
"       </td>",
"       <td rowspan=\"2\">",
"        15 mg IV bolus, then 10 mg/kg IV every 12 hours for four doses; after these, increase dose back to 15 mg/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethylene glycol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Glucagon",
"       </td>",
"       <td>",
"        Beta-adrenergic antagonist",
"       </td>",
"       <td rowspan=\"2\">",
"        0.15 mg/kg IV bolus followed by 0.1 mg/kg per hour IV infusion titrated to effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methylene blue",
"       </td>",
"       <td>",
"        Methemoglobinemia",
"       </td>",
"       <td>",
"        1 to 2 mg/kg slow IV infusion, repeat doses are common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Naloxone",
"       </td>",
"       <td>",
"        Acute opioid poisoning",
"       </td>",
"       <td>",
"        0.4 to 2 mg IV, titrated to effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pralidoxime chloride (PAM)",
"       </td>",
"       <td>",
"        Organophosphate insecticide",
"       </td>",
"       <td>",
"        20 to 40 mg/kg slow IV infusion, followed by 5 to 10 mg/kg per hour continuous infusion or 20 mg/kg every four hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyridoxine",
"       </td>",
"       <td>",
"        Isoniazid (INH)",
"       </td>",
"       <td>",
"        1 gm per gram ingested or empiric dosing 75 mg/kg IV bolus up to 5 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Sodium bicarbonate",
"       </td>",
"       <td>",
"        Tricyclic antidepressant",
"       </td>",
"       <td rowspan=\"2\">",
"        1 to 2 mEq/kg IV bolus, titrate repeat boluses to QRS duration do not exceed arterial pH 7.55)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylates",
"       </td>",
"       <td>",
"        150 mEq + 40 mEq KCl in 1L of D5W infused to maintain urine output at 1 to 2 mL/kg per hour and a urine pH approximately 7.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Dart, RC, Goldfrank, LR, Chyka, PA, Lotzer, D. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med 2000; 36:126 and Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. Ann Emerg Med 1999; 33:735.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42269=[""].join("\n");
var outline_f41_17_42269=null;
var title_f41_17_42270="Flexible hysteroscope";
var content_f41_17_42270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Flexible hysteroscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42270=[""].join("\n");
var outline_f41_17_42270=null;
var title_f41_17_42271="Failed mandibular fusion";
var content_f41_17_42271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Failed midline mandibular fusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arrows mark the unfused ends of the mandible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_17_42271=[""].join("\n");
var outline_f41_17_42271=null;
